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Summary 
Breast cancer is the most frequently diagnosed cancer and the leading cause of 
cancer-related death among women. When metastatic disease is present, i.e. where 
cancer cells disseminate and start proliferating in distant organs, treatment options 
remain very limited. Ferroptosis is a newly identified form of regulated, iron-
dependent cell death. Inhibition of the ferroptotic key enzyme glutathione peroxidase 
4 (GPX4) induces the accumulation of high cellular levels of lipid hydroperoxides 
within cellular membranes, initiating signaling that ultimately leads to cell death. 
Recent studies begun to identify genetic and metabolic contributors to the execution 
of ferroptosis. However, the exact molecular determinants that dictate sensitivity of 
cells to ferroptosis in different cellular contexts remain unclear.  
In my thesis, I set out to study ferroptosis in human mammary epithelial cells 
(HMECs). Thus, my goal was to determine whether ferroptosis plays a role during 
metastatic progression, thereby testing whether targeted induction of ferroptosis 
might provide a new therapeutic strategy specifically against advanced breast 
cancer. Therefore, I initially set out to assess how induction of the Epithelial-
Mesenchymal Transition (EMT) impacts ferroptosis sensitivity. EMT is a process 
implicated in tumor progression and metastasis which is orchestrated by pleiotropic 
transcription factors such as TWIST1. Instead of identifying a link between EMT and 
ferroptosis, I discovered that cell density, or more specifically proximity determined 
by seeding density, is a critical factor determining sensitivity to ferroptosis 
irrespective of cellular state. More precisely, low cell-seeding density sensitized cells 
to ferroptosis while high cell-seeding density, resulting in high cell-cell proximity, 
induced resistance. Experiments with ferroptosis inhibitors like Liproxstatin-1 and 
Ferrostatin-1, and genetic interference with GPX4 confirmed ferroptosis as the cell 
death-modality. Moreover, I discovered that cell density-dependent ferroptosis is an 
intrinsic trait of primary HMECs that occurs irrespective of the immortalization 
process and oncogenic signaling (i.e. HRASG12V and HER2/Neu). Furthermore, cell 
density-dependent ferroptosis could be observed in more physiological conditions 
as well (i.e. low oxygen pressure and three-dimensional organoid culture). Further, 
by using an E-cadherin neutralizing antibody and by co-culture experiments, I 
excluded cell-cell adhesion signaling as well as secreted factors as mediators of 
ferroptosis resistance at high cell densities. Although I was able to unequivocally 
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demonstrate that cell proximity dictates ferroptosis sensitivity, elucidation of the 
exact mechanism of proximity-sensing constitutes the aim for future studies. By 
conducting a proteomics screen which assessed regulated protein levels affected 
both by cell density and upon GPX4-inhibition, I discovered adipose triglyceride 
lipase (ATGL) as a determinant of cell density-dependent ferroptosis. In particular, 
ATGL-upregulation by low cell density triggered the lipolytic breakdown of fatty acids 
(FAs) from triacylglycerides stored in lipid droplets. Then, I elucidated that low cell 
density induces a metabolic switch to fatty acid oxidation which is fueled by ATGL-
liberated FAs. This in turn, increased lipid-mediated stress at low density inducing a 
vulnerable cell state towards GPX4 inhibition.  
In conclusion, cell density as a predictor of ferroptosis sensitivity in HMECs has 
implications for considering ferroptosis as treatment modality for cancer. Hence, 
single, disseminated cancer cells and small cancer cell clusters might be targeted 
by inducing ferroptosis during early stages of metastasis and before the onset of 
outgrowth of dormant cancer cells. Future studies will determine whether the 
mechanism of low cell density ferroptosis also has a physiological role to protect 
epithelial tissue maintenance as well as a role in other cellular contexts in vivo, 
where cells are disseminated, i.e. during neural crest migration.
  Zusammenfassung 
3 
 
Zusammenfassung 
Brustkrebs ist sowohl die am häufigsten, diagnostizierte Krebsart als auch die 
häufigste, krebsbedingte Todesursache bei Frauen. Sobald Metastasen festgestellt 
werden, d.h. wenn sich Krebszellen verteilen und in anderen Organen zu wachsen 
beginnen, sind die Behandlungsmöglichkeiten stark eingeschränkt. Ferroptose ist 
eine neu entdeckte, regulierte Zelltodart, die Eisen-abhängig ist. Die Hemmung des 
ferroptotischen Schlüsselenzymes Glutathionperoxidase 4 (GPX4) führt zur 
Anhäufung von Phospholipid Hydroperoxiden in Zellmembranen, wodurch eine 
Signalkaskade eingeleitet wird, die letztendlich zum Zelltod führt. Jüngste Studien 
haben genetische und metabolische Regulatoren während des Ferroptose 
Prozesses untersucht. Allerdings sind die genauen molekularen Faktoren, die die 
Ferroptose-Sensitivität in unterschiedlichen zellulären Kontexten bestimmen, 
weitgehend unbekannt. 
Ziel meiner Arbeit war die Untersuchung von Ferroptose in humanen Brust-
epithelzellen (HMECs). Dabei wurde geklärt, ob Ferroptose während der 
Metastasierung eine Rolle spielt und ob die gezielte Aktivierung von Ferroptose eine 
neuartige Behandlungsmöglichkeit von fortgeschrittenem Brustkrebs darstellen 
könnte. Zu Beginn wurde untersucht, wie sich die Aktivierung der Epithelialen-
Mesenchymalen Transition (EMT) auf Ferroptose-Sensitivität auswirkt. EMT ist ein 
Prozess, der mit Tumorprogression und Metastasierung assoziiert wird und durch 
pleiotrope Transkriptionsfaktoren, wie zum Beispiel TWIST1, reguliert wird. Ein 
direkter Zusammenhang zwischen EMT und Ferroptose konnte nicht gezeigt 
werden. Stattdessen wurde, unabhängig vom zellulären Phänotyp, die Zelldichte 
und die daraus resultierende Nähe der Zellen zueinander als entscheidendes 
Kriterium für Ferroptose-Sensitivität identifiziert. Dabei zeigte sich, dass Zellen in 
niedriger Zelldichte Ferroptose-sensitiv sind, wohingegen eine hohe Zelldichte zu 
Resistenz gegenüber Ferroptose führt. Durch Experimente mit Ferroptose-
Hemmern, wie zum Beispiel Liproxstatin-1 und Ferrostatin-1, und durch genetische 
Manipulation von GPX4 wurde Ferroptose als Zelltodart bestätigt. Darüber hinaus 
wurde festgestellt, dass Zelldichte-abhängige Ferroptose eine intrinsische 
Eigenschaft von primären HMECs ist, die unabhängig vom 
Immortalisierungsprozess und onkogenen Signalkaskaden (wie zum Beispiel 
HRASG12V und HER2/Neu) ist. Zudem kann Zelldichte-abhängige Ferroptose unter 
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physiologischeren Konditionen, wie zum Beispiel bei niedrigem Sauerstoffdruck und 
in drei-dimensionalen Organoidkulturen, beobachtet werden. Mit Hilfe eines 
E-cadherin neutralisierenden Antikörpers und Ko-Kulturen wurden Zell-Zell-
Adhesion und sezernierte Faktoren als Vermittler von Ferroptose-Resistenz bei 
hoher Zelldichte ausgeschlossen. Obwohl gezeigt werden konnte, dass die 
Zelldichte und die damit resultierende Nähe der Zellen zueinander Ferroptose-
Sensitivität bestimmt, bleiben die genauen Mechanismen, wie Zellen diese Nähe 
signalisiert wird, Bestandteil weiterführender Studien. Mittels einer Proteomik-
Analyse wurden Proteine bestimmt, die sowohl durch die Zelldichte als auch durch 
GPX4-Hemmung reguliert wurden. Hierbei wurde die Adipozyten-Triglycerid-Lipase 
(ATGL) als ein Regulator der Zelldichte-abhängigen Ferroptose identifiziert. In 
niedriger Zelldichte wurde ATGL hochreguliert, was wiederum zum lipolytischen 
Abbau von Fettsäuren aus Triacylglyceriden führte, welche in Lipidtropfen 
gespeichert werden. Durch die ATGL-vermittelte Fettsäuremobilisierung wurde der 
zelluläre Stoffwechsel bei niedriger Zelldichte vermehrt auf Fettsäureoxidation 
umgestellt. Dadurch erhöhte sich der Lipid-induzierte Stress, welcher zu einem 
Anstieg der Sensitivität der Zellen gegenüber GPX4-Hemmung führte. 
Zusammenfassend wurde die Zelldichte als Indikator für Ferroptose-Sensitivität von 
HMECs identifiziert. Darauf basierend könnte man Ferroptose als eine mögliche 
Krebsbehandlungsmodalität in Betracht ziehen. Hierbei könnten einzelne, 
disseminierte Krebszellen sowie kleine Gruppen von Krebszellen durch das 
Auslösen von Ferroptose während frühen Stadien der Metastasierung am 
Auswachsen gehindert werden. Zukünftige Studien werden zeigen, ob der 
Ferroptosemechanismus, induziert durch niedrige Zelldichte, eine physiologische 
Rolle beim Schutz von epithelialen Geweben spielt. Weiterhin ist es von Interesse 
herauszufinden, ob dieser Mechanismus auch in anderen zellulären Kontexten in 
vivo bedeutsam ist, bei denen disseminierte Zellen vorzufinden sind, wie zum 
Beispiel während der Neuralleistenmigration.
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Abbreviations 
  
°C Degree Celsius 
µ micro 
2D/3D 2/3 dimensional 
7-AAD 7-Aminoactinomycin D 
A Ampere 
Å Ångström 
AA Arachidonic acid 
ABDH5 1-acylglycerol-3-phosphate O-acyltransferase  
ACC-1 Acetyl-CoA Carboxylase 1  
ACSF2 Acyl-CoA synthetase family member 2 
ACSL4 Acyl-CoA synthetase long chain family member 4 
AdA Adrenic Acid 
AKR1C Aldo-Keto Reductase Family 1 Member 
AKT Protein kinase B 
AMPK AMP-activated protein kinase  
ANT adenine nucleotide translocase  
APS Ammonium peroxydisulphate  
Atg Autophagy-related gene 
ATGL Adipose triglyceride lipase 
ATGLi Atglistatin 
ATM ATM serine/threonine kinase 
ATP Adenosine triphosphate 
B+ CD10-positive basal cell 
BACE1 β-site amyloid precursor protein cleavage enzyme 1 
BL Burkitt’ Lymphoma  
BL1/2 Basal-like 1/2 
Blast Blastidicin 
bp Base pair 
BPE Bovine Pituitary Extract 
BRCA Breast Cancer, early onset 
BSA Bovine serum albumin 
BSL Biosafety level 
BSO L-buthionine sulfoximine 
BVR biliverdin reductase  
cAMP cyclic adenosine monophosphate  
CARS Cysteinyl-tRNA synthetase 
Cas CRISPR associated 
Casp3 Caspase 3 
CDH1 Cadherin 1 
cDNA complementary DNA 
CH Cumene hydroperoxide 
cm Centimeter 
CMA chaperone-mediated autophagy  
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CMV Cytomegalovirus 
CO2 carbon dioxide 
CoA Coenzyme A 
CoQ10 Coenzyme Q10 
CPT1A Carnitine Palmitoyltransferase 1A 
CPX Ciclopirox 
CRISPR Clustered regularly interspaced short palindromic repeats 
CS Citrate synthase 
Ct Cycle threshold 
CTC Circulating tumor cells 
CTG CellTiter-Glo 
Ctrl Control 
d days 
DAG Diacylglycerol 
DAPI 4′,6-diamidino-2-phenylindole 
DAVID Database for Annotation, Visualization and Integrated 
Discovery 
DCIS Ductal carcinoma in situ  
DDA Data dependent 
DFO Deferoxamine 
DGAT-1 Diacylglycerol acyltransferase1  
DLBCL Diffuse large B cell lymphoma  
DMEM Dulbecco's Modified Eagle Medium 
DMEM/F12 Dulbecco's Modified Eagle Medium F-12 Nutrient Mixture 
DMSO Dimethyl sulfoxide 
DMT1 Divalent metal transporter 1 
DNA Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP Deoxyribonucleotide 
Dox Doxycycline 
DOXO Doxorubicin 
DPYD dihydropyrimidine dehydrogenase  
DS Donkey serum 
dT Deoxythymine 
DTNB 5,5′-Dithiobis(2-nitrobenzoic acid) 
EB Elution buffer 
E-cad E-cadherin 
ECL Enhanced chemoluminescence 
ECM Extracellular matrix 
EDTA Ethylendiaminetetraacetic acid 
EGF Epidermal Growth Factor 
EMT Epithelial-Mesenchymal Transition 
ER Estrogen receptor 
ERA Erastin 
ERK Extracellular signal-regulated kinase 
ESR1 Estrogen receptor 1  
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ETC electron transport chain 
Ex Exon 
FA Fatty Acid 
FACS Fluorescent-activated cell sorting 
FAO fatty acid oxidation 
FASP Filter-aided sample preparation 
FCS Fetal calf serum 
FDR False discovery rate 
Fe2+ ferrous iron 
Fe3+ ferric iron 
Fer1 Ferrostatin-1 
FIN Ferroptosis-inducing agent 
FOXA1 Forkhead Box A1 
FBP1 Fructose-1,6-biphosphatase 
Fsk Forskolin 
FTH1 Ferritin heavy chain 1  
FTL Ferritin light chain  
fwd forward 
g Gram 
g Gravitational force 
GATA3 GATA Binding Protein 3 
GC Guanine-Cytosine 
GCL Glutamate-cysteine ligase  
GCLC Glutamate-cysteine ligase catalytic subunit 
gDNA genomic DNA 
GFP Green fluorescent protein 
GO-term Gene ontology term 
GPX4 Glutathione peroxidase 4 
gRNA guide RNA 
GSH Glutathione 
GSS Glutathione synthetase 
GSSG Glutathione disulfide 
h hours 
H+L Heavy and light chain 
HCC Hepatocellular carcinoma cell lines  
HCl hydrochloric acid 
HEPES N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
Her2/neu Human epidermal growth factor receptor 2 
HF high-fidelity 
hGX sPLA2 human group X secreted phospholipase  
hi high 
HMEC Human mammary epithelial cells 
HMLE Immortalized human mammary epithelial cells 
HMOX1/2 Heme oxygenase 1/2 
HPLC High-performance liquid chromatography 
HR Hormone receptor 
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HRP Horseradish peroxidase 
HSL Hormone-sensitive lipase 
hTERT Human telomerase reverse transcriptase 
HTwist1 HMLE-Twist1 
hU6 human U6 promoter  
i.e. id est: that is 
I/R Ischemia/reperfusion 
IBC Invasive breast cancer 
IC50 Inhibitory concentration 50 
ID Inner diameter 
IDC Invasive ductal carcinoma  
IgG Immunoglobulin G 
IREB2 Iron response element binding protein 2  
IRES Internal ribosomal entry site 
IU International enzyme unit 
kb Kilo base 
KCl Potassium chloride 
kDA Kilo Dalton 
KO Knockout 
KRT18 Keratin 18 
l liter 
LAA alkyne-modified linoleic acid  
LAR Luminal androgen receptor 
LB Lysogeny broth 
LD Lipid Droplet 
LDAH LD-associated hydrolase  
LIP Labile iron pool 
Lip1 Liproxstatin-1 
LKB1 Liver Kinase B1 
log2 Binary logarithm 
L-OOH Lipid hydroperoxides 
LOX Lipoxygenase 
LP Luminal progenitor 
LPCAT3 Lysophosphatidylcholine acyl-transferase 3  
M Molar 
m milli 
m/v mass/volume 
m/z mass-to-charge ratio 
MAGL Monoacylglycerol lipase 
MAPK mitogen-activated protein kinase  
MDA157 MDA-MB-157 
MDA231 MDA-MB-231 
MDA468 MDA-MB-468 
MECGM Mammary epithelial cell growth medium 
med intermediate 
MEF Mouse embryonic fibroblast 
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MEK Mitogen-Activated Protein Kinase Kinase 
MET Mesenchymal-Epithelial Transition 
Milli-Q Ultrapure water 
min Minutes 
miR-200 microRNA 200 family 
Mito Mitochondrial 
MOI Multiplicity of infection 
mRNA messenger RNA 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
mTOR Mammalian target of rapamycin 
n number 
n nano 
n.d. not detected 
n.s. not significant 
N20 20-nucleotide 
NaCl Sodium chloride 
NADPH reduced Nicotinamide adenine dinucleotide phosphate  
NaOH sodium hydroxide 
NCOA4 Nuclear receptor coactivator 4 
Nec1-S 7-Cl-O-Nec1 (Necrostatin1-S) 
nm Nanometer 
NP40 Nonidet P40 
NQO1 Quinone oxidoreductase-1  
NRF2 Nuclear factor erythroid 2-related factor 2 
NSCLC Non-small cell lung cancer 
nt nontargeting 
O2 Oxygen 
OA Oleic Acid 
OE Overexpression 
Oligo Oligonucleotide 
ON over night 
OXPHOS Oxidative phosphorylation 
p phospho 
p53 Tumor suppressor 53 
PARP Poly(ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PC PromoCell 
PCOOH Phosphatidylcholine hydroperoxide 
PCR Polymerase chain reaction 
pCR Pathologic complete response rate 
PE Phosphatidylethanolamine 
PEI Polyethleneimine 
Pen/Strep Penicillin/Streptomycin 
PFA Paraformaldehyde 
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PGC-1α Peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha  
PI Propidium Iodide 
PI3K phosphoinositide 3-kinase 
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic 
Subunit Alpha 
PKA Protein kinase A 
PLIN Perilipin 
PNPLA2 Patatin Like Phospholipase Domain Containing 2 (ATGL) 
PPAR peroxisome proliferator-activated receptor 
PR Progesterone receptor 
PTEN Phosphatase and tensin homolog 
PUFA Polyunsatured fatty acid 
Puro Puromycin 
PVDF Polyvinylidene fluoride 
PyMT Polyoma middle T antigen 
QE Q Exactive 
qPCR real-time semi-quantitative PCR 
RB Retinoblastoma 
rev reverse 
RFP Red fluorescent protein 
RIPA Radioimmunoprecipitation assay 
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1 Introduction 
1.1 Breast cancer  
1.1.1 Epidemiology 
The most frequently diagnosed cancer among women worldwide is breast cancer 
with an estimated number of almost 2.1 million new cases in 2018, accounting for 
approximately 25% of all cancers in women (Bray et al., 2018). Breast cancer is the 
main cause of cancer-related death in women, leading to about 0.7 million cases of 
death with higher relative mortality rates in less developed countries (Bray et al., 
2018). Lower mortality rates were linked to early diagnosis, for example by 
screening mammography, and the application of adjuvant treatment (Berry et al., 
2005; Richards et al., 1999). While localized breast cancer shows a 5-year survival 
rate of almost 100% (Noone et al., 2017), advanced disease and the presence of 
distant metastases decrease 5-year survival rates of women below 20% (Allemani 
et al., 2013). Therefore, it is very important to predict the progression of the disease 
and apply beneficial treatment.  
 
1.1.2 Heterogeneity in breast cancer 
1.1.2.1 Intertumor heterogeneity  
Breast cancer is a highly heterogeneous disease at the clinical, histopathological 
and molecular level (Zardavas et al., 2015). Main clinical parameters include age, 
axillary lymph node status, tumor size and histological grade, but also the 
expression status of histological markers such as estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) 
(Schnitt, 2010). The mammary gland is composed of a complex network of epithelial 
branching ducts arising from the nipple and terminating in alveoli which expand and 
produce milk during pregnancy. Thereby, luminal epithelial cells face the inner 
lumen of the ducts and alveoli while contractile myoepithelial, also termed basal 
cells, are located at an outer position next to the basement membrane. This network 
is embedded in stroma consisting of adipocytes, fibroblasts, endothelial cells and 
immune cells (Visvader, 2009). At the histopathological level, most breast cancers 
are divided either into in situ carcinoma, where cancer cells expand within the ducts 
or alveoli, or into invasive, infiltrating carcinoma, where cancer cells have broken 
through the basement and grown into the adjacent stroma. Invasive breast cancer 
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(IBC) accounts for 80% of diagnosed breast cancer (American Cancer Society, 
2017). The majority of invasive breast cancer arise within the ducts (73.4%) and 
only about 10% arise in the lobules (alveoli cluster) or show a mixed ductal/lobular 
phenotype (Noone et al., 2017). Another level of heterogeneity at the biological level 
is added by the classification into molecular subtypes. Global gene expression 
profiling of human breast cancer samples revealed five molecular intrinsic subtypes: 
luminal A, luminal B, normal breast-like, HER2-enriched and basal-like (Perou et al., 
2000; Sørlie et al., 2001, 2003). Luminal A and B breast cancer belong to the group 
of ER-positive cancer which account for approximately 80% of IBC and are 
characterized by the expression of a gene signature of luminal mammary epithelial 
cells like ESR1 (encoding for ER), GATA3, FOXA1 and KRT18 (American Cancer 
Society, 2017; Perou et al., 2000; Sørlie et al., 2001). However, a distinct 
proliferation signature signifying luminal B subtype, for example, high KI67 
expression, discriminates luminal A and B subtypes, directly relating to a poorer 
outcome of luminal B classified tumors (Hu et al., 2006; Perou et al., 1999; Sørlie et 
al., 2003). Both HER2-enriched and basal-like tumors display low expression of ER 
and ER-associated genes and are associated with poorer survival than luminal A 
tumors (Sørlie et al., 2001, 2003). The HER2-enriched subset is a rare group of IBC 
(5%) amplified in the HER2 locus and therein associated genes (American Cancer 
Society, 2017; Perou et al., 2000; Sørlie et al., 2001). A gene signature associated 
with basal epithelial cells like expression of cytokeratin 5 and 7 or laminin defines 
the basal-like subtype (Perou et al., 2000; Sørlie et al., 2001). The normal-breast 
like subtype showed a distinct gene expression pattern characterized by high 
expression of basal epithelial genes and genes associated with adipose tissue and 
non-epithelial cell types (Sørlie et al., 2001). Further, the claudin-low subtype as 
another molecular subtype was described for both human and murine breast cancer 
data sets characterized by low expression of tight junction proteins claudin 3,4 and 
7 as well as E-cadherin (E-cad), an important cell adhesion protein, but was 
enriched for the expression of mesenchymal and stem cell markers (Herschkowitz 
et al., 2007; Prat et al., 2010). Clinically, IBC lacking hormone receptor- (HR) and 
HER2-expression are grouped as triple-negative breast cancer (TNBC), occurring 
in approximately 12% of cases (American Cancer Society, 2017). At the molecular 
level, most TNBCs are classified as the basal-like subtype (70-80%) (Koboldt et al., 
2012; Sabatier et al., 2014). However, within the claudin-low subtype, about 50% of 
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tumors are also TNBC and have a poor prognosis similar to that of basal-like tumors 
(Sabatier et al., 2014). In general, apart from the molecular subtype, tumors 
classified as TNBC are more likely to be associated with a higher stage and risk for 
metastases, thus resulting in a worse prognosis and reduced overall survival 
compared to HR+ tumors (Lin et al., 2012). Within the clinical group of TNBC tumors, 
another study identified six different TNBC subtypes based on gene expression 
profiling that were refined into four different TNBC subtypes five years later showing 
distinct sensitivities to chemotherapy (Lehmann et al., 2016, 2011). Along these 
lines, further genomic and transcriptomic analyses of about 2000 breast cancer 
samples through the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) yielded ten different subtypes with distinct disease-free 
survival probabilities (Curtis et al., 2012), adding further complication to breast 
cancer classification and heterogeneity. In contrast, the Cancer Genome Atlas 
Network (TCGA) combined integrative information on primary breast cancer 
samples derived by different molecular techniques (genomic DNA copy number 
arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA 
sequencing and reverse-phase protein arrays) and thereby, portrayed four main 
breast cancer classes (Luminal A and B, HER2-enriched and Basal-Like) that were 
highly heterogeneous within each class. Importantly, while only a few genes such 
as TP53, PIK3CA or GATA3 were frequently mutated across all breast cancer 
patients (>10%), subtypes were enriched for these mutations. For example, PIK3CA 
is mutated in half of luminal A tumors and only in 7% of basal-like tumors which 
harbor a TP53 mutation at a high frequency (84%) in contrast to luminal A tumors 
(12%) (Koboldt et al., 2012). Together, these data indicate a tremendous intertumor 
heterogeneity of breast cancer linked to different treatment and prognostic outcome 
implying the need for precise patient stratification.  
 
1.1.2.2 Intratumor heterogeneity  
Tumors are not only heterogeneous between different patients, but can be also 
heterogeneous within one patient at a spatial and temporal level. Recent studies 
analyzing different areas at the genetic level in breast cancer samples identified 
several clonal cell lineages present within one tumor. Matched lymph node 
metastases showed further genomic variability (Ellsworth et al., 2015; Torres et al., 
2007). A more detailed study showed that clonal subpopulations could be located in 
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distinct areas or be intermixed within the tissue (Navin et al., 2010). Single-nucleus-
sequencing of 100 cells from one polygenomic TNBC suggested the emergence of 
three clonal expansions at an early stage with subsequent genetic variations. 
Thereby, intratumoral heterogeneity was illustrated by the presence of a KRAS-
amplified subpopulation intermixed with one without KRAS amplification at the same 
anatomical area (Navin et al., 2011). With regard to frequently mutated genes in 
breast cancer such as TP53 and PIK3CA, TNBCs showed a clonal dominance for 
these mutations, but low- and high clonal tumors with a diverse spectrum of 
mutations could exist as well (Shah et al., 2012). Further, the appearance of both 
ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) components in 
the same breast cancer tissue sections reflects heterogeneity at the phenotypic level 
(Wong et al., 2010). Compared to size-matched pure IDC, DCIS-IDC were 
associated with less metastatic potential and lower proliferation (Wong et al., 2010). 
Interestingly, studies analyzing synchronous DCIS-IDC showed that they share 
some genetic similarities, but the progression from DCIS to IDC can also select for 
clones. For instance, CDH1, the gene coding for E-cadherin, was most commonly 
lost, while, at the same time, MYC-amplified clones emerged (Hernandez et al., 
2012; Heselmeyer-Haddad et al., 2012). Temporal intratumoral heterogeneity can 
also arise as a consequence of innate tumor progression from primary to metastatic 
disease or due to therapeutic interventions. Therapy-naïve primary breast cancer 
and synchronous metastases shared 60% of somatic mutations, especially 
frequently mutated genes like TP53, PIK3CA and GATA3, but gained additional 
mutational burden, for example affecting genes related to the epithelial-
mesenchymal transition (EMT), a process implied in metastasis (Ng et al., 2017). 
Similarly, metastases detected 9 years after the removal of primary lobular breast 
cancer had acquired a significant amount of novel somatic coding mutations 
compared to the primary tumor while only some mutations, present in minor 
subclones of the primary tumor, were enriched in metastatic cells (Shah et al., 2009). 
Conclusively, intratumoral heterogeneity further complicates treatment since 
sensitivities towards therapeutic interventions might greatly differ between 
subclones and therefore, one general treatment regimen might not fit for the whole 
tumor. 
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1.2 Breast cancer treatment  
Currently, IBC is removed by surgery followed by radiation therapy. To reduce the 
risk of recurrence or if metastatic disease is present at diagnosis, chemotherapy, 
anti-hormone therapy and/or targeted therapy are applied at a systemic level 
(American Cancer Society, 2017). Both radiation and chemotherapy induce 
unspecific DNA damage like double-strand breaks or DNA crosslinks, which 
ultimately lead to cell death if they accumulate (Cheung-Ong et al., 2013; Lomax et 
al., 2013). In order to shrink the tumor prior to surgery, chemotherapy can be also 
applied in a neoadjuvant setting that does neither impact survival nor overall disease 
progression compared to surgery followed by adjuvant chemotherapy (Mauri et al., 
2005). Since HR+ breast cancer patients express ER, these patients are eligible to 
targeted adjuvant endocrine therapy, including tamoxifen and aromatase inhibitor 
treatment, which modulate estrogen receptor effects and estrogen levels (American 
Cancer Society, 2017). For example, 5-year adjuvant tamoxifen therapy was shown 
to reduce recurrence risk by about 40% within the first ten years and mortality risk 
by one third within 15 years (Abe et al., 2011). Further, patients with HER2-amplified 
breast cancer benefit from a HER2-targeted therapy using specific anti-HER2 
antibodies such as trastuzumab, thus inhibiting the highly proliferative and survival 
signaling induced by HER2 amplification (Ménard et al., 2003). Addition of 
trastuzumab to chemotherapy reduced the risk of recurrence and death for early-
stage as well as metastatic disease compared to adjuvant chemotherapy alone 
(Romond et al., 2005; Slamon et al., 2001). Since patients with TNBC lack 
expression of HR and HER2, therapy is mainly based on surgery, radiotherapy and 
chemotherapy (Wahba et al., 2015). Although pathologic complete response rates 
(pCR) to neoadjuvant chemotherapy are significantly higher in TNBC compared to 
non-TNBC (22% vs 11%) (Liedtke et al., 2008), TNBC generally display a more 
aggressive phenotype with a higher risk recurrence and reduced overall survival (Lin 
et al., 2012). However, if pCR is achieved, TNBC and non-TNBC patients have a 
similar prognosis irrespective of HR status (Guarneri et al., 2006; Liedtke et al., 
2008). Importantly, distant relapse after therapy is still associated with poor survival 
without any superior improvement over the last decades (Tevaarwerk et al., 2013). 
Likewise, only a small proportion of patients (3.1%) with metastatic breast cancer at 
diagnosis showed a complete response to chemotherapy for more than 5 years 
(Greenberg et al., 1996). Since chemotherapy induces adverse side effects such 
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nausea, fatigue and hair loss, but can also impact the quality of life by inducing long-
term effects such as cardiovascular toxicity or loss of fertility (Agrawal, 2014; Kayl 
and Meyers, 2006), recent studies aim to stratify patients to avoid over- or under-
treatment. For example, gene expression profiling was employed to predict the 
occurrence of metastasis in breast cancer based on a 70-gene prognosis profile, 
linking it to a decreased overall 10-year survival and providing a strategy to stratify 
patients for beneficial adjuvant therapy (van ’t Veer et al., 2002; van de Vijver et al., 
2002). Along these lines, another study, predicting prognosis using a 21-gene 
expression profile, emphasized that HR-positive, HER2-negative breast cancer 
patients with low risk of recurrence do not benefit from additional adjuvant 
chemotherapy, but endocrine treatment alone is sufficient (Sparano et al., 2015). 
Accordingly, dividing TNBC into molecular subtypes further enabled to evaluate the 
probability of achieving a pCR by neoadjuvant chemotherapy (Lehmann et al., 2016, 
2011). Exemplarily, TNBC belonging to the subgroup of basal-like 1 (BL1 and BL2) 
were shown to highly express genes involved in cell cycle and DNA damage 
response such as BRCA, therefore presenting a highly proliferative subtype which 
lost cell-cycle checkpoint control, but in turn increased DNA damage response. 
Accordingly, antimitotic chemotherapeutics such as paclitaxel and DNA-damaging 
agents such radiotherapy induced significantly higher pCR in TNBC patients with 
BL1 or BL2 subtypes than in a mesenchymal-like or luminal androgen receptor 
(LAR) TNBC subtype (Lehmann et al., 2011). In line with these data, chemical 
inhibition of poly(ADP-ribose) polymerase1 (PARP1), involved in DNA strand-break 
repair, specifically killed BRCA1-deficient tumors in mice (Rottenberg et al., 2008) 
and in combination with chemotherapy resulted in a better overall response rate and 
progression-free-survival compared to chemotherapy alone in a clinical trial with 
metastatic TNBC patients (O’Shaughnessy et al., 2009). Mutations in BRCA1 or 
BRCA2 have been linked to a higher risk of developing breast cancer (Easton et al., 
1995; Ford et al., 1998) and since BRCA1 and 2 are involved in DNA double-strand 
break repair and PARP is a key enzyme therein, additional PARP inhibition further 
damages DNA and thereby induces cell cycle arrest and apoptosis (Bryant et al., 
2005; Farmer et al., 2005). Although there are several compounds available for the 
treatment of breast cancer, targeted therapies, especially for TNBC, are still limited. 
Further, novel treatment strategies are urgently needed for recurrent breast cancer 
and metastatic disease since metastatic disease highly impacts survival. 
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1.3 Epithelial-Mesenchymal Transition is essential for developmental and 
pathological processes  
The Epithelial-Mesenchymal Transition (EMT) is a process by which epithelial cells 
are transdifferentiated in a mesenchymal cell state. Epithelial cells show a 
cobblestone-like morphology with an apicobasal polarity and tight cell-cell adhesion. 
When EMT is induced, epithelial cells downregulate proteins involved in cell-cell 
adhesions like E-cadherin, thereby loose detachment to each other. Subsequently, 
mesenchymal proteins like N-cadherin or fibronectin are upregulated accompanied 
by the acquisition of a single, spindle-shaped and front-to-back polarized cell 
morphology. Additionally, EMT-converted mesenchymal cells gain migratory 
abilities that enable the invasion through the adjacent extracellular matrix (ECM) 
(Hay, 1995; Yang and Weinberg, 2008). The process of EMT was first observed and 
described for cell movements in the primitive streak in chick embryos (Hay, 1968; 
Trelstad et al., 1967). During embryonic gastrulation, leading to the development of 
the three germ layers (ectoderm, mesoderm and endoderm), epithelial cells 
invaginate at the primitive streak in the primitive ectoderm. After the reorganization 
of cellular shape and cell organelles, cells detach from the primitive streak by locally 
breaking the basement membrane and then migrate underneath the primitive 
ectoderm to form the mesoderm (Yang and Weinberg, 2008). Apart from mesoderm 
formation, EMT processes and its reverse process, mesenchymal-epithelial 
transition (MET), are crucial for neural crest formation and the generation of tissues 
like the pancreas, reproductive tracts and the heart (Thiery et al., 2009). However, 
EMT can be reactivated in both physiological processes like tissue regeneration and 
wound healing or during pathological processes such as fibrosis, cancer progression 
and metastasis (Kalluri and Weinberg, 2009; Thiery et al., 2009).  
EMT programs enable epithelial cancer cells to detach from the primary tumor by 
loosening cell-cell adhesions and gaining the ability to break the basement 
membrane and invade into the adjacent stroma (Figure 1). Thereby, cancer cells 
obtain access to surrounding blood vessels which facilitate systemic dissemination. 
Extravasation at distant sites allows the formation of non-proliferating 
micrometastases which eventually grow out as detectable macrometastases 
(Scheel and Weinberg, 2012).  
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1.3.1 EMT in cancer progression and metastasis 
The process of EMT is mediated by a group of transcription factors like TWIST1, 
SNAI1/2 (Snail1/Slug), ZEB1/2, Goosecoid and FOXC2 that interact together to 
induce phenotypic, transcriptional and functional changes. Together, they induce 
the repression of epithelial and upregulation of mesenchymal genes (De Craene 
and Berx, 2013). Thereby, E-cadherin (CDH1), the main component of epithelial 
cell-cell adherens junctions, is transcriptionally repressed by direct binding of EMT-
TFs like Snail1, Slug, ZEB1 or ZEB2 to the CDH1 promotor (Batlle et al., 2000; Cano 
et al., 2000; Comijn et al., 2001; Hajra et al., 2002; Shirakihara et al., 2007). Other 
EMT-TFs like TWIST1 induce EMT without directly binding to the CDH1 promoter 
and instead mediate its repression through induction of other EMT-TFs such as Slug 
(Casas et al., 2011; De Craene and Berx, 2013). Further, epithelial dedifferentiation 
is accompanied by the downregulation of desmosomal junctions as well tight 
 
Figure 1: The metastatic cascade 
Early steps of metastasis are enabled by the Epithelial-Mesenchymal Transition (EMT). During 
EMT, epithelial cancer cells (blue) are converted to invasive, migratory mesenchymal cells (red 
cells) that are able to invade into the surrounding tissue (grey) and intravasate into blood 
circulation. Upon systemic dissemination and extravasation at distant sites (beige), cells reside 
in a non-proliferating cell state (Dormancy). The outgrowth of cancer cells as secondary tumors 
is thought to require the reversion back to an epithelial cell state by the Mesenchymal-Epithelial-
Transition (MET). Figure was adapted from (Scheel and Weinberg, 2012). 
Primary tumor 1. Invasion
2. Intravasation
3. Systemic 
dissemination
4. Extravastion
Secondary tumor
5. Dormancy
6. Colonization
EMT
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junctional proteins like claudins by EMT-TFs (Cano et al., 2000; Ikenouchi et al., 
2003; Martínez-Estrada et al., 2006; Moreno-Bueno et al., 2006; Vandewalle et al., 
2005). In turn, mesenchymal markers, for example vimentin, N-cadherin and 
fibronectin, are upregulated, along with a gain in single cell motility and invasive 
capabilities (Cano et al., 2000; Casas et al., 2011; Shirakihara et al., 2007; 
Vandewalle et al., 2005; Yang et al., 2004). In several mouse models, forced 
expression of EMT-TFs induced the dissemination and the appearance of metastatic 
cells (Casas et al., 2011; Mani et al., 2007; Moody et al., 2005; Yang et al., 2004). 
Further, EMT-TF expression was observed at the invasive front of primary tumors 
formed in xenograft experiments (von Burstin et al., 2009; Cano et al., 2000) 
Similarly, loss of E-cadherin was shown to induce metastasis (Onder et al., 2008; 
Wendt et al., 2011). Mechanistically, early studies suggested that EMT leads to 
tumorigenic potential by conferring stem-cell-like traits to cells. Thereby, 
mesenchymal immortalized mammary epithelial cells (HMLE) undergoing EMT by 
EMT-TF activation acquired a CD44high/CD24‒/low cell surface profile which was 
associated with tumor-initiating capacity both in vitro and in vivo (Mani et al., 2008; 
Morel et al., 2008). A prior study showed that as few as 100 CD44high/CD24‒/low cells 
isolated from metastases of breast cancer patients engrafted in immunodeficient 
and –compromised mice and could be serially passaged in mice while CD44+/CD24+ 
cells failed to do so (Al-Hajj et al., 2003). However, there is recent experimental 
evidence that for successful outgrowth as macroscopically visible metastases, the 
reversion of the mesenchymal to an epithelial phenotype by MET is required at the 
distant site (Celià-Terrassa et al., 2012; Ocaña et al., 2012; Schmidt et al., 2015; 
Tsai et al., 2012), contrasting the stemness hypothesis. These observations are in 
line with clinical data showing that both primary tumors, as well as metastases of 
IDC, express E-cadherin, although expression was often weaker in the primary 
tumor compared to metastases (Bukholm et al., 2000; Jeschke et al., 2007; Kowalski 
et al., 2003). A decrease in E-cadherin levels could be explained by the finding that 
CDH1 promotor hypermethylation is dynamically increased during malignant 
progression in primary ductal breast cancer (Graff et al., 2000; Nass et al., 2000; 
Shargh et al., 2014). However, there are also seemingly contradictory observations 
about EMT-TFs and EMT in patient samples. Another report associated Snail1 and 
Slug overexpression in primary breast cancer samples with lymph node metastasis, 
although Snail1 and Slug were shown to co-localize with E-cadherin-positive tumor 
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cells (Côme et al., 2006). Yet, in another study, nuclear Snail1 expression was linked 
to higher tumor grade, stage and size as well as lymph node metastasis. Further, 
high Snail1 expression correlated with basal-like subtypes and served as an 
independent prognostic factor for overall survival for luminal B and basal-like 
subtypes (Muenst et al., 2013). Along these lines, EMT marker genes were 
correlated with the basal-like subtypes of IBC (Sarrió et al., 2008), but were also 
shown to be enriched in claudin-low subtypes (Herschkowitz et al., 2007; Prat et al., 
2010; Taube et al., 2010). Interestingly, recent data suggest that dissemination does 
not necessarily require a full EMT, i.e. repression of E-cadherin. For instance, Twist1 
expression leads to disseminated mammary epithelial cells both in in vitro and in 
vivo without the repression of epithelial adherens junctions (Shamir et al., 2014). 
Similarly, circulating tumor cells (CTC) clusters are highly metastatic compared to 
single CTCs, whereby intracellular adhesion mediated by plakoglobin within these 
cluster is crucial for their metastatic ability (Aceto et al., 2014). These observations 
are in line with another report showing that cells of an oncogene-induced breast 
cancer mouse model (polyoma middle T antigen (PyMT) mice) spontaneously 
undergo EMT. However, both epithelial and mesenchymal cells have been shown 
to be equally able to form E-cadherin positive metastases, indicating a high plasticity 
of both cell states (Beerling et al., 2016).  
 
1.3.2  Roles of EMT-TF beyond EMT 
In a model of skin cancer, Twist1 expression was shown to be required for tumor 
initiation and p53-dependent apoptosis resistance, a programmed form of cell death, 
irrespective of E-cadherin repression. However, high levels of Twist1 were 
necessary for the malignant progression of benign tumors (Beck et al., 2015). 
Similarly, sequential Zeb1 induction following mutation of the tumor suppressor 
Retinoblastoma 1 (RB1) and tumor oncogene Ras were necessary to overcome 
oncogene-induced senescence and thus initiate tumor formation and progression of 
mouse embryonic fibroblasts (MEFs) in nude mice (Liu et al., 2013). In line with 
these data, comparable effects in overriding Ras-induced senescence by disrupting 
p53 and RB pathways were described for Twist1, which was shown to induce 
transformation and invasiveness in cooperation with Ras (Ansieau et al., 2008). 
These results were corroborated by another study showing cooperative effects 
between EMT-TFs like Zeb1 and Twist1 with Ras in malignant transformation of 
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mammary epithelial cells. Further, the combined expression of Twist1 and 
oncogenic Ras in murine luminal mammary epithelial cells induced claudin-low, 
basal breast tumors (Morel et al., 2012). Apart from the effects on overcoming 
cellular senescence, several reports suggest that EMT-TFs confer radio- and 
chemoresistance as well (Cheng et al., 2007; Kajita et al., 2004; Kurrey et al., 2009; 
Li et al., 2009; Vega et al., 2004). For instance, hyperactivation of the ATM 
serine/threonine kinase (ATM) and upregulated Zeb1 levels were observed in 
radioresistant breast cancer cells both in in vitro and in vivo. Thereby, ionizing 
radiation induces inducing single- and double-strand DNA break which activates 
ATM. ATM in turn was shown to stabilize Zeb1 which subsequently promotes 
homologous recombination-dependent DNA repair by interacting with downstream 
effectors of the DNA-damage response (Zhang et al., 2014). Resistance to 
chemotherapy which specifically targets actively proliferating cells, might be 
explained due to reduced proliferation of cells undergoing EMT (Mejlvang et al., 
2007; Schmidt et al., 2015; Vega et al., 2004). Accordingly, cancer cells deleted in 
Snail1 or Twist1 were more proliferative without any effects on invasiveness in an 
invasive pancreatic ductal adenocarcinoma mouse model. However, EMT-TF 
deletion induced increased sensitivity to gemcitabine chemotherapy and improved 
the overall survival of mice (Zheng et al., 2015b). Another study showed that lung 
metastases emerged from non-EMT cells that were targetable by 
cyclophosphamide treatment in a spontaneous breast cancer metastasis model. In 
contrast, chemotherapy-resistant recurrent metastases were generated by EMT-
induced breast cancer cells (Fischer et al., 2015). Likewise, an enrichment of a 
CD44high/CD24‒/low gene signature, linked to stem-cell-like traits and EMT, was 
connected with the claudin-low subtype. Similarly, enrichment of this stem-cell 
signature as well as an enrichment of EMT-associated genes was observed in 
residual cells of ER+ breast cancer surviving both endocrine treatment and 
chemotherapy (Creighton et al., 2009). High expression of EMT-TFs like Twist1 was 
further associated with reduced relapse-free survival (Grzegrzolka et al., 2015; Van 
Nes et al., 2012). Together, EMT-TF and thereby EMT might contribute to tumor 
progression and metastasis predominantly by driving therapy resistance and tumor 
recurrence. Therefore, employing and studying models for EMT might unravel novel 
treatment options for basal-like and claudin-low subtypes, but might also identify 
mechanisms to avoid recurrence or to treat recurrent breast cancer. 
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1.3.3 Redox regulation, metabolism and EMT 
To accomplish the process of EMT and acquire migratory and invasive properties, 
several studies suggest that profound changes at the metabolic level occur during 
EMT-TF activation and EMT. For instance, it was found that a set of high-grade 
carcinoma cell lines showing a mesenchymal gene signature were marked by high 
expression of 44 metabolic genes involved in several pathways like nucleotide, 
amino acid, lipid and redox metabolism. Genes of this “mesenchymal metabolic 
signature” were induced during Twist1-induced EMT in HMLE cells (Shaul et al., 
2014). Further, dihydropyrimidine dehydrogenase (DPYD), a pyrimidine-degrading 
enzyme, was shown to be required for EMT in vitro and for metastasis to the lungs 
in vivo, but did not generally impact cell viability or proliferation (Shaul et al., 2014). 
Another group reported that Snail1 leads to a metabolic switch to glycolysis through 
epigenetic silencing of fructose-1,6-biphosphatase (FBP1), an enzyme involved in 
gluconeogenesis. This process was shown to be involved in the development of 
basal-like breast cancer and associated with the maintenance of stem-cell-like traits 
by lowering reactive oxygen species (ROS), presumably generated by oxidative 
phosphorylation (OXPHOS) in the mitochondria (Dong et al., 2013). Accordingly, 
reducing the content of mitochondrial DNA generated an EMT-like phenotype 
characterized by the suppression of E-cadherin, upregulation of EMT-TFs and 
mesenchymal markers and a gain in migratory and invasive properties in human 
mammary epithelial cells and a breast cancer cell line (Guha et al., 2014). However, 
the impact of ROS and mitochondria on metastasis is not clear yet. For example, an 
increase in mitochondria and thus OXPHOS by higher expression of the peroxisome 
proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α) was implicated 
in promoting invasiveness and metastasis. Indeed, knockdown of PGC-1α inhibited 
invasive properties and metastasis but did not impact primary tumor growth or the 
process of EMT (LeBleu et al., 2014). Mitochondrial ROS, especially superoxide, 
generated during the electron transport chain (ETC) during OXPHOS, were 
implicated to be necessary for tumor cell migration, invasion and metastasis. 
Thereby, either overload of the ETC or partial ETC inhibition yielded higher 
mitochondrial superoxide levels (Porporato et al., 2014), possibly explaining the 
seemingly contradictory observations mentioned before. Further, oxidative stress 
was shown to be increased in metastatic cells. However, metastatic outgrowth was 
shown to require metabolic changes that limit oxidative stress at the distant site 
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(Piskounova et al., 2015). Interestingly, a recent report identified that loss of 
fumarate hydratase, an enzyme of the tricarboxylic cycle, led to the accumulation of 
fumarate which in turn induced EMT by epigenetic suppression of the miR-200 
microRNA family which targets the EMT-TF Zeb1 (Sciacovelli et al., 2016). 
However, fumarate accumulation was connected with increased oxidative stress, 
inducing cellular senescence in vitro and in vivo. Overcoming oxidative stress-
induced senescence initiated renal cancer (Zheng et al., 2015a), hinting to the 
possibility that EMT-TF activation and EMT might be a mechanism to promote 
tumorigenesis by bypassing premature oncogene-senescence as suggested earlier 
(Ansieau et al., 2008). Conclusively, these studies indicate some connections of 
EMT-TFs and EMT to metabolic pathways and ROS generation while the exact 
contribution to tumor initiation, progression and metastasis remain unresolved. 
 
1.4 Ferroptosis 
One of the hallmarks of cancer is the resistance to cell death. In 2011, Hanahan and 
Weinberg described the evasion of apoptosis as one of the important mechanisms 
for the malignant progression of cancer cells. Further, cancer cells obtain 
advantages for tumor progression by exploiting autophagy, the recycling of cell 
organelles in nutrient-limited conditions, or by switching necrotic cell death to a pro-
tumorigenic mode (Hanahan and Weinberg, 2011). Recently, another regulated cell-
death modality termed ferroptosis was revealed in specific cancer entities (Dixon et 
al., 2012; Lachaier et al., 2014; Miess et al., 2018; Yang et al., 2014), thus offering 
novel opportunities to tackle otherwise resistant cancer cells. The term ferroptosis 
was introduced in 2012 by Dixon and colleagues, describing an iron-dependent and 
lipid-mediated mode of cell death induced by the small molecule Erastin (ERA) 
(Dixon et al., 2012) (Figure 2). Two years later in 2014, glutathione peroxidase 4 
(GPX4) which removes lipid hydroperoxides (L-OOH), was shown to be a central 
regulator of ferroptosis. Consequently, inhibition of GPX4 by the small molecule 
(1S,3R)-RSL3 (RSL3) or genetic interference with GPX4 led to an aberrant 
accumulation of L-OOH in membrane phospholipids, ultimately resulting in 
ferroptosis (Yang et al., 2014) (Figure 2). 
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Figure 2: Overview of signaling pathways and regulators involved in ferroptosis 
Accumulation of high lipid peroxidation (-OOH) levels in phospholipids (PL), unless reduced by 
glutathione peroxidase 4 (GPX4) to the corresponding alcohol (-OH), results in ferroptosis. 
Ferroptosis is induced by direct inhibition of GPX4, i.e. by (1S,3R)-RSL3 or by depleting 
glutathione (GSH) upstream of GPX4 by inhibition of system xc‒, supplying cysteine for GSH 
synthesis, by Erastin, Glutamate, Sulfasalazine or Sorafenib or by inhibition of glutamate-
cysteine ligase (GCL) by buthionine sulfoximine (BSO). Reduction of cystine to cysteine is 
mediated by GSH or by thioredoxin reductase 1 (TXNRD1) and cysteine can be supplied by the 
transsulfuration pathway as well. Ferrous iron (Fe2+) via Fenton reaction and lipoxygenases 
(LOX) contribute to lipid peroxidation during ferroptosis and iron chelators like deferoxamine and 
ciclopirox and LOX-inhibitors are able to rescue ferroptosis. Iron levels are controlled by 
transferrin receptor-mediated import of iron and storage and release (ferritinophagy) of iron from 
ferritin. Susceptibility to ferroptosis is regulated by the amount of esterified polyunsaturated fatty 
acids (PUFAs) into PLs or specifically in phosphatidylethanolamines (PEs) by PUFA-related-
enzymes like lysophosphatidylcholine acyl-transferase 3 (LPCAT3) and acyl-CoA synthetase 
long-chain family member 4 (ACSL4). Inhibition of ACSL4 by thiazolidinediones (TZN) and 
likewise the inhibition of lipid peroxidation by lipophilic antioxidants like Ferrostatin-1, 
Liproxstatin-1 and α-tocopherol protects from ferroptosis. GSS: glutathione synthetase. Figure 
was adapted from (Conrad et al., 2016; Stockwell et al., 2017) with modifications.  
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Initially, ERA and RSL3 were identified through genetic screens to selectively kill 
tumorigenic fibroblast expressing Small T oncoprotein and oncogenic HRASG12V 
without affecting their normal counterparts (Dolma et al., 2003; Yang and Stockwell, 
2008). These early studies already ruled out caspase activation and thus apoptosis  
as cell-death modality, but showed an involvement of iron and lipid reactive oxygen 
species (ROS) by the ability of rescuing the cell death with deferoxamine (DFO), an 
iron chelator, and vitamin E, a lipophilic antioxidant (Dolma et al., 2003; Yagoda et 
al., 2007; Yang and Stockwell, 2008). Since then, several molecular mechanisms 
such as the enrichment of oxidation-prone polyunsaturated fatty acids (PUFA) within 
cellular membranes by the enzyme acyl-CoA synthetase long-chain family member 
4 (ACSL4) and biomarkers like NADPH levels as a predictor for ferroptosis 
sensitivity were identified (Doll et al., 2017; Shimada et al., 2016a). However, in 
contrast to apoptosis, ferroptosis has not yet been linked to normal physiological 
function (Stockwell et al., 2017). Thus far, mechanistic insights were predominantly 
achieved by inducing ferroptosis in cancer cells or by studying the role of ferroptosis 
in other pathological conditions such as ischemia/reperfusion (I/R) injury in liver, 
heart and kidney (Friedmann Angeli et al., 2014; Gao et al., 2015; Jiang et al., 2015; 
Linkermann et al., 2014; Yang et al., 2014). Therefore, current research aims to 
further describe and define biological contexts and signaling pathways involved in 
ferroptosis.  
 
1.4.1 Molecular mechanisms involved in ferroptosis 
1.4.1.1 Thiol and Glutathione metabolism 
Ferroptosis is triggered when GPX4 function is impaired and consequently, a deadly 
threshold of L-OOH is exceeded (Stockwell et al., 2017). Almost four decades ago, 
GPX4 was isolated from pig liver and shown to reduce phospholipid hydroperoxides 
to the corresponding alcohols in presence of glutathione (GSH) (Ursini et al., 1982, 
1985). During this reaction, two molecules of GSH are oxidized to glutathione 
disulfide (GSSG), highlighting the importance of GSH for maintaining GPX4 function 
(Brigelius-Flohé and Maiorino, 2013). In the context of ferroptosis, the system xc− 
plays an important role to supply cysteine for GSH biosynthesis and was identified 
to modulate GPX4 function (Friedmann Angeli et al., 2014; Yang et al., 2014). The 
system xc− is an antiporter consisting of a light chain xCT and a heavy chain 4F2hc 
which imports one molecule cystine (oxidized form of two molecules cysteine 
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connected via a disulfide bridge) in exchange for glutamate (Bannai, 1986; Sato et 
al., 1999). Imported cystine is readily reduced to cysteine by GSH or thioredoxin 
reductase 1 (TXNRD1) (Bannai, 1986; Mandal et al., 2010). Thereby, cysteine 
availability directly controls GSH biosynthesis (Ishii et al., 1987). The rate-limiting 
reaction catalyzed by the glutamate-cysteine ligase (GCL) yields γ-glutamylcysteine 
and addition of glycine by glutathione synthetase (GSS) forms GSH in a second 
reaction (Bannai and Tateishi, 1986). Thereby, compounds initiating ferroptosis 
through GSH depletion were classified as class I ferroptosis-inducing agents (FINs) 
(Yang et al., 2014). ERA, glutamate, sulfasalazine and sorafenib deplete GSH 
indirectly by targeting the system xc− while buthionine sulfoximine (BSO) inhibits 
GCL, the rate-limiting enzyme for GSH synthesis (Dixon et al., 2012, 2014; Seiler et 
al., 2008; Yang et al., 2014). A recent study showed that knockdown of CARS, a 
cysteinyl-tRNA synthetase, protects from ERA-induced ferroptosis by supplying 
cysteine from methionine via the transsulfuration pathway (Hayano et al., 2016), 
thus reflecting a mechanism to bypass dependence on system xc−. Interestingly, 
sensitivity to ERA-induced ferroptosis is also regulated by the tumor suppressor p53 
which represses xCT (SLC7A11) expression, thereby reducing cysteine availability 
and conferring tumor suppressive activities (Jiang et al., 2015). However, murine 
p53 with four mutated acetylation sites was unable to transcriptionally repress 
SLC7A11 in tumor cells, resulting in resistance to ERA-induced ferroptosis and 
entailing important implications for tumor progression (Wang et al., 2016). In 
contrast to Class I FINs, Class II FINs directly impair GPX4 function. This can be 
achieved by covalent GPX4 inhibitors such as RSL3 or by GPX4-degrading 
compounds such as FIN56 (Shimada et al., 2016b; Yang et al., 2014).  
 
1.4.1.2 Lipid-related metabolism 
Downstream of the direct or indirect impairment of GPX4 function results in the 
accumulation of lipid peroxidation, leading to ferroptosis (Dixon et al., 2012; Yang et 
al., 2014). However, there is still uncertainty about the precise mechanism of how 
and where lipid peroxidation is initiated and how exactly it induces cell death (Yang 
and Stockwell, 2016). For sure, lipid peroxidation is a critical event in ferroptosis 
since its prevention by administration of lipophilic antioxidants such as α-tocopherol 
(α-toc), ferrostatins like ferrostatin-1 (Fer1) and liproxstatin-1 (Lip1) rescue 
ferroptosis induced by chemical compounds or genetic knockout of GPX4 (Dixon et 
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al., 2012; Friedmann Angeli et al., 2014; Seiler et al., 2008; Skouta et al., 2014; 
Yang et al., 2014). In this context, recent studies highlight the importance of 
polyunsaturated fatty acids (PUFA) metabolism and oxidation in ferroptosis 
execution (Doll et al., 2017; Kagan et al., 2017). For example, a haploid screen 
identified the involvement of two PUFA metabolism-linked enzymes, namely ACSL4 
and lysophosphatidylcholine acyl-transferase 3 (LPCAT3), in RSL3- and ML162-
induced ferroptosis, but not in ERA-induced ferroptosis (Dixon et al., 2015). ACSL4 
activates preferentially arachidonic acid (AA) or other long-chain fatty acids (FAs) 
by ligating them with free coenzyme A, thus generating acyl-CoAs (Van Horn et al., 
2005; Soupene and Kuypers, 2008). In turn, LPCAT3 re-esterifies these acyl-CoAs 
into membrane phospholipids (Shindou and Shimizu, 2009). ACSL4 but not LPCAT3 
expression was further established as a critical player in ferroptosis sensitivity in 
MEFs as well as in a panel of breast cancer cell lines (Doll et al., 2017). 
Mechanistically, ACSL4 yields long chain acyl-CoAs containing AA or adrenic acid 
(AdA) that are enriched in phosphatidylethanolamines (PE) which presents a 
specific class of phospholipids. Ferroptosis induction occurs through oxidation of 
these AA- or AdA-containing PEs, thus serving as an execution signal (Doll et al., 
2017; Kagan et al., 2017). Genetic deletion or pharmacological inhibition of ACSL4 
by thiazolidinediones conferred increased resistance to ferroptosis in vitro and 
delayed mortality in a ferroptosis mouse model in vivo (Doll et al., 2017). Enzymes 
such as lipoxygenases (LOX) are implicated in inducing these lipid peroxidation 
death signals in ferroptosis (Kagan et al., 2017; Seiler et al., 2008; Yang et al., 2016). 
LOX enzymes dioxygenate PUFAs like AA and linoleic acid at different positions to 
the corresponding hydroperoxide which in turn serve as bioactive lipid mediators or 
impact diverse biological processes (Kuhn et al., 2015). Blocking LOX activity by 
small molecules such as PD146176 or BWA4C was shown to protect from 
ferroptosis in vitro (Friedmann Angeli et al., 2014; Yang et al., 2016). Knockdown of 
all LOX enzymes using a pool of siRNAs or knockdown of specific LOX enzymes 
such as ALOX15B and ALOXE3 rescued the fibrosarcoma cell line HT1080 from 
ERA-induced ferroptosis (Yang et al., 2016). Likewise, genetic deletion of a specific 
LOX (ALOX15) induced resistance to BSO-induced ferroptosis in vitro (Seiler et al., 
2008). However, ALOX15 knockout (KO) did not rescue from ferroptosis-induced-
acute renal failure and mortality in a tamoxifen (TAM)-inducible GPX4-KO mouse 
model. Further, knockdown of ALOX5, which could possibly compensate for 
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ALOX15-KO, did not protect these ALOX15/GPX4-double KO cells from ferroptosis 
in vitro (Friedmann Angeli et al., 2014). Together, the role of LOX enzymes in 
ferroptosis remains obscure and further research is required to establish the exact 
source of death signals. Since supplementation of cells with AA or other PUFAs was 
shown to elicit ferroptosis sensitivity (Yang et al., 2016), the oxidation of PUFA-
containing lipids by whatever means seems to be indeed a hallmark in ferroptosis. 
This notion is further supported by the finding that several aldo-keto reductase 
members of the AKR1C family, which detoxify reactive aldehyde species occurring 
as end-products during lipid peroxidation, are highly overexpressed in ERA-selected 
resistant DU-145 prostate cancer cell clones (Dixon et al., 2014). However, it still 
has to be elucidated to what extent these pathways downstream of lipid peroxidation 
depend on cellular context and the means of ferroptosis-induction.  
 
1.4.1.3 Iron-related metabolism 
Earlier studies suggested iron-dependence in ferroptosis (Dixon et al., 2012; Yang 
and Stockwell, 2008). This was determined by rescue experiments with iron 
chelators such as deferoxamine and the observation that ferroptosis sensitive cell 
lines had higher iron levels, ultimately impacting the terminology of ferroptosis 
(Dixon et al., 2012; Yang and Stockwell, 2008). However, the mechanistic role of 
iron in ferroptosis remains obscure (Doll and Conrad, 2017). In a model of oncogenic 
Ras-expressing fibroblasts, ferroptosis-sensitive cells showed higher expression of 
transferrin receptor 1 (TFR1), leading to increased iron uptake into cells, while iron 
storage-related genes such as ferritin heavy chain 1 (FTH1) and ferritin light chain 
(FTL) were downregulated compared to the parental cells (Yang and Stockwell, 
2008). 30% of circulating ferric iron (Fe3+) is bound to transferrin (TF) and this 
complex is internalized via endocytosis upon binding to TFR1. Acidification of the 
early endosome induces the release of iron from TF and a subsequent reduction to 
ferrous iron (Fe2+) by the six-transmembrane epithelial antigen of prostate protein 
family (STEAP). This is followed by the transport into the cytosol via DMT1 (divalent 
metal transporter 1). Fe2+ contributes to the labile iron pool (LIP) in the cytosol which 
is used for storage as Fe3+ bound to ferritin, exported as Fe3+ via Ferroportin (FPN) 
or for metabolic pathways, for example in heme or iron-sulfur cluster-containing 
enzymes (Muckenthaler et al., 2017). In accordance with earlier findings, a recent 
study demonstrated that TF-bound iron import is required for ferroptosis induction in 
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amino acid-starved MEFs (Gao et al., 2015). Likewise, the release of iron from 
ferritin involved an autophagic/lysosomal process termed ferritinophagy and was 
shown to contribute to ERA- and RSL3-induced ferroptosis in N-Ras mutated 
HT1080 cells (Torii et al., 2016). Additionally, expression of the heme oxygenase 1 
(HMOX1) was implicated in ERA-mediated ferroptosis sensitivity of HT1080 cells 
(Kwon et al., 2015). HMOX1 releases iron by the degradation of heme or heme-
containing proteins (Poss and Tonegawa, 1997a). Accordingly, silencing the iron 
response element binding protein 2 (IREB2), a master regulator of iron metabolism, 
resulted in resistance to ERA- or sorafenib-induced ferroptosis in different cancer 
cell lines (Dixon et al., 2012; Louandre et al., 2013). An explanation of how iron 
contributes to ferroptosis might be the initiation of lipid peroxidation by the Fenton 
reaction, further supported by the ability of iron chelators to bind the redox active 
LIP (Cao and Dixon, 2016). The reaction of Fe2+ of the LIB with hydrogen peroxide 
results in the generation of Fe3+ and a highly reactive hydroxyl radical (OH•) which 
in turn initiates a damaging oxidation cascade in lipids, but also in proteins and DNA 
(Doll and Conrad, 2017; Torii et al., 2016). Another explanation why iron chelation 
rescues from ferroptosis might be the inhibition of iron-containing enzymes. For 
instance, LOX enzymes contain iron in their active site that can be chelated by DFO, 
thereby inhibiting their activity (Abeysinghe et al., 1996; Barradas et al., 1989).  
 
1.4.1.4 Additional pathways regulating ferroptosis 
Several other pathways were shown to regulate ferroptosis sensitivity. For instance, 
L-glutamine was shown to induce ferroptosis in amino-acid-deprived MEFs via the 
process of glutaminolysis (Gao et al., 2015). Glutamine is converted to glutamate by 
glutaminases and subsequently to a-ketoglutarate which is used in the tricarboxylic 
acid cycle for diverse metabolic pathways such as mitochondrial respiration, fatty 
acid synthesis or NADPH production (Yang et al., 2017). Inhibition of glutaminases 
by Compound 968 also ameliorated ferroptosis-induced I/R injury in an ex vivo heart 
model (Gao et al., 2015). Along these lines, genes involved in mitochondrial fatty 
acid metabolism like acyl-CoA synthetase family member 2 (ACSF2) and citrate 
synthase (CS), which partly depend on glutaminolysis, were shown to be required 
for ferroptosis induction by ERA (Dixon et al., 2012). Interestingly, the amount of 
NADPH, which is an important reductant within cells, was established as a 
biomarker for ferroptosis sensitivity in a large panel of cancer cell lines. Thereby, 
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high levels of NADPH correlated with resistance to FINs (Shimada et al., 2016a). 
Another study showed that increasing cellular coenzyme Q10 (CoQ10) concentrations 
inhibit ERA-, RSL3- and FIN56-induced ferroptosis in HT1080 cells which is most 
likely independent from the mitochondrial function of CoQ10 (Shimada et al., 2016b). 
CoQ10 is important for mitochondrial respiration as an electron carrier and further 
has antioxidant activity. Production of CoQ10 occurs within the mevalonate pathway 
which is inhibited by Statins (Deichmann et al., 2010). Likewise, treatment with 
Statins elicits ferroptosis-sensitivity, possibly by reducing CoQ10 levels and reduced 
GPX4 abundance (Shimada et al., 2016b; Viswanathan et al., 2017). Biosynthesis 
of selenoproteins like GPX4 is controlled by a selenocysteine tRNA (tRNA (Sec)) 
that requires isopentenylation for proper function. Inhibition of the mevalonate 
pathway by Statins was shown to impair tRNA(sec) maturation and therefore 
selenoprotein synthesis (Kryukov et al., 2003; Warner et al., 2000). The presence 
of oncogenic Ras was described to induce a selective susceptibility to FINs and 
employing MEK inhibitors, thereby disrupting Ras signaling, rescued cell death 
(Dixon et al., 2012; Dolma et al., 2003; Yang and Stockwell, 2008; Yang et al., 2014). 
However, an association between RAS mutational status and ferroptosis sensitivity 
was not observed when analyzing 117 cancer cell lines (Yang et al., 2014). Further, 
sensitivity to sorafenib- and ERA-induced ferroptosis is not dictated by common 
tumor mutations like RAS, RAF, PIK3CA and TP53 in a panel of cancer cell lines 
(Lachaier et al., 2014). For hepatocellular carcinoma cell lines (HCC), the nuclear 
factor erythroid 2-related factor 2 (NRF2) was shown to preserve ferroptosis 
protection (Sun et al., 2016). NRF2 is a master regulator in inducing the transcription 
of a variety of genes all involved in the cellular response against oxidative damage 
(Jaramillo and Zhang, 2013). Knockdown of downstream targets of NRF2 such as 
quinone oxidoreductase-1 (NQO1), FTH1 or HMOX1 increased ferroptosis 
sensitivity in HCC cells in vitro and knockdown of NRF2 augmented ferroptosis 
induction by ERA and sorafenib in vivo, leading to smaller tumors formed by Hepa1-
6 cells compared to the control group (Sun et al., 2016). This is in contrast to the 
finding that the presence of HMOX1 increases ferroptosis-sensitivity to ERA 
treatment in HT1080 cells (Kwon et al., 2015), indicating that the cellular signaling 
context strongly influences ferroptosis sensitivity, and single genes and proteins 
might differently contribute therein. 
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1.4.2 Relevance of ferroptosis for human diseases 
Since ferroptosis was not yet directly linked to a normal physiological function, the 
relevance of ferroptosis for human diseases comes mainly from in vitro and in vivo 
studies in mouse models (Stockwell et al., 2017). Systemic deletion of GPX4 results 
in an embryonic lethal phenotype during gastrulation stage (Imai et al., 2003; Yant 
et al., 2003), highlighting that GPX4 function is indeed necessary for embryonic 
development. Further, numerous studies observed an important role of GPX4 in 
neuronal development and homeostasis. Conditional knockout of GPX4 leads to 
neurodegeneration in the cerebral cortex and hippocampus (Seiler et al., 2008; 
Wirth et al., 2010, 2014; Yoo et al., 2012). Along these lines, a reduction of GPX4 
levels, thereby increasing lipid peroxidation, were implicated in mouse models of the 
neurodegenerative disease Alzheimer’s (Chen et al., 2008; Yoo et al., 2010). 
Mechanistically, higher lipid peroxidation levels might lead to upregulation of the β-
site amyloid precursor protein cleavage enzyme 1 (BACE1) which is required for the 
generation of β-amyloid plaques, a fundamental cause in Alzheimer’s disease (Chen 
et al., 2008). Likewise, Parkinson’s disease was associated with a regulation of 
GPX4 levels and increased ferroptosis in dopaminergic neurons (Bellinger et al., 
2011; Do Van et al., 2016). In vitro, reprogramming of astrocytes into neurons was 
shown to be accompanied by increased lipid peroxidation induced by the switch from 
glycolytic to oxidative energy metabolism. Reducing these levels by the ferroptosis 
inhibitor Lip1 or the lipophilic antioxidant α-toc ameliorated reprogramming into 
neurons (Gascón et al., 2016). Additionally, ferroptosis inhibitors such as Fer1 and 
Lip1 alleviated injuries in mouse models induced by I/R of the liver, heart, brain and 
kidney, indicating that ferroptosis contributes in I/R injuries as a harmful mechanism 
(Dixon et al., 2012; Friedmann Angeli et al., 2014; Gao et al., 2015; Linkermann et 
al., 2014; Skouta et al., 2014; Tuo et al., 2017). Accordingly, GPX4 was shown to 
be essential for hepatocellular survival and function. Thus, diminishing GPX4-KO-
induced lipid peroxidation by α-toc supplementation counteracted GPX4-mediated 
hepatocyte loss (Carlson et al., 2016). Interestingly, GPX4 activity is also critical for 
hair follicle morphogenesis in the skin (Sengupta et al., 2013), for the maturation of 
photoreceptor cells (Ueta et al., 2012) and for the expansion of T-cells in the 
periphery in response to acute infections (Matsushita et al., 2015). Possible 
ferroptosis-sensitive tumor entities might be diffuse large B cell lymphoma (DLBCL) 
and renal cell carcinomas (RCCs), assessed by in vitro sensitivity towards ERA-
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induced ferroptosis in the NCI-60 cell line panel (Yang et al., 2014). In experiments 
using tumor xenografts, ferroptosis induction reduced tumor growth and led to cell 
death induction (Jiang et al., 2015; Sun et al., 2016; Yang et al., 2014). In contrast, 
TAM-inducible GPX4-ablated fibroblasts, transformed with c-Myc and HRas 
oncogenes, were able to generate subcutaneous tumors similar to GPX4 wildtype 
(WT) cells while survival was highly impacted in 2D cultures in vitro (Schneider et 
al., 2010). Together, these studies show an important role of GPX4 and ferroptosis 
for development as well for pathological conditions. Especially when it comes to 
neoplastic diseases such as cancer, further research is necessary to describe and 
understand the conditions conferring sensitivity or resistance to ferroptosis. 
 
1.5 Aim of the study 
Breast cancer is a frequently diagnosed cancer among women, leading to the 
highest mortality rate across all cancer entities in women (Bray et al., 2018). 
Particularly, the presence of metastatic disease drastically decreases 5-year 
survival to less than 30% (Noone et al., 2017). Currently, treatment options for 
metastatic disease are limited, especially for the subset of TNBC (Zeichner et al., 
2016). EMT-TF and the process of EMT were linked to tumor progression and 
metastasis. Additionally, EMT was shown to induce resistance to therapeutic 
interventions and thus cancer recurrence (Ansieau et al., 2014; Nieto et al., 2016). 
As recent reports suggested a connection between EMT and metabolic rewiring, 
including redox regulation and lipid metabolism (Dong et al., 2013; Sciacovelli and 
Frezza, 2017; Shaul et al., 2014), I hypothesized that ferroptosis might be employed 
as a potential cell death mechanism to target otherwise resistant cells, i.e. induced 
by EMT. Ferroptosis was identified as a novel iron-dependent cell death mechanism, 
involving the lethal accumulation of lipid peroxidation. Mechanistically, ferroptosis is 
distinct to known other cell death modalities like apoptosis or necrosis and relies on 
the proper function of GPX4 which reduces lipid peroxides within membranes. 
Several cancer entities like diffuse large B cell lymphoma and renal cell carcinomas 
were shown to be particularly sensitive to ferroptosis (Dixon et al., 2012; Yang et al., 
2014). Several genetic and metabolic contributors involved in ferroptosis and 
predicting ferroptosis sensitivity and resistance were identified. However, there are 
still many open questions about the determinants of ferroptosis, especially when it 
comes to different cellular contexts. Therefore, I aimed to study ferroptosis in human 
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mammary epithelial cells and to elucidate whether EMT-induction by TWIST1 
expression, leading to mesenchymal transdifferentiation, impacts ferroptosis 
susceptibility. Throughout the study, I established cell density as a critical 
determinant of ferroptosis sensitivity in human mammary epithelial cells. Therefore, 
I extended the aim to determine the molecular mechanisms underlying cell density-
dependent ferroptosis in human mammary epithelial cells. 
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2 Materials 
2.1 Cell lines 
HMLE (Immortalized human mammary epithelial cells): Primary mammary 
epithelial cells were transduced with retroviruses containing the SV40 large T early 
region, leading to inactivation of the tumor suppressor proteins p53 and RB as well 
as Protein Phosphatase 2, thus driving progression through cell cycle. Additionally, 
they were transduced retrovirally with the telomerase catalytic subunit of the hTERT 
gene, which is sufficient to induce telomerase activity (Elenbaas et al., 2001). HMLE 
cells are neither tumorigenic nor express the estrogen receptor (Ince et al., 2007). 
Cells were kindly provided by Robert A. Weinberg (Massachusetts Institute of 
Technology, USA). 
 
HMLE-Twist1: HMLE cells were transduced with a pBabe-Puro-Twist1 vector, 
thereby leading to constitutive overexpression of TWIST1 and thus induction of an 
EMT (Mani et al., 2008; Yang et al., 2004a). Cells were kindly provided by Robert 
A. Weinberg (Massachusetts Institute of Technology, USA). 
 
HMLE-Ras: HMLE cells were transduced with a pBabe-Puro-Ras (V12H) retroviral 
vector, leading to the overexpression of a constitutively active form of HRAS 
(Elenbaas et al., 2001). Cells were kindly provided by Robert A. Weinberg 
(Massachusetts Institute of Technology, USA). 
 
HMLE-neuNT: HMLE cells were transduced with a pWZL vector containing a 
mutated, constitutively active form of the HER2/neu oncogene (Mani et al., 2008). 
Cells were kindly provided by Robert A. Weinberg (Massachusetts Institute of 
Technology, USA). 
 
HMLE-Twist1-Ras: HMLE-Twist1 cells were transduced with a pWZL retroviral 
vector containing V12H-RAS oncogene, leading to the overexpression of a 
constitutively active form of hRas (Mani et al., 2008). Cells were kindly provided by 
Robert A. Weinberg (Massachusetts Institute of Technology, USA). 
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HMLE-Twist1-ER: HMLE cells were transduced with a pWZL-Blast-Twist1-ER 
vector and are cultured in growth medium containing 10 µg/ml blasticidin, leading to 
the constitutive overexpression of an inducible TWIST1 protein. For this purpose, 
Twist1 was fused to a mutated estrogen ligand binding-domain that keeps Twist1 
inactive unless 4-hydroxytamoxifen is added (Casas et al., 2011; Mani et al., 2008). 
Cells were kindly provided by Robert A. Weinberg (Massachusetts Institute of 
Technology, USA). The CD44+/CD24high population, termed HMLE-Twist1-ER 24hi, 
was derived by FACS-sorting and was kindly provided by Dr. Johanna Schmidt 
(Schmidt et al., 2015). 
 
HMLE-Snail1-ER: HMLE cells were transduced with a pWZL-Blast-Snail1-ER 
vector, resulting in the overexpression of a 4-hydroxytamoxifen inducible Snail1 
protein (see also HMLE-Twist1-ER) (Mani et al., 2008). Cells were kindly provided 
by Robert A. Weinberg (Massachusetts Institute of Technology, USA). The 
CD44+/CD24high population, termed HMLE-Snail1-ER 24hi, was derived by FACS-
sorting and was generated during my master thesis (Schmidt et al., 2015). 
 
Breast cancer cell line panel: MCF7 (ATCC® HTB-22™), T-47D (ATCC® HTB-
133™), MDA-MB-468 (ATCC® HTB-132), MDA-MB-231 and MDA-MB-157 (both 
from panel ATCC® TCP-1002™) cell lines were purchased from ATCC. 
 
HEK293T: Human embryonic kidney cells containing the SV40 T-antigen that were 
employed for production of lentivirus and were purchased from ATCC (CRL-3216™) 
(DuBridge et al., 1987; Pear et al., 1993). 
 
HMLE-Twist1-ER 24hi_PTEN_wt and HMLE-Twist1-ER 24hi_PTEN_KO clones: 
Single-cell clones were derived from HMLE-Twist1-ER 24hi expressing wildtype (wt) 
PTEN or containing homozygous PTEN-deletions (Knockout, KO) generated by 
CRISPR/Cas9 genome-editing. For this purpose, cells were transduced with 
lentiviruses containing a doxycycline-inducible Cas9 protein (pCW-Cas9, Addgene 
#50661) and with the pLX-sgRNA vector (Addgene#50662) containing the sgRNA 
PTEN target sequence TGTGCATATTTATTACATCG. Cells were kindly generated 
and provided by Hilary M. Ganz (Mammary Stem Cells, Institute of Stem Cell 
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Research, Helmholtz Center Munich) according to published protocols (Wang et al., 
2014). 
 
2.2 Primary mammary epithelial cells 
Primary mammary epithelial cells were kindly provided by Lisa Meixner (Mammary 
Stem Cells, Institute of Stem Cell Research, Helmholtz Center Munich), who 
isolated, processed and banked these cells from reduction mammoplasties 
according to a published protocol (Stingl et al., 2005) with modifications (Linnemann 
et al., 2015) and in accordance with the regulations of the ethics committee of the 
Ludwig-Maximilians-University Munich (ethics vote EK397-12). Luminal progenitor 
(LP) and basal B+ subpopulations were sorted and provided by Lisa Meixner as 
described (Linnemann et al., 2015). 
Donors used in this study: M16, M19 and M29 
 
2.3 Cell culture media and solutions 
Product Supplier (Catalog No) 
Dulbecco's Modified Eagle Medium 
(DMEM) 
Gibco®, Life Technologies™; Thermo 
Fisher Scientific (41965-039) 
Dulbecco’s Modified Eagle Medium F-12 
Nutrient Mixture (DMEM/F12) 
Gibco®, Life Technologies™; Thermo 
Fisher Scientific (11320-074) 
fetal calf serum (FCS) PAN-Biotech (30-2602) 
Mammary Epithelial Cell Growth Medium 
(MECGM) including Mammary Epithelial 
Cell Growth Medium SupplementPack: 
0.004 ml/ml Bovine Pituitary Extract (BPE) 
10 ng/ml Epidermal Growth Factor (EGF, 
recombinant human) 
5 µg/ml Insulin (recombinant human) 
0.5 µg/ml Hydrocortisone  
PromoCell (C-21010, C-39115) 
Penicillin/Streptomycin (10,000 U/ml) Gibco®, Life Technologies™; Thermo 
Fisher Scientific (15140122) 
Trypsin-EDTA 0.05%, 0.25% Gibco®, Life Technologies™; Thermo 
Fisher Scientific (25300, 25200) 
Trypsin Neutralizing Solution (TNS) PromoCell (C-41120) 
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2.4 Reagents and chemicals 
Reagent Supplier (Catalog No) 
1,7-Dichloro-octamethyltetrasiloxane Santa Cruz (sc-229834) 
1S,3R-RSL3 Cayman Chemicals (Cay19288) 
2-Mercaptoethanol Sigma (63689) 
2-Propanol Roth (9866) 
5,5′-Dithiobis(2-nitrobenzoic acid) Sigma (D8130) 
7-Cl-O-Nec1 Abcam (ab221984) 
α-tocopherol Sigma (258024) 
β-Nicotinamide adenine dinucleotide 2′-phosphate 
reduced tetrasodium salt hydrate (NADPH) 
Sigma (N1630) 
Acetic acid (glacial) Th.Geyer (2234) 
Agarose, universal, peqGOLD VWR (35-1020) 
Albumin Fraction V (BSA) Roth (8076) 
Aluminum potassium sulfate Sigma (A-7167) 
Ammonium peroxydisulphate (APS) Roth (9592) 
Ampicillin sodium salt Roth (K029) 
Ampicillin sodium salt Serva Electrophoresis (13399) 
Aqua-Poly/Mount  Polysciences (18606) 
Atglistatin Sigma (SML1075) 
Blasticidin S HCl (10 mg/ml) Gibco®, Life Technologies™; 
Thermo Fisher Scientific 
(A1113903) 
Bromophenol Blue Sigma (B0126) 
Buffer P1 (500 ml) Qiagen (19051) 
Buffer P2 (500 ml) Qiagen (19052) 
Buffer P3 (500 ml) Qiagen (19053) 
BW A4C Sigma (B7559) 
Carmine Sigma (C-1022) 
Ciclopirox Sigma (SML2011) 
CHAPS hydrate Sigma (C9426) 
cOmplete™ Protease Inhibitor Cocktail Sigma (11697498) 
Collagen type I rat tail Corning (354236) 
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Reagent Supplier (Catalog No) 
DAPI Sigma (D9542) 
Deferoxamine Sigma (D9533) 
Deoxynucleotide (dNTP) Solution Mix NEB (N0447) 
Dimethyl sulfoxide (DMSO) Sigma (D8418) 
Doxorubicin hydrochloride Sigma (D1515) 
Doxycycline Hydrochloride (Dox) Sigma (D3072) 
Erastin Sigma (E7781) 
Ethanol Merck (100983)  
Ethylenediaminetetraacetic acid (EDTA) Roth (X986) 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid 
Sigma (O3778) 
Etomoxir Sigma (E1905) 
Ferrostatin-1 Sigma (SML0583) 
Forskolin Biomol (AG-CN2-0089) 
Gelatin, powdered Applichem (147116) 
Gel Loading Dye, Orange (6X) New England Biolabs (B7022S) 
Glycerol Roth (3783) 
Glycine Roth (3790) 
Hoechst 33342 Solution (20 mM) Thermo Fisher Scientific (62249) 
Hydrochloric acid 32% (HCl) Merck (100319) 
Inactive stereoisomer of RSL3 Kind gift of Dr. Marcus Conrad 
Kanamycin sulfate Sigma (60615) 
LB Broth (Lennox) Roth (X964) 
LB Broth with agar (Lennox)  Sigma (L2897) 
L-α-Phosphatidylcholine Sigma (P7443) 
L-Glutathione (reduced) (GSH) Sigma (G6013) 
Linoleic Acid Sigma (L1012) 
Liproxstatin-1 Sigma (SML1414) 
Methanol Roth (4627) 
Mirus TransIT-X2® dynamic delivery system Mirus Bio LLC (MIR 6003) 
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Reagent Supplier (Catalog No) 
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic 
acid, 1M HEPES 
Gibco®, Life Technologies™; 
Thermo Fisher Scientific (15630) 
n-heptane Applichem (1948) 
non-fat dried milk powder Roth (T145) 
Normal donor donkey serum GeneTex (GTX73205) 
Normal goat serum GeneTex (GTX73206) 
Nonidet® P40 (NP40) Applichem (A1694) 
Oleic Acid-Albumin from bovine serum (OA) Sigma (O3008) 
PageRuler™ Plus protein ladder Thermo Fisher Scientific (26619) 
Paraformaldehyde 16% (w/v) (PFA) VWR International (43368.9M) 
PD 146176 Sigma (P4620) 
Phosphate Buffered Saline (PBS) pH 7.4 Gibco®, Life Technologies™; 
Thermo Fisher Scientific (10010-
015) 
Phosphatase Inhibitor Cocktail 2 Sigma (P5726) 
Phosphatase Inhibitor Cocktail 3 Sigma (P0044) 
Polyethyleneimine (PEI), linear Alfa Aesar (43896) 
Potassium chloride (KCl) Sigma (4504) 
Potassium phosphate dibasic (K2HPO4) Sigma (P3786) 
Potassium phosphate monobasic (KH2PO4) Sigma (P5655) 
Protease Inhibitor Cocktail Sigma (P8340) 
Puromycin Dihydrochloride Gibco®, Life Technologies™; 
Thermo Fisher Scientific 
(A1113803) 
Rosiglitazone Sigma (R2408) 
Rotiphorese® Gel 30 Roth (3029) 
S.O.C. Medium Invitrogen™, Thermo Fisher 
Scientific (15544034) 
Sodium chloride (NaCl) Roth (P029) 
Sodium Deoxycholate Applichem (A1531) 
Sodium dodecyl sulfate (SDS) Roth (4360) 
Sodium hydroxide  Merck (30620-M) 
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Reagent Supplier (Catalog No) 
Sucrose   Sigma (16104) 
SYBR™ Safe DNA Gel Stain Invitrogen™, Thermo Fisher 
Scientific (S33102) 
TE Buffer Invitrogen™, Thermo Fisher 
Scientific (12090015) 
TEMED Roth (2367) 
Thymol Sigma (T0501) 
TransIT-X2® Transfection Reagent Mirus Bio LLC (MIR 6003) 
Trichloroacetic acid (TCA) Sigma (T6399) 
TriDye™ 1 kb Plus DNA Ladder New England Biolabs (N3270S) 
Triton X-100 Sigma (T8787) 
Tris (Trizma base) Sigma (T1503) 
TWEEN® 20 Sigma (P1379) 
UltraPure™ DNase/RNase-Free Distilled Water  Thermo Fisher Scientific 
(10977035) 
Water (sterile-filtered) Sigma (W3500) 
Y-27632 Biomol (AG-CR1-3564) 
(Z)-4-Hydroxytamoxifen Sigma (H7904) 
z-VAD-fmk R&D Systems (FMK001) 
 
2.5 Flow cytometry dyes 
Dye Supplier (Catalog No) 
Laser 
(nm) 
Filter 
(nm) 
7-Amino-Actinomycin D 
(7-AAD) 
BD (559925) 488 695/40  
BODIPY™ 493/503 Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (D3922) 
488 530/30I 
BODIPY® 581/591 C11 Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (D3861) 
488 530/30I 
CellROX™ Deep Red for 
oxidative stress 
Molecular Probes®, Life 
Technologies™, Thermo 
640 660/20 
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Dye Supplier (Catalog No) 
Laser 
(nm) 
Filter 
(nm) 
detection/Flow Cytometry 
Assay Kit 
Fisher Scientific (C10422, 
C10491) 
MitoSOX™ Red 
Mitochondrial Superoxide 
Indicator 
Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (M36008) 
561 586/15 
Propidium Iodide (PI) Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (P3566) 
561 610/20 
SYTOX® Blue Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (S34857) 
405 450/40 
ThiolTracker™ Violet 
(glutathione detection 
reagent) 
Molecular Probes®, Life 
Technologies™, Thermo 
Fisher Scientific (T10096) 
405 530/30II 
 
2.6 Antibodies 
2.6.1 Primary Antibodies 
Epitope [Clone] Host Supplier (Catalog No) 
Application, 
Dilution 
ACSL4 [A5] Mouse Santa-Cruz (sc-271800) WB, 1:100 
ATGL Rabbit Cell Signaling Technology 
(2138) 
WB, 1:1000 
beta-actin (AC-15) Mouse Abcam (ab6276) WB, 1:6000 
Caspase 3 Rabbit Cell Signaling Technology 
(9662) 
WB, 1:1000 
cleaved Caspase 3 
Asp175 (5A1E) 
Rabbit Cell Signaling Technology 
(9664) 
WB, 1:1000 
E-cadherin 
(EP700Y) 
Rabbit GeneTex (GTX61329) WB, 1:25000 
E-cadherin (HECD-
1) 
Mouse Thermo Fisher Scientific 
(13-1700) 
Inhibition Assay,  
1 µg/ml 
ERK1/2 (137F5) Rabbit Cell Signaling Technology 
(4695) 
WB, 1:1000 
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Epitope [Clone] Host Supplier (Catalog No) 
Application, 
Dilution 
GPX4 
(EPNCIR144) 
Rabbit Abcam (ab125066) WB, 1:2000 
HMOX1 
(EPR1390Y) 
Rabbit Abcam (ab68477) WB, 1:10000 
Ki67 Rabbit Abcam (ab15580) IF, 1:300 
pan Akt (C67E7) Rabbit Cell Signaling Technology 
(4691) 
WB, 1:1000 
PARP Rabbit Cell Signalling Technology 
(9542) 
WB, 1:1000 
phospho-Akt 
Ser473 (D9E) 
Rabbit Cell Signalling Technology 
(4060) 
WB, 1:2000 
phospho-ERK1/2 
Thr202/Tyr204 
(D13.14.4E) 
Rabbit Cell Signaling Technology 
(4370) 
WB, 1:2000 
Vimentin (V9) Mouse Abnova (MAB3578) IF, 1:100 
Zeb1 Rabbit Sigma (HPA027524) WB, 1:5000 
 
2.6.2 Secondary Antibodies 
Host Epitope Conjugation 
Supplier 
(Catalog No) 
Application, 
Dilution 
Donkey Mouse IgG Alexa Fluor 488 Thermo Fisher 
Scientific (A21202) 
IF, 1:250 
Donkey Rabbit IgG Alexa Fluor 546 Thermo Fisher 
Scientific (A10040) 
IF, 1:250 
Goat Mouse IgG (H+L) HRP-conjugated Jackson 
ImmunoResearch 
(115-036-062) 
WB, 1:12500 
Goat Rabbit IgG (H+L) HRP-conjugated Jackson 
ImmunoResearch 
(111-036-045) 
WB, 1:12500 
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2.7 Oligonucleotides 
Oligonucleotides used as primers and templates for PCR reactions and for 
sequencing were purchased from Eurofins. Sequences of oligonucleotides are listed 
in the respective sections of the methods. 
 
2.8 Mixtures and Kits 
Kit Supplier (Catalog No.) 
Amersham™ ECL™ Prime Western Blotting 
Reagent 
GE Healthcare (RPN2232) 
CellTiter-Glo® Luminescent Cell Viability Assay Promega (G7572) 
Click-iT™ Lipid Peroxidation Imaging Kit - Alexa 
Fluor™ 488 
Thermo Fisher Scientific (C10446) 
DNA Clean & Concentrator™-5 Zymo Research (D4014) 
DC™ Protein Assay Bio-Rad Laboratories (5000112) 
Hemacolor® Rapid Staining Merck (111661) 
Mix2Seq Kit Eurofins (3094-000MSK) 
Monarch® DNA Gel Extraction Kit New England Biolabs (T1020) 
QIAGEN Plasmid Midi Kit Qiagen (12143) 
RNase-Free DNase Set Qiagen (79254) 
RNeasy Mini Kit Qiagen (74106) 
 
2.9 Enzymes 
Enzyme/Enzyme Mix Supplier (Catalog No.) 
AgeI-HF New England Biolabs (3552S) 
BamHI-HF New England Biolabs (R3136S) 
DpnI, recombinant New England Biolabs (R0176) 
Gibson Assembly® Master Mix New England Biolabs (E2611) 
Glutathione Reductase Sigma (G3664) 
MluI-HF New England Biolabs (R3198S) 
NotI-HF New England Biolabs (R3189S) 
OneScript® Plus cDNA Synthesis Kit Applied Biological Materials (G236) 
Phusion® High-Fidelity DNA Polymerase New England Biolabs (M0530) 
Power SYBR™ Green PCR Master Mix Applied Biosystems (4367659) 
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Enzyme/Enzyme Mix Supplier (Catalog No.) 
Q5® High-Fidelity DNA Polymerase New England Biolabs (M0491) 
RNase A (17,500 U) Qiagen (19101) 
RNase A (10 mg/ml) Thermo Fisher Scientific (EN0531) 
T4 DNA Ligase New England Biolabs (M0202S) 
Taq DNA Polymerase with ThermoPol® Buffer New England Biolabs (M0267) 
PvuI-HF New England Biolabs (R3150S) 
SalI New England Biolabs (R0138S) 
XbaI New England Biolabs (R0145S) 
XhoI New England Biolabs (R0146S) 
 
2.10 Bacterial Strains 
Bacterial Strain Manufacturer 
XL10-Gold Ultracompetent Cells Agilent Technologies (200314) 
MAX Efficiency™ Stbl2™ Competent Cells Invitrogen™, Thermo Fisher Scientific 
(10268019) 
 
2.11 Plasmids 
Plasmid Description Source 
StagR_Neo Backbone vector for StagR cloning, 
Ampicillin resistance 
Kindly provided by 
Christopher Breunig 
and Stefan Stricker 
(Addgene #102992) 
(Breunig et al., 2018) 
STAGR_gRNAScaffold
_hU6 
template for StagR cloning to 
generate StagR fragments, 
Kanamycin resistance 
kindly provided by 
Christopher Breunig 
and Stefan Stricker 
(Addgene #102840) 
(Breunig et al., 2018) 
pSpCas9(BB)-2A-GFP 
(PX458) 
Transfectable Cas9 expression 
plasmid fused to 2A-GFP as a 
selection marker. There is the 
possibility to directly clone and 
Gift from Christopher 
Breunig and Stefan 
Stricker (Addgene 
#48138) (Breunig et 
al., 2018) 
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Plasmid Description Source 
express a sgRNA, Ampicillin 
resistance 
pGIPZ GPX4 
targeting shRNAs 
V2LHS_228172 (sh#1) 
V3LHS_310275 (sh#2) 
V3LHS_332098 (sh#3) 
V3LHS_332100 (sh#4) 
Lentiviral vector expressing 
turboGFP and connected through 
an IRES element puromycin. In 
addition, single shRNA against 
GPX4 are expressed, Ampicillin 
resistance 
Dharmacon 
(RHS4531-EG2879) 
pTRIPZ nontargeting 
shRNA control 
Lentiviral expression vector where 
turboRFP and shRNA expression 
is driven by a tetracycline-inducible 
promoter, Ampicillin resistance 
Dharmacon 
(RHS4743) 
pLVX-puro vector Lentiviral expression vector, 
Ampicillin resistance 
Clontech Laboratories 
(632164) 
pCMV-VSV-G Plasmid expressing VSV-G 
envelope protein necessary for 
retro- or lentiviral particle 
assembly, Ampicillin resistance 
Kindly provided by 
Robert A. Weinberg 
(Addgene #8454) 
pCMV-dR8.2 dvpr 2nd generation lentiviral packaging 
plasmid, Ampicillin resistance 
Kindly provided by 
Robert A. Weinberg 
(Addgene #8455) 
 
2.12 Consumables 
Product Supplier 
15mL Conical Centrifuge Tubes Corning 
25 Culture-Inserts 2 Well for self-insertion Ibidi 
384 PCR Plates Kisker Biotech 
6-, 12-, 24-, 96-well plates (Falcon) Becton Dickinson 
Falcon® Permeable Support for 24 well plates, 8 µm pore 
(Inserts) 
Corning 
Cell culture flasks (T75, T175) Greiner Bio-One  
Cell Scraper lila, UltraCruz® Cell Lifter Santa Cruz 
Cell Strainer Snap 40µM Corning 
Cover Glasses, 13 mm, round VWR International 
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Product Supplier 
Falcon Round-Bottom Polypropylene Tubes Corning  
KOVA™ Glasstic™ Slide 10 with Grids Kova International  
Micro cover glasses 22 mm x 40 mm VWR International 
Microlite 1+ Plate white flat bottom Fisher Scientific 
Microscopy slides, cut edges, matt strip Thermo Fisher Scientific 
Millex 33mm Durapore PVDF 0.22 µm Merck 
Millex 33mm Durapore PVDF 0.45µm Merck 
Mr. Frosty™ Freezing Container Thermo Fisher Scientific 
Nitril® NextGen® Gloves Meditrade  
Nunc® CryoTubes®  Thermo Fisher Scientific  
Nunc™ Cell Culture Dishes (6-cm, 15-cm) Thermo Fisher Scientific 
PCR Tubes, 0.5 mL, PCR clean Eppendorf 
Petri dish, polystyrene (for Agar plates) Greiner Bio-One  
Pipette tips (filtered) Starlab 
Pipette tips (unfiltered) Starlab 
Protein LoBind Tubes, 1.5 ml Eppendorf 
PVDF blotting membrane GE Healthcare 
QIAshredder Qiagen 
Reagent reservoirs  Corning 
Rotilabo® Blotting papers, thick 1.5 mm, 580x600 mm Roth 
Safe-Lock Tubes 1.5ml PCRclean Eppendorf 
Safe-Lock Tubes 2.0ml Eppendorf 
Scalpels VWR International 
Sterile Serological Pipets (2, 5, 10, 25, 50 ml) Greiner Bio-One  
TC-flask T175 Sarstedt 
TC-treated Cell Culture Dish (10-cm) Corning  
Test Tube with Cell Strainer Snap Cap (FACS tube) Corning 
TUBE, 50 ML, PP Greiner Bio-One  
Ultra - Clear - Film for RT - PCR Kisker Biotech 
X960 PCR TUBE STRIPS EPPENDORF 8 TUBES Eppendorf 
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2.13 Instruments 
Instrument Manufacturer 
2D Rocker IKA® 
Blue light table, LED transilluminator Serva Electrophoresis 
ChemiDoc™ MP Imaging System  Bio-Rad Laboratories 
Eppendorf Mastercycler® nexus gradient Eppendorf AG 
FACSAria IIIu Becton Dickinson 
FLUOVIEW FV1200 inverted Confocal Laser Scanning 
Microscope 
Olympus 
HERAcell® 240i incubator Thermo Fisher Scientific  
Heraeus™ Fresco™ 21 Thermo Fisher Scientific  
Heraeus™ Megafuge™ 40R centrifuge Thermo Fisher Scientific  
Heraeus™ Pico™ 21 Thermo Fisher Scientific  
Horizontal Roller CAT 
iMark Microplate Absorbance Reader Bio-Rad Laboratories 
Leica DFC 450 C camera module Leica Microsystems 
Leica DM IL LED microscope Leica Microsystems 
Luminometer Centro XS3 LB 960 Berthold Technologies 
Mini-PROTEAN® Tetra System Bio-Rad Laboratories 
NanoDrop® ND 1000 Spectrophotometer Thermo Fisher Scientific  
Orbital Multi Bio 3D Shaker Biosan 
PerfectBlue™ gel system Peqlab 
PowerPac™ HC Bio-Rad Laboratories 
QuantStudio™ 12K Flex qPCR System Applied Biosystems™, 
Thermo Fisher Scientific 
Safe 2020 Class II Biological Safety Cabinet Thermo Fisher Scientific 
SteREO Lumar V.12 Carl Zeiss Microscopy 
ThermoMixer® C 1.5 ml Eppendorf 
Zeiss Axio Imager M.2 with Colibri 7 Carl Zeiss Microscopy 
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2.14 Software 
Product Manufacturer 
FACS Diva™ v6.1.3 Becton Dickinson 
FlowJo® 10.5.0 FlowJo, LLC 
FV10-ASW software Ver 4.2.b Olympus 
GIMP 2.8.22 The GIMP Team 
GraphPad Prism 7 GraphPad Software 
Hugin (2018.0.0.5abfb4de7961) GPL, Free Software Foundation 
Image Composite Editor 2.0.3.0 Microsoft Corporation 
Image Lab 5.2.1 Bio-Rad Laboratories 
ImageJ 1.52 NIH 
Leica Application Suite 4.2 Leica Microsystems 
MikroWin, v4.41 Mikrotek Laborsysteme GmbH 
MS Office 2016 Microsoft Corporation 
QuantStudio™ 12K Flex Real-Time PCR 
System 1.2.2 
Applied Biosystems™, Thermo Fisher 
Scientific 
ZEN pro 2.3 Carl Zeiss Microscopy 
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3 Methods 
3.1 Cultivation of cells 
Cell culture and cell culture-related experiments were performed in a sterile safety 
cabinet. For maintenance, cells (see Section 2.1) were cultured in 6- or 10-cm 
diameter cell culture dishes in a 37°C HERAcell 240i incubator with a humidified 
atmosphere of 5% CO2 at ambient oxygen levels (20% O2). Primary cells (see 
Section 2.2) were maintained at 3% O2, mimicking physiological tissue pressure 
(normoxia). Composition of media employed for maintenance culture is shown in 
Table 1. Cells were grown until they reached 70-80% confluence. For passaging, 
media was aspirated from dishes, cells were washed with PBS and then 0.15% 
Trypsin-EDTA was applied to cells with subsequent incubation for 10 min at 37°C. 
After visually confirming detachment of cells, the trypsinization process was stopped 
using 3 volumes of TNS. The cell suspension was transferred to 15 ml falcon tubes 
and pelleted by centrifugation at 490 x g in a Heraeus Megafuge for 5 minutes at 
4°C. The supernatant was aspirated, cells suspended in their respective growth 
medium and transferred to plates at 1:4-1:10 dilutions. 
HMLE-Twist1-ER and HMLE-Snail1-ER cells were kept in growth medium 
containing blasticidin (Blast-maintenance medium, Table 1). For activation of the 
respective EMT-TF, growth medium containing tamoxifen was applied (usually for 
15 days, EMT-induction medium, Table 1). After thawing or sorting primary 
mammary epithelial cells into subpopulations, cells were plated in survival medium 
for five days in 2D culture for establishment prior to changing medium to primary cell 
maintenance medium and subsequent experimental usage such as seeding into cell 
viability assays (Linnemann et al., 2015).  
 
Table 1: Composition of cell culture media for cells used in this study 
Name Composition Cell line 
Standard PC-
medium 
MECGM (0.004 ml/ml BPE, 10 
ng/ml EGF, 5 µg/ml Insulin, 0.5 
µg/ml Hydrocortisone), 1% 
Pen/Strep 
HMLE, HMLE-Twist1, HMLE-
Ras, HMLE-Twist1-Ras, 
HMLE-neuNT 
Blast-maintenance 
medium 
Standard PC-medium, 10 µg/ml 
blasticidin 
HMLE-Twist1-ER, HMLE-
Snail1-ER and derivatives 
(sorted populations, PTEN-KO 
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Name Composition Cell line 
and PTEN-WT single cell 
clones)  
EMT-Induction 
medium 
Standard PC-medium, 10 µg/ml 
Blasticidin, 20 nM 4-
hydroxytamoxifen 
HMLE-Twist1-ER, HMLE-
Snail1-ER and derivatives 
(sorted populations, PTEN-KO 
and PTEN-WT single cell 
clones) during EMT-induction 
GPX4-KO 
maintenance 
medium 
Standard PC-medium, 1 µM 
Liproxstatin 
GPX4-KO and GPX4-WT 
single cell clones of HMLE 
and HMLE-Twist1 cells 
Puromycin-
selection medium 
Standard PC-medium, 1 µg/ml 
puromycin 
HMLE-derivatives transduced 
with pLVX-puro or pTRIPZ-
vectors 
shRNA-induction 
medium 
Standard PC-medium, 1 µg/ml 
puromycin, 0.5 µg/ml doxycycline 
HMLE-derivatives transduced 
with pTRIPZ-vectors 
Standard DMEM DMEM, 10% FCS, 1% 1% 
Pen/Strep 
HEK293T 
Standard 
DMEM/F12 
DMEM/F12, 10% FCS, 1% 
Pen/Strep 
MCF7, T-47D, MDA-MB-468, 
MDA-MB-231, MDA-MB-157 
Survival Medium Standard PC-medium, 0.5% 
FCS, 10 µM Forskolin, 3 µM Y-
27632 
Primary mammary epithelial 
cells for first 5 days of initial 
seeding (after thawing and 
sorts in 2D and 3D) 
Primary cell 
maintenance 
Medium 
Standard PC-medium, 10 µM 
Forskolin 
Primary mammary epithelial 
cells after 5 days of initial 
seeding 
 
3.2 Cell Counting  
For experiments that required specific cell numbers, a 10 µl aliquot of cell 
suspension was pipetted into the grid chamber of a KOVA Glasstic Slide and live 
cells of three large grids, discriminated based on morphology and intracellular 
granularity, were counted using a 10x objective on a Leica DM IL Led light 
microscope. The number of cells per ml was determined by counting three aliquots 
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of cell suspension, averaging the counted three large grids within each aliquot and 
then averaging the means of the three aliquots multiplied by 104.  
 
3.3 Freezing and thawing of cells 
After centrifugation of the desired amount of passaged cells, cells were resuspended 
in ice-cold Freezing Medium, 1 ml cell suspension per cryotube was added on ice 
and cooled to -80°C in ice-cold freezing containers. For long-term storage, cells 
were transferred to liquid nitrogen. For re-cultivation, cells were quickly thawed in a 
37°C water bath, transferred to 3 ml cell culture medium and centrifuged. After 
aspirating the supernatant, cells were resuspended in medium and plated in 6-cm 
dishes. The next day, the medium was refreshed in order to remove dead cells and 
cells were cultivated as described. 
 
Freezing Medium: 50% FCS, 40% respective cell culture medium, 10% DMSO 
  
3.4 3D-culture in collagen gels 
To model growth in a physiological environment, cells were grown in a 3D-
environment in a collagen-based matrix (3D collagen gels). 3D collagen gels were 
prepared and cultured as previously described with some minor modifications 
(Linnemann et al., 2015). 24-well plates were coated for 30 sec with a siloxane 
coating solution and rinsed three times with PBS and once with sterile Milli-Q water. 
After trypsinization, cells were filtered through a 40 µm cell strainer to remove cell 
clumps. The desired number of cells in growth medium was mixed with neutralizing 
solution (one-tenth of the volume of collagen I) and collagen I at a final concentration 
of 1.3 mg/ml. 400 µl of this mixture was pipetted per well into siloxane-pre-coated 
24-well plates and allowed to polymerize for 1h at 37°C. 500 µl medium and if 
necessary, 100 µl 10x concentrated supplements were carefully added to the 
solidified collagen gels to reach a final concentration of 1x of the respective 
supplements (total volume of gel and medium 1 ml). Detachment of 3D collagen 
gels was achieved by surrounding the gel with a pipet tip prior to carefully shaking 
the plate. For each experimental condition, three to four collagen gels were 
prepared. For primary cells, 5000 primary bulk cells or sorted luminal progenitor (LP) 
or basal B+ were seeded in 3D collagen gels and survival medium (see Table 1) 
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was added for five days before starting any treatment in primary cell maintenance 
medium. Seeding of primary cells into 3D collagen gels was kindly performed by 
Lisa Meixner (Mammary Stem Cells, Institute of Stem Cell Research, Helmholtz-
Center Munich). For GPX4-knockdown cells, 500 cells were seeded per gel in 
Standard PC-medium containing DMSO as solvent control or in sh-RNA induction 
medium containing 0.5 µg/ml doxycycline (Dox). For GPX4-knockout cells, 675, 225 
and 75 cells were seeded per gel in Standard PC-medium (−Lip1) or supplemented 
with 500 nM Lip1 (+Lip1) and after three days, all gels were washed twice with PBS. 
For the +/−Lip1 condition, supplementation with 500 nM Lip1 was removed from the 
Standard PC-medium. For 3D-collagen gels, treatment medium was replaced every 
2-3 days and cells were cultured for 8-12 days. Pictures of single colonies grown in 
3D collagen gels were taken on a Leica DM IL Led microscope using 5- to 10-fold 
magnification. 
 
Siloxane coating solution: n-heptane, 25 g/l 1,7-Dichlorooctamethyltetrasiloxane 
Neutralizing Solution: 500 mM HEPES in 11x PBS 
 
3.5 Cell density experiments 
For initial cell density experiments, cells were seeded in 96-well plates at a cell 
density of 3000 (high, hi), 1000 (intermediate, med) and 333 (low) cells. For cell 
density experiments in other well sizes and in dishes, if not otherwise stated, the 
number of cells to be seeded in a particular format [a] at a high, intermediate or low 
cell density was calculated using the following equation:  
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑜 𝑏𝑒 𝑠𝑒𝑒𝑑𝑒𝑑 𝑖𝑛 [𝑎] =
𝐺𝑟𝑜𝑤𝑡ℎ 𝑎𝑟𝑒𝑎 [𝑎]
𝐺𝑟𝑜𝑤𝑡ℎ 𝑎𝑟𝑒𝑎 [96−𝑤𝑒𝑙𝑙]
× 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 [96 − 𝑤𝑒𝑙𝑙]  
 
Table 2 shows the cell culture format with respective growth areas and the 
calculated seeding number (rounded), using 3000 seeded cells (high cell density) in 
a 96-well as reference cell number. 
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Table 2: Overview of calculated cell densities depending on the cell culture format and growth area 
Format [a] Growth area [cm2] Number of cells to be seeded in [a] 
96-well (reference) 0.32  3 x 103  
24-well 1.9 1.8 x 104 
12-well 3.8 3.6 x 104 
6-well 9.5 9 x 104 
6-cm 21 2 x 105 
10-cm 55 5.16 x 105  
15-cm 145 1.4 x 106 
 
3.6 Cell viability assay in 96-well plates 
Cell viability assays using CellTiter-Glo were performed to determine the viability of 
cells upon treatment with chemical compounds such as small molecule inhibitors or 
upon genetic manipulations such as knockout, knockdown or overexpression of 
genes. The CellTiter-Glo assay is a luciferase-based assay that determines the 
number of viable cells by measuring ATP levels, which correlate with the amount of 
metabolically active cells. For this purpose, 100 µl cell suspension at respective, 
indicated cell density was seeded per well in a 96-well plate (3-6 technical 
replicates). For cell lines, the respective treatment was started the next day for 20-
24h while for primary cells, treatment was performed 48h after seeding. Solvent 
control, usually DMSO, served as a control treatment. For GPX4-knockout cell lines, 
that were maintained in GPX4-KO maintenance medium (Table 1) which served as 
a control treatment, Lip1 was removed from culture medium on the day of plating 
into viability assays. For rescue-experiments, chemical compounds were added 
during RSL3-treatment with the exception of Rosiglitazone (ROSI), Oleic Acid (OA), 
and Atglistatin (ATGLi). For these compounds, cells were additionally pre-treated 
for 24-48h in 96-wells and/or prior to seeding into the viability assay. For cell 
scattering experiments using the E-cadherin neutralizing antibody HECD-1, cells 
were 24h pre-treated with 1 µg/ml HECD-1 prior to plating cells into the viability 
assay. HECD-1 treatment was applied during viability assay as well. For GPX4-
knockdown experiments, sh-nt and sh-GPX4 containing HMLE 24hi cells were 
seeded at indicated cell densities in 96-wells in respective medium (Table 1). The 
next day, 0.5 µg/ml Dox-treatment was applied for 48h prior to the addition of 10 nM 
RSL3 or 0.01% DMSO for 24h in presence of Dox. For all experiments using cell 
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lines, except for GPX4-knockdown cells, 48h after plating and after visual inspection, 
cell viability was measured using the CellTiter-Glo assay with a slightly modified 
protocol. The assessment of cell viability was performed 72h after plating for primary 
cells and 96h after plating for Dox-induced GPX4-knockdown HMLE 24hi cells. To 
do so, the growth medium was removed and replaced by 50 µl DMEM/F12 and 50 
µl (1 volume) CellTiter-Glo reagent was added. The contents of the well were mixed 
for 2 min at RT on an orbital shaker, followed by an incubation of 30-40 min at RT 
in the dark to allow sufficient lysis of the adherent cells and stabilization of the 
luminescent signal. After an additional 2 min mixing on an orbital shaker, 95 µl of 
the supernatant was transferred to white opaque 96-well plates and the 
luminescence signal was immediately measured on a luminometer using luciferase-
specific settings and an integration time of 0.25 sec per well. Wells without 
supernatant served as blank control. Measured blank controls were averaged and 
subtracted from measured RLU values. Then, obtained RLUs of technical replicates 
were averaged and normalized to respective solvent control (mostly DMSO) or Lip1 
control.  
 
CellTiter-Glo reagent: 1 mix of CellTiter-Glo buffer and CellTiter-Glo substrate 
 
3.7 Cell viability assay in 24-well plates 
Cell viability of HMLE 24hi cells containing Dox-inducible shRNA against GPX4 was 
assessed by counting viable cells (see Section 3.22.3 and 3.23.2). To do so, HMLE 
24hi cells containing shRNAs (sh-nt and sh-GPX4) were seeded in triplicates in 24-
well plates at a low (1200 cells) or intermediate (3600 cells) cell density in puromycin 
selection medium (Table 1). The next day, shRNA expression was induced by 0.5 
µg/ml Dox-treatment. After 48h Dox-treatment, cells were additionally treated with 
10 nM RSL3 or 0.01% DMSO (solvent control), the next day trypsinized and total 
cell number assessed by counting (see Section 3.1 and 3.2).  
 
3.8 Cell proliferation in 96-well plates 
To measure cell proliferation, HMLE and HMLE-Twist1 cells were plated at low, 
intermediate and high cell density in 96-wells (10 technical replicates per timepoint 
and cell density) (see Section 3.5). Proliferation was monitored every 24h over a 
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period of 96h using CellTiter-Glo assay (see Section 3.6). Growth medium was 
refreshed every 24h. Data obtained was normalized to the 24h time point for every 
cell density within each cell line. 
 
3.9 Co-culture 
Co-culture experiments were employed to assess whether cells seeded at high cell 
density secrete a soluble factor protecting them from cell death. To do so, a co-
culture system using transwell inserts with 8 µm pore size was employed, thereby 
separating cells seeded at the bottom well from those seeded into the upper 
transwell. Of note, HMLE 24hi cells containing shRNAs against GPX4 or non-
targeting shRNAs were first plated in 6-well plates and the next day treated with 0.5 
µg/ml Dox for 24h to induce shRNA expression prior to seeding cells into co-culture 
experiments with further Dox-stimulation. For co-culture experiments, 500 µl cell 
suspension of 2 x 103 cells (low cell density) was seeded in triplicates into 24-well 
plates. After 1h, transwell inserts were placed into the well and 500 µl of 2 x 104 cells 
(slightly more than high cell density) were added into the transwell inserts for co-
culture, while 500 µl medium was added to control wells containing only cells in the 
bottom well. The next day, complete medium was replaced with treatment medium 
(0.1% DMSO or 100 nM RSL3 for HMLE and HMLE-Twist1 cells and 0.01% DMSO 
or 10 nM RSL3 for HMLE 24hi cells containing shRNAs) and cells were treated for 
20-24h. After visual inspection, inserts were fixed and stained with the Hemacolor 
Rapid staining set and cell viability assessed using CellTiter-Glo assay as described 
in Section 3.6 with minor modifications. 100 µl basal DMEM/F12 together with 100 
µl CellTiter-Glo reagent was applied to 24-well plates. After incubation, 50 µl of 
supernatant was diluted in 50 µl basal DMEM/F12 in white opaque 96-well plates 
before measuring luminescence as described. For Hemacolor Rapid staining of 
insert, cells grown in inserts were fixed by applying the methanol-based Fixing 
Solution for 30 sec. After a brief wash in Milli-Q water, Staining Solution 1 was added 
to inserts for 2 min to stain the cytoplasm and after washing with Milli-Q, Staining 
Solution 2 was employed for another 2 min to stain nuclei. Inserts were washed 
using a buffer sold with the Kit and inserts air-dried overnight prior to taking pictures 
on a Leica DM IL LED microscope.  
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3.10 Viability assays using sticky Culture-Inserts with 2 wells  
In order to assess whether resistance mechanisms to RSL3 were related to cell-cell 
adhesions or depended on the size of growing colonies, 3x104 cells were either 
seeded triplicates in one well of a sticky culture-insert (Ibidi) with a growth area of 
0.22 cm2 placed in 6-cm dishes (to yield one large dense, compact colony) or the 
same cell number was directly plated in 6-cm dishes (to yield several sparse, small 
colonies). 3 x104 cells represents approximately 450 seeded cells in a 96-well (see 
Section 3.5), thus at an intermediate-low seeding density at which cells were 
sensitive to RSL3 treatment. The next day, the cell culture-inserts were removed 
and 0.1% DMSO or 100 nM RSL3 treatment applied for 18h. Viability was assessed 
by CellTiter-Glo assay applying 200 µl basal DMEM/F12 and 200 µl CellTiter-Glo 
reagent as described in Section 3.6. For measurement, 20 µl of supernatant were 
diluted in 80 µl basal DMEM/F12 in white opaque 96-well plates. 
 
3.11 Methods working with 3D collagen gels 
3.11.1 Fixation of 3D collagen gels 
After a period of 8-12 days of culturing cells in 3D-collagen gels, growth medium 
was removed and gels were washed with 1 ml PBS. All subsequent steps were 
performed using an orbital shaker. After removal of PBS, gels were fixed with 1 ml 
4% PFA for 15 min, washed again briefly with PBS prior to three subsequent PBS 
washing steps for 10 min each. Gels were kept in PBS at 4°C until further use. 
  
4% PFA: 1:4 dilution of 16% paraformaldehyde in PBS 
 
3.11.2 Carmine Staining 
To visualize colonies grown in 3D collagen gels, PFA-fixed gels were stained with 1 
ml carmine solution overnight at RT on an orbital shaker and kept in carmine solution 
at 4°C until further use. To image colonies, gels were transferred to microscopy 
slides and excess solution removed with a pipette and a kimwipe tissue. 6-8 images 
per gel were taken on a Zeiss SteREO Lumar.V12 microscope with a NeoLumar S 
0.8 objective with a 10- to 20-fold magnification. Images were stitched using Hugin 
or Image Composite Editor Software to obtain a whole mount picture and colonies 
were counted using ImageJ software. First, a binary image (black/white) was 
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produced and then, by setting a manual threshold, areas containing colonies (black) 
were extracted from the background. Colonies were automatically counted by using 
the “Analyze particles” feature setting the area between 400 and 90000 µm2 (20 – 
300 µM diameter) and a circularity of 0.5-1. 
 
Carmine solution: 1g carmine, 2.5 g aluminum potassium sulfate in 500 ml Milli-Q water, 
1 crystal of Thymol 
 
3.11.3 3D immunofluorescence 
All steps were carried out on an orbital shaker and each washing step with 1 ml PBS 
washing was performed for 10 min. First, cells within collagen gels were 
permeabilized for 10 min using 1 ml permeabilization solution and washed twice with 
PBS before applying 1 ml blocking solution for 2-3h. Gels were washed with PBS 
prior to incubation with 100 µl primary antibody solution overnight at 4°C. After three 
PBS washing steps, respective secondary antibody solutions (100 µl) were applied 
for 2-3h at RT, followed by washing gels twice with PBS. To stain nuclei, 100 µl of 
DAPI solution was added for 5 min before washing gels two times with PBS and 
once with Milli-Q water for 5 min. Collagen gels were placed on microcopy slides 
and excess water was carefully removed using a pipette and kimwipe tissues. Two 
drops of Aqua-Poly/Mount mounting medium were applied to gels prior to covering 
with a cover slip. Slides were dried for 1-2 days in the dark at RT before sealing with 
nail polish and storing at -20°C until imaging. Images were taken on an FLUOVIEW 
FV1200 inverted Confocal Laser Scanning Microscope using FV10-ASW software 
and 20-fold magnification (UPlanSApo 20x objective lense). Images were processed 
with Gimp 2.8.22. 
 
Permeabilization solution: 0.2% Triton X-100, PBS 
Blocking Solution: 10% donkey serum, 0.1% BSA, PBS 
Antibody solution: Respective antibody diluted in 0.1% BSA in PBS 
DAPI Solution: 167 ng/ml DAPI in PBS 
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3.12 Methods working with proteins 
3.12.1 Protein Isolation 
To assess protein expression levels, whole cell lysates using RIPA buffer lysis were 
prepared. To do so, cells were seeded in 10- or 15-cm dishes at indicated cell 
densities as calculated in Section 3.5. If cells were treated or starved, cells were 
washed once with PBS 24h after seeding and the medium was changed to 
respective treatment medium or starvation medium for another 20-24h. 48h after 
seeding, proteins were isolated with all subsequent steps performed on ice. Cells 
were washed once with PBS, then 1 ml PBS was applied to cells to facilitate scraping 
with a cell scraper prior to collection of cells in 1.5 ml Eppendorf tubes. Cells were 
pelleted by centrifuging at 4°C at 2500 x g in Heraeus Fresco 21 centrifuge for 5 
min. The supernatant was removed and protein lysis buffer, usually 30 – 200 µl 
depending on cell pellet, was applied and vigorously mixed by vortexing. To further 
increase lysis, samples were frozen for at least 1h at -80°C. Then, samples were 
thawed on ice and cell debris pelleted by centrifugation at 4°C at 14000 x g for 10 
min. The supernatant containing the protein fraction was transferred to a clean tube. 
Protein extracts were stored at -80°C.  
 
Starvation medium: basal DMEM/F12 
RIPA buffer: 50 mM Tris pH 8.0, 150 mM NaCl, 1% (w/v) NP-40, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 5 mM EDTA pH 8.0, Milli-Q water 
Lysis buffer: RIPA buffer, freshly added Phosphatase Inhibitor Cocktail 2 and 3 and 
Protease Inhibitor Cocktail (each 1:100), 4°C 
 
3.12.2 Protein concentration measurement 
Protein concentration was measured using the colorimetric, detergent-compatible 
DC Protein Assay which is based on the Lowry method (Lowry et al., 1951). Protein 
standards (0.5 µg, 1 µg, 2 µg, 5 µg, 7.5 µg, 10 µg, and 25 µg) from 1 mg/ml 
BSA/RIPA stock, 3 µl RIPA buffer as well as 3 µl of each sample were pipetted in 
duplicate into a 96-well plate. The assay was then performed according to the 
manufacturer’s instructions and the absorbance was measured at 750 nm on a 
microplate reader. The concentration of the protein samples was calculated from a 
standard curve that was obtained using the RIPA buffer only as blank and the protein 
standard as a reference. 
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3.12.3 SDS-PAGE 
SDS-PAGE is used to separate proteins samples based on their molecular weight. 
A 12.5% separating SDS-polyacrylamide gel was prepared in glass plates of the 
Mini-PROTEAN Tetra Cell system and then overlaid with isopropanol until 
polymerization. Then, isopropanol was removed and the stacking gel, as well as a 
10-well or 15-well comb, were added. 10-20 µg of each protein sample was mixed 
with 5x SDS loading buffer and then proteins were denatured for 5 min at 95°C. Gels 
were loaded with samples and with 8 µl of PageRuler Prestained Protein ladder 
serving as a reference for protein size. Gel electrophoresis was run for 60-90 min in 
1x Running buffer for 120V. 
 
12.5% separating gel: 1.95 ml 30% Rotiphorese, 2.75 ml Milli-Q water, 1.25 ml 1 M Tris 
pH 8.8, 50 µl 10% (w/v) SDS, 3.75 µl Temed, 37.5 µl 10% (w/v) APS 
Stacking gel: 416.5 µl 30% Rotiphorese, 1.73 ml Milli-Q water, 312.5 µl 1 M Tris pH 6.8, 
25 µl 10% (w/v) SDS, 2.5 µl Temed, 12.5 µl 10% (w/v) APS 
5x SDS loading buffer: 30% (v/v) Glycerol, 10% (w/v) SDS, 0.25 M Tris/HCl pH 6.8, 0.05% 
(w/v) bromophenol blue, 10% (v/v) β-Mercaptoethanol, Milli-Q water 
1x Running buffer: 25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS, Milli-Q water 
 
3.12.4 Immunoblotting 
Proteins separated by SDS-PAGE were transferred to a PVDF membrane using a 
Tank/Wet Blotting System from Bio-Rad. The PVDF membrane was activated in 
methanol prior to assembling the wet blot according to manufacturer’s instructions. 
Electroblotting was performed with 300 mA for 1.5 to 2 hours in an ice-cooled 
chamber using ice-cold 1x Transfer buffer. The PVDF membrane was briefly 
washed with TBS/T on a 2D Rocker and subsequently, depending on the antibody 
requirements, blocked with 5% milk or 5% BSA for 1h. Membranes were incubated 
in a 50 ml falcon with primary antibody solution according to manufacturer’s 
requirements overnight at 4°C on a horizontal roller. The next day, membranes were 
washed three times with TBS/T for 10 min and respective HRP-conjugated 
secondary antibodies were applied in 5% milk or 5% BSA for 1h at RT. Membranes 
were again washed three times with TBS/T and once with TBS for 10 min prior to 
applying 600 µl ECL Prime Western Blotting Detection Reagent per membrane 
according to manufacturer’s instructions. Chemiluminescence was visualized on a 
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ChemiDoc Imaging System using the Image Lab software. ImageJ software was 
used for densitometric analysis of protein bands. Briefly, the grey mean value was 
measured using the same frame for the background above each protein band and 
each protein band across one protein lane. The measured values were first inverted 
(255-grey mean value) and then the background value subtracted from the 
respective protein band value. Obtained values were normalized to values of beta-
actin loading control.  
 
1x Transfer buffer: 25 mM Tris, 192 mM Glycine, 20 % (v/v) Methanol 
10x TBS: 1.5 M NaCl, 0.1 M Tris, MilliQ-water, pH 7.2-7.4 with HCl 
1x TBS/T: 10% (v/v) 10x TBS, 0.1% (v/v) Tween 20, MilliQ-water 
5% skim milk: 5% (m/v) non-fat dried milk powder in 1x TBS/T 
5% BSA: 5% (m/v) bovine serum albumin fraction V in 1x TBS/T 
 
3.13 Proteomics 
To assess changes in the proteome of cells seeded in cell density and upon RSL3-
treatment, a proteomic study was kindly performed by Dr. Christine von Toerne and 
Dr. Ann-Christine Koenig at the Research Unit Protein Science headed by Dr. 
Stefanie Hauck at the Helmholtz Center Munich. For each condition in the study, 
four independent biological replicates were prepared, measured and analyzed. 
 
3.13.1 Conditions for proteomics 
HMLE and HMLE-Twist1 cells were seeded in 10-cm dishes in a cell density that 
corresponds to 3000 (high), 1000 (med) and 333 (low) seeded cells in 96-well plates 
(see Section 3.5). For high cell density, cells were seeded in one 10-cm dish. For 
intermediate cell density, cells were seeded in five 10-cm dishes, two serving as cell 
density control and three for RSL3 treatment. For low cell density, cells were plated 
in four 10-cm dishes. The next day, cells seeded in three 10-cm dishes at 
intermediate cell density were treated for 5h with 100 nM RSL3 before isolating 
proteins. For all other conditions, the medium was refreshed and protein isolation 
was performed 48 hours after plating into dishes. Proteins extracts from the same 
condition were pooled during protein isolation. Protein isolation and concentration 
measurement were carried out as indicated in Sections 3.12.1 and 3.12.2. Of each 
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sample, 10 µg protein were pipetted into Protein LoBind 1.5 ml Eppendorf tubes, 
resuspended with 20 µl lysis buffer (see Section 3.12.1) and stored at -80°C until 
the proteomic study was performed. 
 
3.13.2 Sample preparation for mass spectrometry 
A modified filter-aided sample preparation (FASP) protocol was used to 
enzymatically digest each sample (10 µg) according to published protocols 
(Grosche et al., 2016; Wiśniewski et al., 2009). Peptides were frozen at -20°C until 
the measurement by mass spectrometry. 
 
3.13.3 Measurement by mass spectrometry 
The measurements by mass spectrometry (MS) were carried out in data dependent 
(DDA) mode. A Q Exactive (QE) high field (HF) mass spectrometer (Thermo Fisher 
Scientific) was used to obtain MS data. Briefly, about 0.5 µg of each sample was 
automatically supplied to the online coupled RSLC (Ultimate 3000, Thermo Fisher 
Scientific) HPLC system. A nano trap column was employed (300 μm inner diameter 
(ID) × 5 mm, packed with Acclaim PepMap100 C18, 5 μm, 100 Å; LC Packings, 
Sunnyvale, CA) prior to separation by reversed phase chromatography (Acquity 
UPLC M-Class HSS T3 Column 75µm ID x 250mm, 1.8µm; Waters, Eschborn, 
Germany) at 40°C. Peptides were eluted from the column at a rate of 250 nl/min 
applying a gradient of increasing acetonitrile concentrations in 0.1% formic acid 
ranging from 3% to 41 % over 105 min. A high-resolution (60 000 full width at half-
maximum) MS spectrum was obtained with a mass range from 300 to 1500 m/z. 
The value for the automatic gain control target was 3 x 106 and the maximum 
injection time was 50 ms. From the high-resolution MS prescan, the ten most 
abundant peptide ions were chosen for fragmentation (MS/MS) in case that they 
were at least doubly charged, with a dynamic exclusion of 30 sec. The record of 
MS/MS spectra was performed at 15 000 resolution whereby automatic gain control 
target was set to 1 x 105 and a maximum of 100 msec injection time. All spectra 
were run at a normalized collision energy set to 28 and acquired in profile type. 
 
3.13.4 Label-free quantification 
The recorded spectra of each sample were analyzed with the Progenesis QI 
software for proteomics (Version 3.0, Nonlinear Dynamics, Waters, Newcastle upon 
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Tyne, U.K.) for label-free quantification according to a previous description (Grosche 
et al., 2016) with a modification regarding peptide identification. Briefly, after export 
of MS/MS spectra from the Progenesis QI software, peptide identification occurred 
against the SwissProt human database (Release 2017.02, 553473 sequences). 
Search parameters employed were 10 ppm peptide mass tolerance, 20 mmu 
fragment mass tolerance and only one missed cleavage site was allowed. 
Cysteine carbamidomethylation was set as fixed modification while methionine 
oxidation and deamidation of asparagine and glutamine were permitted as variable 
modifications. A false discovery rate (FDR) of 1% was used in the Mascot integrated 
decoy database search. 
 
3.13.5 Analysis of proteomics 
For data analysis, normalized abundances were averaged between the four 
replicates for each protein. Within each cell line (HMLE and HMLE-Twist1), a ratio 
of the averaged abundances between low and high cell density conditions as well 
as between 5h RSL3-treated and intermediate control cell density condition was 
calculated. Then, proteins were filtered for a regulation of at least 1.5-fold up- or 
downregulation within each ratio (for upregulation ratio higher than 1.5, for 
downregulation ratio below 0.67). Statistical analysis was performed using log2 
transformed normalized abundances and an unpaired, two-tailed T-test with Welch’s 
correction was applied. 
Proteins with a p-value below 0.05 and a 1.5-fold up or downregulation for both cell 
lines were considered for GO term enrichment analysis using DAVID (Huang et al., 
2009b, 2009a). Interesting GO terms and potential hit proteins were submitted to 
extensive literature research prior to validation and further functional analyses. 
 
3.14 Flow cytometry 
3.14.1 Analysis of cells by flow cytometry using fluorescent probes 
Flow cytometry was employed to assess ROS levels (lipid ROS, mitochondrial ROS, 
and general ROS) by fluorescent dyes that increase or shift fluorescence upon 
oxidation by ROS and therefore serve as a proxy measure of ROS levels. Further, 
ThiolTracker Violet was employed to assess reduced glutathione levels. Glutathione 
represents the majority of free thiols and Thioltracker Violet reacts with free thiols, 
therefore it can be used a proxy for reduced glutathione content. In addition, the 
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neutral triacylglyceride (TAG) content, which represents the lipid droplet (LD) 
content of cells, was measured by staining with BODIPY 493/503. Cells were 
seeded in 6-cm dishes at indicated cell densities (see Section 3.5), the next day 
medium was refreshed and 48h after plating, cells were analyzed. Treatment with 
RSL3, oleic Acid and cumene hydroperoxide (CH), serving as a positive control for 
lipid peroxidation, was performed 24h to 48h after plating for the indicated time 
points. For GPX4-knockout clones which were plated in 1 µM Lip1-containing 
medium or in medium not containing Lip1 for induction of ferroptosis, the analysis 
was performed 24h after plating. For the respective staining, cells were washed 
once with PBS before applying 1 ml 2 µM BODIPY-C11 581/591, 5 µM MitoSox or 
5 µM CellROX Deep Red staining solution in medium for 30 min at 37°C in a tissue 
incubator to assess lipid peroxidation, mitochondrial ROS or general ROS 
respectively. For assessment of reduced glutathione, cells were stained with 10 µM 
ThiolTracker Violet in PBS for 30 min at 37°C and for LD staining, 2 µM BODIPY 
493/503 staining solution in medium was applied for 15 min at 37°C. One sample 
per cell line was not stained in order to serve as a reference to draw negative and 
positive gates. Cells were washed with PBS, harvested by trypsinization, 
resuspended in 120-150 µl ice-cold FACS buffer and filtered through a 35 µm cell 
strainer into 5 ml round-bottom FACS tubes on ice. To distinguish between live and 
dead cells, cells were incubated for 5 min with 1 µM Sytox blue prior to analysis. For 
Thioltracker Violet staining, live/dead cell discrimination was performed by 1 µg/ml 
Propidium iodide (PI) staining for 5 min. Cells were analyzed on a FACSAria IIIu 
using laser and filters according to manufacturer’s recommendations (see Section 
2.5). First, cell doublets and debris were excluded by applying forward and side 
scatter gates and then cells were gated on the live population (Sytox-negative or PI-
negative gates). At least 10000 events per sample were recorded for the live 
population. Data analysis was conducted using FlowJo Software. 
 
FACS buffer: 1% bovine serum albumin fraction V in PBS, sterile filtered 
 
3.14.2 Fluorescence-activated cell sorting (FACS) 
Fluorescence-activated cell sorting is a method to separate single cells based on 
fluorescent labeling. FACS was performed on a FACSAria IIIu flow cytometer using 
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the 70 µm nozzle and set-ups according to manufacturer’s recommendations. 7-
AAD employed for live/dead cell discrimination was excited using the 488 nm laser 
and detected by the 695/40 nm filter, while GFP, also excited by the 488 nm laser, 
was detected by the 530/30 nm filter. Transfected cells (see Section 3.23.1) were 
trypsinized, collected in 500 µl ice-cold FACS buffer and strained through a 35 µm 
filter. 5 µl 7-AAD staining solution was applied for at least 10 min and gating was 
performed as described in Section 3.14.1. Gates for GFP were drawn using non-
transfected cells (GFP-negative) and GFP-positive cells were sorted into 2 ml 
complete growth medium using purity mode. Sorted cells were centrifuged for 5 min 
at 490 x g at 4°C and resuspended in complete growth medium prior to subsequent 
experiments. 
 
3.15 Cell cycle analysis 
For cell cycle analysis, HMLE and HMLE-Twist1 cells were seeded at low, 
intermediate or high cell density in 10-cm dishes (see Section 3.5). After 48h, cells 
were harvested by trypsinization. Cells were resuspended in 600 µl PBS and then 
fixed by adding drop-wise 1.4 ml ice-cold (-20°C) 100% ethanol while mixing cells 
by vortexing. Cells were incubated overnight at -20°C. The next day, fixed cells were 
pelleted by centrifugation at 850 x g for 10 min, washed twice with PBS and 
resuspended in 100 µl PBS. To remove RNA, fixed cells were incubated with 50 
µg/ml RNase A for 20 min at 37°C prior to staining of DNA with 50 µg/ml PI at 4°C 
overnight. The next day, fixed and PI-stained cells were washed 1x with PBS, 
resuspended in FACS buffer and analyzed by flow cytometry as described in Section 
3.14.1. A linear scale was used to visualize PI staining, thus cell cycle distribution. 
 
3.16 Detection of lipid peroxidation using the Click-iT™ Lipid Peroxidation 
Imaging Kit 
The Click-iT™ Lipid Peroxidation Imaging Kit is a method to detect lipid-
peroxidation-derived protein modifications. To do so, cells are incubated with an 
alkyne-modified linoleic acid (LAA, Component A) which is a polyunsaturated fatty 
acid that incorporates into cell membranes. In the presence of lipid peroxidation, 
oxygenation of LAA leads to chemical reactions with intracellular proteins. Modified 
proteins can be subsequently detected with Click-iT® chemistry. As a result, the 
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fluorophore Alexa Fluor 488 yields green fluorescence. All steps were performed 
according to the manufacturer’s instructions. 
 
3.16.1 Detection of lipid peroxidation by immunofluorescence 
For detection of lipid peroxidation by immunofluorescence, coverslips were placed 
into 24-well plates, covered with 1% gelatin and then incubated overnight at 4°C. 
The next day, gelatin was removed and coverslips were washed three times with 
PBS. Then, 1.5 x 104 HMLE or HMLE-Twist1 cells were seeded in 24-well plates 
containing gelatin-coated coverslips and were grown for 48h. Cells were incubated 
for 1.5h with 50 µM LAA together with 0.1% DMSO, 100 nM RSL3, 500 nM Fer1 or 
with a combination of RSL3 and Fer1 at 37°C in a tissue incubator. As a positive 
control, cells were incubated for 1.5h with 50 µM LAA together with 100 µM CH with 
or without 500 nM Fer1. After three washing steps with PBS, cells were fixed for 15 
min with 4% PFA at RT followed by three subsequent washing steps using PBS. 
After applying the permeabilization solution for 2 min at RT and three additional 
washing steps, blocking solution was applied for 1 hour at RT to reduce nonspecific 
background. Meanwhile, Click-iT™ reaction cocktail was freshly prepared in the 
order as listed in Table 3 according to manufacturer’s instructions. After two washing 
steps, 300 µl of the Click-iT™ reaction cocktail was added per coverslip and 
incubated for 30 min at RT protected from light. The reaction cocktail was removed 
and coverslips were washed four times with PBS. DAPI solution was applied to stain 
nuclei and then coverslips were dipped 10 times in PBS followed by dipping the 
coverslips 10 times in Milli-Q water. Coverslips were mounted on microscopy slides 
using Aqua-Poly/Mount mounting medium and dried at RT prior to storage at -20°C. 
Images were acquired on a Zeiss Axio Imager M.2 microscope using Zen Pro 
Software and 20-fold magnification. Images were edited with Gimp 2.8.22.  
 
Table 3: Composition of Click-iT™ reaction cocktail 
Click-iT™ reaction cocktail 1x  
1X Click-iT® reaction buffer (Component C) 258 µl  
CuSO4 (Component D) 12 µl 
Alexa Fluor® 488 azide (Component B) 0.72 µl 
1X Click-iT® buffer additive (Component E) 30 µl 
Total Volume 300 µl 
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4% PFA: 1:4 dilution of 16% paraformaldehyde in PBS 
Permeabilization solution: 0.2% Triton X-100, PBS 
Blocking Solution: 10% goat serum, 0.1% BSA, PBS 
DAPI Solution: 167 ng/ml DAPI in PBS 
 
3.16.2 Detection of lipid peroxidation by flow cytometry 
For detection of lipid peroxidation by flow cytometry, 8 x 104 HMLE or HMLE-Twist1 
cells were seeded per well of a 6-well plate. After 48h, cells were treated for 1.5h 
with 50 µM LAA together with 0.1% DMSO, 100 nM RSL3, 500 nM Fer1 or with a 
combination of RSL3 and Fer1 at 37°C in a tissue incubator. Then, cells were 
washed three times with PBS, harvested by trypsinization and transferred into 5 ml 
round-bottom FACS tubes on ice. All subsequent steps were performed in FACS 
tubes, washed each time with PBS and pellet by centrifugation prior to the next step. 
Cells were fixed, permeabilized and blocked as described in Section 3.16.1. Then, 
300 µl of the Click-iT™ reaction cocktail (Table 3) was added per FACS tubes as 
described in Section 3.16.1. After 30 min incubation at RT, protected from light, cells 
were washed twice with PBS and pelleted. Cells were resuspended in 120-150 µl 
ice-cold FACS buffer and filtered through a 35 µm cell strainer into 5 ml round-
bottom FACS tubes on ice. Then, FACS analysis was performed as described in 
Section 3.14.1. Alexa Fluor 488 fluorescence was analyzed with the 488 nm laser 
and detected by the 530/30I filter. 
 
FACS buffer: 1% bovine serum albumin fraction V in PBS, sterile filtered 
 
3.17 GPX4-specific enzyme activity 
The GPX4-specific enzyme activity was kindly measured by Dr. Irina Ingold from the 
group of Dr. Marcus Conrad at the Institute of Developmental Genetics at the 
Helmholtz Center Munich. GPX4-activity was determined in an enzymatically 
coupled test of whole cell lysates as previously described (Roveri et al., 1994). 
Thereby, GPX4 reduces phosphatidylcholine hydroperoxide (PCOOH), a GPX4-
specific substrate. GPX4 is recycled by reduced GSH which in turn gets oxidized. 
Oxidized GSH (GSSG) is reduced by glutathione reductase in presence of non-
limiting concentrations of NADPH which gets oxidized. During the reaction, a 
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decrease in reduced NADPH can be measured spectrometrically at λ=340 nm. To 
do so, 2-4 x 106 epithelial (‒TAM) and TAM-induced mesenchymal HMLE-Twist1-
ER 24hi cells were seeded in 15-cm dishes (4 technical replicates per cell line). 
When cells reached 80% confluency, cells were washed twice with ice-cold PBS 
prior to harvest cells by scraping in PBS. After pelleting cells and removing the 
supernatant, cell pellets were snap-frozen in liquid nitrogen to retain GPX4 
enzymatic activity and were stored at -80°C. After resuspension of cell pellets in 100 
µl protein lysis buffer and incubation for 15 min on ice, homogenate was centrifuged 
for 10 min at 18400 x g at 4°C followed by a transfer of the supernatant to a new 
tube. A reaction mix was prepared consisting of 1 ml assay buffer, 200 µM NADPH, 
3 mM GSH, 0.6 U/ml glutathione reductase and 20-30 µM PCOOH. 50 µl of protein 
supernatant was added to the reaction mix. GPX4 enzyme activity was determined 
spectrometrically at λ=340 nM for 10 min on a SpectraMax microplate reader 
(Molecular Device GmbH), thereby measuring the decrease in NADPH 
concentration. GPX4-specific activity was calculated by subtracting a background 
measurement of NADPH without PCOOH addition from measurements containing 
the reaction mix and protein supernatant. For data normalization, protein 
concentration was measured of each sample using the Pierce 660 nm Protein Assay 
Reagent (Thermo Fisher Scientific) according to manufacturer’s instructions. 
 
PCOOH: enzymatically oxidized phosphatidylcholine as previously described (Roveri et al., 
1994) 
Protein lysis buffer: 100 mM KH2PO4/K2HPO4 (pH7.4), 150 mM KCl, 0.05% CHAPS, 2 
mM β-mercaptoethanol, 1% protease inhibitor cocktail 
Assay buffer: 100 mM Tris (pH 7.8), 5 mM EDTA, 0.1% Triton X-100 
 
3.18 Assessment of free total thiols and GSH 
The measurements of free total thiols and GSH were kindly performed by Dr. José-
Pedro Friedman Angeli form the group of Dr. Marcus Conrad at the Institute of 
Developmental Genetics at the Helmholtz Center Munich. 
 
3.18.1 Assessment of free total thiols 
1.5 – 1.6 x 105 parental (‒TAM) and 1.9 – 2.1 x 105 15d TAM-induced mesenchymal  
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HMLE-Twist1-ER 24hi cells were plated in triplicates in 12-well plates. Two days 
later, cells were washed twice with PBS prior to addition of 1 ml serum-free and 
phenol red-free DMEM. 2 µM ERA was applied to wells as a positive control to inhibit 
xc‒ and thus thiol release. The release of free total thiols into the cell culture medium 
was assessed at desired time points by collecting 60 µl aliquots and measured as 
previously described (Bannai and Ishii, 1982). For background measurements, the 
collected supernatants were mixed with an equal volume of thiol assay buffer and 
absorbance was directly measured at λ=412 nm on a SpectraMax microplate reader 
(Molecular Device GmbH). Then, 10 µl of 10 mM 5,5’-dithiobis (2-nitrobenzoic acid) 
(DTNB) was added on ice to samples and incubated for 2 min prior to a second 
measurement at 412 nm. As a blank measurement, thiol assay buffer was mixed 
with serum-free and phenol red-free DMEM. A standard curve to calculate the 
amount of released thiols was generated by measuring reduced GSH. In order to 
normalize data, cells were harvested by trypsinization and cell numbers were 
determined by counting. 
  
Thiol assay buffer: 0.2 M KH2PO4/K2HPO4, 10 mM EDTA, pH 7.2 
 
3.18.2 Assessment of intracellular total GSH levels 
1.5 – 1.6 x 105 parental (‒TAM) and 1.9 – 2.1 x 105 15d TAM-induced mesenchymal  
HMLE-Twist1-ER 24hi cells were plated in triplicates in 12-well plates. The next day, 
2 µM ERA was applied to wells as a positive control to inhibit xc‒ and thus GSH 
metabolism. After 48h, cells were washed twice with ice-cold PBS. Then, 5% 
tricholoacetic acid (TCA) was added to cells for 30 min to enable membrane 
permeabilization of cells that allows the release of low molecular proteins like 
reduced and oxidized GSH. The supernatant was collected in tubes and TCA was 
removed by ether extraction. Total GSH levels were measured in the aqueous phase 
using an enzymatic method as previously described (Tietze, 1969). Thereby, the 
reduction of 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB) to 2-nitro-5-thiobenzoate 
(TNB‒) at the expense of NADPH by GSH was measured. To do so, 500 µl of the 
aqueous phase of each sample was mixed with 1.2 ml thiol assay buffer (see Section 
3.18.1), 10 µM DTNB, 1 IU glutathione reductase and 3.62 mg/ml NADPH. The total 
GSH content was measured by assessing the reduction of DTNB to TNB‒, resulting 
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in a colorimetric intensity change, over a period of 5 min at λ=412 nm absorbance. 
A GSH standard curve was used to determine the total GSH content. For 
normalization, proteins content was determined in cells permeabilized with TCA. 
Therefore, 0.5 M NaOH was added to cells overnight to disrupt cellular membranes 
to enable the release of proteins. Then, protein concentration was measured using 
the Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific) according to 
manufacturer’s instructions. 
 
3.19 RNA-related methods 
3.19.1 RNA Isolation and cDNA synthesis 
Cells were grown in 6-well to 6-cm dishes at respective densities. To isolate total 
RNA, the RNeasy Mini Kit was employed. Briefly, cells were washed once with PBS 
on ice and 300-350 µl RLT buffer containing 10 µl β-mercaptoethanol per ml RLT 
was added to dishes on ice. Cells/lysate were scraped using a cell scraper, collected 
in nuclease-free Eppendorf tubes and shortly frozen at -80°C to enable disruption of 
cells. Lysates were thawed on ice, loaded on Qiashredder columns to further lyse 
cells and centrifuged at 14000 x g for 2 min. RNA isolation of homogenized lysates 
was performed according to the manufacturer’s instruction for the RNeasy Mini Kit. 
In addition, an on-column DNase digestion step to minimize potential DNA 
contamination using the RNase-free DNase Set was performed. RNA was eluted in 
30 µl RNase-free water. RNA concentration and quality was measured on a 
NanoDrop spectrophotometer at λ=260 nm. Isolated RNA was stored at -80°C. 
Up to 1 µg total RNA was reverse transcribed into complementary DNA (cDNA) 
using the OneScript® Plus cDNA Synthesis Kit according to manufacturer’s 
instruction. For priming, Oligo(dT) primers were used and for quality control, a 
control without RNA (water control) and one control without the reverse transcriptase 
(−RT) was run. The reverse transcription reaction was performed in a thermocycler 
for 60 min at 50°C and terminated at 85°C for 5 min. cDNA was stored at -20°C. 
 
3.19.2 Real-time semi-quantitative PCR (qPCR)  
To measure and quantify the expression of different transcripts in a cDNA sample a 
qPCR reaction using the Power SYBR Green PCR Master Mix was performed. A 10 
µl reaction consisting of 2 µl (10 ng) cDNA, 0.25 µl (500 nM) of each, respective 
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forward and reverse primer, 5 µl 2x SYBR Green reagent and 2.5 µl nuclease-free 
water was prepared in triplicates for each cDNA sample and primer pair in 384-well 
plates. The gene RPL32 was used as internal control to normalize data. For quality 
controls, cDNA of the water control and –RT control (see Section 3.19.1) were 
included for RPL32 primers and for each primer pair a water control without any 
cDNA was prepared. Samples were run in triplicates on a QuantStudio 12K Flex 
qPCR system using the cycling steps shown in Table 4. By checking the obtained 
values from control samples and the melting curve for each reaction, quality as well 
as reaction specificity was assessed and ensured. Obtained data were analyzed 
using the ΔCT method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008) 
by subtracting the CT value of the gene of interest from the CT value of the internal 
control RPL32. The relative fold change of the gene of interest compared to the 
internal control RPL32 was calculated with the formula 2ΔCT. For illustration of the 
relative gene expression, the obtained values were multiplied by 1000. Primer 
sequences used in qPCR reactions were obtained from a public available resource 
for PCR Primer (PrimerBank: https://pga.mgh.harvard.edu/primerbank/) and are 
listed in Table 5.  
 
Table 4: Cycling steps for qPCR 
Step Temperature Duration Cycles 
Initialization 95°C 10 min 1x 
Denaturation 95°C 15 sec 
40x Annealing 60°C 30 sec 
Extension 72°C 16 sec 
Melting Curve 70 to 95°C   
 
Table 5: Primer sequences used for qPCR 
Target Sequence (Forward, Reverse) 
ABDH5 ACAGACCTGTCTATGCTTTTGAC, AGGGCACATCTCCACTCTTCA 
ACAA2 CTGCTCCGAGGTGTGTTTGTA, GGCAGCAAATTCAGACAAGTCA 
CPT1A ATCAATCGGACTCTGGAAACGG, TCAGGGAGTAGCGCATGGT 
GCLC CTTTCTCCCCAGACAGGACC, CAAGGACGTTCTCAAGTGGG 
GPX4 GAGGCAAGACCGAAGTAAACTAC, CCGAACTGGTTACACGGGAA 
HMOX1 AAGACTGCGTTCCTGCTCAAC, AAAGCCCTACAGCAACTGTCG 
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Target Sequence (Forward, Reverse) 
PNPLA2 ATGGTGGCATTTCAGACAACC, CGGACAGATGTCACTCTCGC 
SLC7A11 TCTCCAAAGGAGGTTACCTGC, AGACTCCCCTCAGTAAAGTGAC 
RPL32 CAGGGTTCGTAGAAGATTCAAGGG, 
CTTGGAGGAAACATTGTGAGCGATC 
 
3.20 Methods working with bacteria 
3.20.1 Transformation of chemically competent bacteria 
XL10-Gold and Stabl2 bacteria were stored at -80°C. One aliquot of ultracompetent 
bacteria of the strains XL10-Gold or Stabl2, if plasmids larger than >10kb were used, 
were thawed on ice for 5-10 min. Meanwhile, plasmid DNA (less than 1 µg, usually 
0.5-1 µl) was placed on the bottom of a fresh 1.5 ml Eppendorf tube on ice. 25 µl 
bacteria were added to the DNA and incubated for 10 min on ice. Bacteria were 
exposed to a 30 sec heat shock in a 42°C water bath and immediately placed on ice 
for 2 min. To allow regeneration of bacteria, 200 µl S.O.C. medium was added prior 
to incubation on a Thermomixer for at least 60 min at 37°C with constant shaking 
(1000 rpm). Afterwards, bacteria were plated on LB agar plates containing the 
appropriate antibiotics (50 µg/ml Kanamycin or 100 µg/ml Ampicillin) for selection 
and incubated overnight at 37°C for colony formation. 
 
LB Agar: 35 g/l LB Broth with agar powder in MilliQ-water, autoclaved, addition of antibiotics 
prior to pouring of plates, stored at 4°C 
  
3.20.2 Isolation of bacterial plasmid DNA 
A single colony was picked from an LB agar plate (see Section 3.20.1) and used to 
inoculate 3 ml (Mini preparation) or 100 ml (Midi preparation) LB medium containing 
the appropriate selection antibiotic (50 µg/ml Kanamycin or 100 µg/ml Ampicillin). 
Cultures were incubated overnight at 37°C with vigorous shaking (120 rpm). Plasmid 
DNA from the Midi preparation was isolated using the QIAGEN plasmid midi kit 
according to the manufacturer’s instructions and resuspended in 150-200 µl TE 
buffer. Plasmid DNA from the Mini preparation was isolated using buffers supplied 
by the QIAGEN Midi Kit. Briefly, 2 ml of overnight grown bacterial culture was 
transferred to a 2 ml Eppendorf tube and centrifuged for 5 min at 18000 x g at 4°C. 
After removing the supernatant, cells were resuspended in 300 µl 100 µg/ml RNase 
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A containing Buffer P1, followed by addition of 300 µl lysis Buffer P2 and lysis of 
bacteria for 5 min at RT. The lytic process was neutralized by the addition of 300 µl 
Buffer P3. After centrifugation for 10 min at 18000 x g at 4°C, the supernatant 
containing plasmid DNA was transferred to a clean, nuclease-free 1.5 ml Eppendorf 
tube and 600 µl isopropanol was added. The tube was inverted four to five times to 
precipitate the plasmid DNA prior to pelleting the plasmid DNA for 30 min at 18000 
x g at 4°C. The supernatant was removed and plasmid DNA washed once with 500 
µl 70% ethanol for 5 min at 18000 x g at 4°C. The supernatant was removed and 
the open tubes were placed briefly in a thermoblock at 85°C in order to allow the 
ethanol to evaporate and the pellet to dry. Plasmid DNA was resuspended in 30 µl 
elution buffer. The concentration of plasmid DNA was measured on a NanoDrop 
spectrophotometer at λ=260 nm. Only DNA with a purity greater than 1.8 based on 
260/280 nm ratio was used for subsequent experiments. 
 
LB medium: 20 g/l LB Broth (Lennox) powder in MilliQ-water, autoclaved, respective 
antibiotics were freshly added to bacterial cultures 
 
3.21 Methods working with DNA 
3.21.1 Genomic DNA (gDNA) extraction from single-cell clones and cell lines 
Single-cell clones (SCCs) and cell lines were grown in 12-well plates until they were 
at least 60% confluent. Cells were washed once with PBS and 200 µl DNAzol 
reagent was added per well and cell culture plates were agitated to facilitate lysis. 
DNA isolation was either immediately performed or plates were stored for 1-2 days 
sealed with parafilm at 4°C. DNA was precipitated by addition of 125 µl 100% ultra-
pure ethanol per well and plates were agitated and incubated for 5 min. 500 µl 70% 
ethanol was pipetted in nuclease-free 1.5 ml Eppendorf tubes and DNA, becoming 
visible as a cloudy precipitate, was swirled with a pipet tip and transferred to the 
tube. After centrifugation for 1 min at 18000 x g, the supernatant was carefully 
removed and DNA was washed one more time with 500 µl 70% ethanol. The 
supernatant was again removed and the remaining ethanol evaporated by placing 
the open tube for 1 min at 85°C on a thermoblock. DNA was dissolved in 30 µl 8 mM 
NaOH, adjusted for a final pH of 7.5 with 0.1 M HEPES. DNA concentration was 
measured on a NanoDrop spectrophotometer at λ=260 nm and a 260/280 ratio 
greater than 1.8 was considered as pure. DNA was stored at -20°C. 
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3.21.2 Restriction digest 
Restriction endonucleases were purchased from New England Biolabs and 
restrictions digestions were used to either prepare DNA (for example bacterial 
plasmids or PCR products) for cloning or to monitor cloning accomplishments. 20-
50 µl reactions were set up to digest DNA according to the manufacturer’s protocol.  
 
3.21.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is used to separate DNA fragments based on their size 
alongside with a molecular weight marker allowing analysis of the length of the 
fragment. Agarose gel electrophoresis was used to purify respective DNA fragments 
from gels for cloning purposes or to monitor for example restriction digestions or 
PCR amplification reactions. Agarose powder at a concentration of 0.8 to 1.2% was 
dissolved in 1X TAE buffer, SYBR Safe DNA stain was added at a ratio of 1:10000 
and the gel solution was poured into gel carriers applying appropriate gel combs. 
After solidification, gels were placed in gel running system, filled with 1x TAE buffer 
and the gel comb was carefully removed. 6x orange loading dye was added to DNA 
samples before loading samples and the DNA weight marker into the gel pockets. 
DNA fragments were separated at 120 V for 30-60 min. For cloning and subsequent 
purification of plasmid DNA from the gel, DNA fragments were visualized using a 
blue light table. For all other purposes, pictures of gels were taken on a ChemiDoc 
UV transilluminator. 
 
10x TAE: 0.4 M Tris, 0.2 M acetic acid, 10 mM EDTA 
 
3.21.4 Gel extraction of DNA fragments 
For cloning purposes, digested bacterial plasmids or amplified PCR products were 
run on an agarose gel and separation of DNA fragments visualized on a blue light 
table (see Section 3.21.3). Fragments of interest were cut out from the gel using a 
scalpel and purified from the gel using the Monarch Gel Extraction Kit according to 
the manufacturer’s instructions. DNA was eluted using 15 µl of 50°C pre-heated EB 
and concentration measured on a NanoDrop spectrophotometer. 
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3.21.5 Ligation of DNA fragments using T4-DNA-Ligase 
Digested and purified DNA fragments were used for a ligation reaction using T4-
DNA-ligase according to manufacturer’s instructions. 50-200 ng backbone DNA and 
insert DNA fragment at a molar ratio of 1:3 to 1:10 (backbone:insert) were used. The 
required amount of insert was calculated using the NEBioCalculator for DNA ligation 
(http://nebiocalculator.neb.com/#!/ligation) which is based on the following formula: 
𝑚𝑎𝑠𝑠(𝑖𝑛𝑠𝑒𝑟𝑡) =  𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜
𝑖𝑛𝑠𝑒𝑟𝑡
𝑏𝑎𝑐𝑘𝑏𝑜𝑛𝑒
× 𝑚𝑎𝑠𝑠(𝑏𝑎𝑐𝑘𝑏𝑜𝑛𝑒) × 𝑙𝑒𝑛𝑔𝑡ℎ
𝑖𝑛𝑠𝑒𝑟𝑡
𝑏𝑎𝑐𝑘𝑏𝑜𝑛𝑒
 
The ligation reaction was mixed and incubated overnight for 16h at 4°C in a 
thermoblock and 4 µl ligation reaction were transformed into 25 µl competent 
bacteria (see Section 3.20.1). 
 
3.21.6 Ligation of DNA using Gibson assembly 
Gibson assembly is a method to connect DNA fragments with overlapping ends of 
at least 15 bp. In this study, Gibson assembly was used to assemble PCR products 
into a vector backbone with 1-4 insert fragments of 16 to 25 bp homology (see 
Section 3.22.1). A Gibson Assembly reaction was set up using the 2x Gibson 
Assembly Master Mix together with 50-100 ng purified vector backbone PCR and 1-
4 insert fragments (StagR or oligo fragments, 2-3 fold molar excess) according to 
the manufacturer’s instructions. The reaction was incubated for 45-60 min at 50°C 
on a thermoblock and afterward diluted 1:4 in nuclease-free water prior to 
transformation of 2 µl diluted Gibson reaction added to 25 µl competent bacteria 
(see Section 3.20.1). 
 
3.21.7 Colony-PCR  
Colony-PCR was utilized to screen clones containing Gibson assembled plasmids 
with the desired amount of sgRNA flanked by the hU6 promotor and sgRNA scaffold 
(see Section 3.21.6). At least 24 single bacterial clones were analyzed by picking a 
single bacterial clone, smearing it to the bottom of a single PCR reaction tube prior 
to inoculation with 2 ml LB medium containing 100 µg/ml Ampicillin. In accordance 
with the published protocol for StagR cloning (Breunig et al., 2018), a 10 µl PCR mix 
using Taq polymerase and primers binding within the vector backbone was 
prepared, added to each PCR reaction tube prior to run the PCR with the published 
settings. PCR products were analyzed on a 1% agarose gel and clones showing a 
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PCR product of the desired length were used to inoculate cultures for mini 
preparations (see Section 3.21.3 and 3.20.2).  
 
Primer used for colony-PCR: StAgR_seq_fwd2 (ACTGGATCCGGTACCAAGG), 
StAgR_seq_rev (TTACGGTTCCTGGCCTTTTG) 
Expected PCR products containing sgRNAs: hU6 265 bp, gRNA scaffold 83 bp, 1 
sgRNA ~370 bp, 2 sgRNAs ~740 bp, 3 sgRNAs ~1.1kb, 4 sgRNAs ~1.5kb 
 
3.21.8 Genotyping of single-cell clones 
SCCs were analyzed at the genomic level in order to assess genetic insertions or 
deletions introduced by CRISPR/Cas9 technology. To do so, PCR reactions were 
performed using primers flanking the exon or exons of a gene of interest that was 
targeted by sgRNAs during CRISPR/Cas9 genome-editing (Table 6). For each new 
primer pair, respective annealing temperatures were established with the help of a 
temperature gradient using isolated gDNA from bulk cells. For genotyping, 25 µl 
reactions using 200 ng gDNA of each SCCs were mixed with nuclease-free water 
and the following reagents at a final concentration of 1x Q5 reaction buffer, 200 µM 
dNTPs, 0.5 µM of each primer and 20 Units/ml Q5 high-fidelity polymerase. The 
cycling program shown in Table 9 was run on a Thermocycler with the adjusted 
annealing temperature shown below (Table 6). As primers were designed to yield 
small PCR fragments and thereby allowing visualization of small insertions and 
deletions on 1 to 1.5% agarose gels, genotyping served as a method to screen for 
modified SCCs prior to subsequent analyses such as sequencing, immunoblotting 
and functional assays.  
 
Table 6: Primer sequences used for genotyping of single-cell clones 
Gene Primer (for, rev) 
Product 
length (wt) 
Annealing 
Temp 
ACSL4, gDNA 
Exon 4/5 
AACTGCCTTGGCTGTACTGCTA, 
ATGCAAGCAAAGACCCTCCTCT 
940 bp 70°C 
HMOX1, gDNA 
Exon3 
AGGGATTACAGGGGTTTGAGCC,  
CTCACCTGGATGTTGAGCAGGA 
808 bp 70°C 
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3.22 Cloning 
3.22.1 Cloning of two to four sgRNAs into the StagR_neo vector using StagR 
cloning 
String assembly gRNA cloning (StagR) was employed to generate vectors 
containing two to four sgRNAs targeting several critical exons of individual genes. 
The strategy of using two to four sgRNAs per gene simultaneously was employed 
to increase the probability of generating genomic deletions flanked by the sgRNAs. 
StagR cloning was performed according to a recently published protocol (Breunig et 
al., 2018). Critical exons of individual human genes were identified using the 
Ensembl genome browser 94 (https://www.ensembl.org/index.html) and sgRNAs 
targeting these exons were designed using the MIT CRISPR tool 
(http://crispr.mit.edu/) and the Benchling platform (https://benchling.com/). A 
distance of about 120 bp to a maximum of 250 bp was chosen between the target 
sequences of single sgRNAs within one gene (Table 7). The StagR_neo backbone 
vector was used for StagR cloning where expression of the sgRNA target sequence 
and scaffold sequence is driven by a hU6 promoter. Therefore, primer pairs of each 
sgRNA target sequence with the addition of either scaffold (forward primer) or hU6 
(reverse primer) overlapping overhangs were ordered from Eurofins as followed 
(see Table 7 for sgRNA target sequence): 
 
Forward primer: 5‘N20(sgRNA target sequence)GTTTTAGAGCTAGAAATAGCAAGTT3‘ 
Reverse primer: 5‘N20(complementary to sgRNA forward target sequence)CGGTGTTTCGTCCTTT3‘ 
 
Lyophilized primers were dissolved in nuclease-free water to a final concentration 
of 100 µM. PCRs using the Phusion High-Fidelity Polymerase to achieve maximal 
sequence accuracy were performed according to the published PCR protocols 
(Breunig et al., 2018). Briefly, depending on the desired order of sgRNA within the 
vector, the forward primer of the last sgRNA target sequence and reverse primer of 
the first sgRNA target sequence were used to amplify the StagR_neo backbone. For 
amplification of StagR fragments, the forward primer of the first target sequence and 
reverse primer of the second sgRNA target sequence and so on are combined for 
PCRs using the STAGR_gRNAScaffold_hU6 plasmid as template. Thereby, 
overhangs for Gibson Assembly were generated. The backbone PCR reaction was 
digested using DpnI enzyme according to manufacturer’s instructions for at least 1h 
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at 37°C in a thermoblock to digest methylated template plasmid. DpnI-digested 
backbone PCR and StagR fragments were separated on a 1% agarose gel and 
purified by gel extraction prior to ligation using Gibson assembly and transformation 
into XL10-Gold competent bacteria. Bacterial clones containing the plasmid with the 
desired amount of sgRNAs were identified by Colony-PCR (see Section 3.21.7). 
Plasmids were isolated by mini preparations and cleaned up using the Zymo DNA 
Clean & Concentrator-5 Kit according to the manufacturer’s instructions. The correct 
sequence was validated via sequencing by Eurofins using the Mix2SeqKit according 
to manufacturer’s instructions using the listed sequencing primer prior to 
amplification of correct plasmids by midi preparations. 
 
Sequencing primers: StAgR_seq_fwd2 (ACTGGATCCGGTACCAAGG), StAgR_seq_rev 
(TTACGGTTCCTGGCCTTTTG) 
 
Table 7: sgRNA target sequences cloned into the StagR_neo vector using StagR cloning 
Gene Oligo label Target Sequence 
ACSL4 ACSL4_Ex4_sg1 ATTGTTATTAACAAGTGGAC 
ACSL4_Ex4_sg2 CTAGCTGTAATAGACATCCC 
ACSL4_Ex5_sg2 TGCAATCATCCATTCGGCCC 
GPX4 Gpx4_Ex2_gRNA2 TTTCCGCCAAGGACATCGAC 
Gpx4_Ex4_gRNA4 ACTCAGCGTATCGGGCGTGC 
HMOX1 HO1_Ex_gRNA19 CACATAGATGTGGTACAGGG 
HO1_Ex3_gRNA2 CTATGTGAAGCGGCTCCACG 
 
3.22.2 Cloning one sgRNA into the StagR_neo vector 
To generate constructs targeting only one sequence within a gene of interest, one 
sgRNA was cloned into the StagR_neo vector using a slightly altered protocol kindly 
provided by Christopher Breunig, from the group of Dr. Stefan Stricker (Functional 
Epigenetics, Institute of Stem Cell Research, Helmholtz-Center Munich). Briefly, in 
a 50 µl reaction, 5 µg of StagR_neo vector were digested with 2.5 µl AgeI in 1x 
CutSmart buffer overnight at 37°C. Linearization of the vector was confirmed by a 
1% test agarose gel and digestion reaction was cleaned up using the Zymo DNA 
Clean & Concentrator-5 Kit. sgRNA target sequences were designed as described 
in Section 3.22.1 and an oligo containing the GPX4 sgRNA target sequence (see 
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below) flanked by the addition of overhangs (partial sequences of hU6 and Scaffold) 
was ordered from Eurofins: 
 
Oligo: TCTTGTGGAAAGGACGAAACACCGN20(sgRNA target sequence)GTTTTAGAGCTAGAAATAGCAA 
GTTAAAATAAGGCT 
 
50 ng of the oligo template were amplified using the Phusion high-fidelity DNA 
polymerase and primers annealing to the flanking sequences in a 50 µl reaction 
according to manufacturer’s protocol using the cycling protocol shown in Table 8. 
Upon column-based cleanup of the PCR product using the Zymo DNA Clean & 
Concentrator-5 Kit, purified AgeI-digested vector backbone and PCR fragment 
containing the sgRNA were submitted to Gibson Assembly (see Section 3.21.6). 
After transformation and isolating plasmids from approximately 12 mini-cultures, 
plasmids were screened for sgRNA containing bacterial clones by a test 
endonuclease restriction. 2 µl of plasmid DNA were digested using AgeI and PvuI 
double digest in a 10 µl reaction according to manufacturer’s protocol and analyzed 
on a 1% agarose gel. This strategy yields two fragments for negative clones and 
one fragment for sgRNA positive clones as AgeI restriction site should be lost during 
Gibson assembly. Positive clones were sequenced (Mix2SeqKit, Eurofins) using 
StagR_seq_fwd1 primer and a plasmid containing the correct sequence amplified 
by midi preparation. 
 
GPX4 sgRNA target sequence: Gpx4_Ex3_gRNA3TP (CGTGTGCATCGTCACCAACG) 
PCR primer: LibGen_U6_fwd (CTTGTGGAAAGGACGAAACA), LibGen_Scaffold_rev 
(GCCTTATTTTAACTTGCTATTTCTAGC) 
Sequencing primer: StAgR_seq_fwd1: GAGTTAGGGGCGGGACTATG (for 1 sgRNA),  
 
Table 8: Cycling program to amplify oligo template for cloning of one sgRNA into StagR_neo 
Step Temperature Duration Cycles 
Initialization 98°C 30 sec 1x 
Denaturation 98°C 10 sec 
35x Annealing 66°C 10sec 
Extension 72°C 10 sec 
Final Extension 72°C 10 min 1x 
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3.22.3 Cloning of GPX4 shRNAs from pGIPZ into the doxycycline-inducible 
pTRIPZ vector 
Since a doxycycline-inducible pTRIPZ vector containing shRNAs against GPX4 was 
not available, GPX4 shRNAs were subcloned from purchased pGIPZ vectors to the 
nontargeting shRNA containing pTRIPZ vector (see Section 2.11). Cloning was 
performed as recommended by the manufacturer’s protocol. Briefly, midi cultures 
containing 100 µg/ml Ampicillin were inoculated from purchased glycerol stocks, 
plasmids isolated using QIAGEN Plasmid Midi Kit and quality of plasmids controlled 
by SalI restriction followed by agarose gel visualization. 10 µg of each shRNA 
containing pGIPZ and control pTRIPZ vector were digested using MluI and XhoI for 
2h at 37°C in a 20 µl reaction, followed by purification of GPX4 shRNAs (345 bp) 
and pTRIPZ backbone (13061 bp) from 1.2% agarose gels. Ligation reactions of 
each GPX4 shRNA with the digested pTRIPZ backbone were performed using 300 
ng pTRIPZ backbone and 79.24 ng insert (1:10 ratio) in 20 µl T4-ligase reactions 
overnight at 16°C (see Section 3.21.5). Stabl2 competent bacteria were transduced 
prior to preparing 6-10 mini-cultures for bacterial colonies for each construct. 2 µl of 
isolated plasmids were test-digested with combinations of either NotI/MluI or 
XhoI/MluI (in case MluI/XhoI restriction sites got lost during cloning) in 20 µl 
reactions according to manufacturer’s instructions for 20 min at 37°C. After a 
cleanup with Zymo DNA Clean and Concentrator Kit 5, plasmids showing the correct 
fragment sizes on agarose gels were sequenced to validate correct sequence using 
pTRIPZ_seq primer. pTRIPZ plasmids containing shRNAs against GPX4 were 
amplified by Midi cultures prior to subsequent experiments. 
 
Sequencing primer: pTRIPZ_seq (GGAAAGAATCAAGGAGG) 
 
3.22.4 Cloning of HMOX1 cDNA into the pLVX-puro vector 
The pLVX-puro vector was used to express HMOX1 cDNA in HMLE cells via 
lentiviral gene transfer. cDNAs transcribed from RNA isolated from HMLE-Twist1 
cells at low cell density in 6-cm dishes (see Section 3.5 and 3.19.1) were purified 
using the Zymo DNA Clean and Concentrator 5 Kit. 5 ng of purified cDNAs were 
used to amplify full-length HMOX1 cDNA in 50 µl reactions using Q5 high-fidelity 
DNA polymerase and 1x Q5 high GC enhancer according to manufacturer’s protocol 
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with the cycling steps shown in Table 9. Primers employed annealed to sequences 
containing the start and stop codons flanked by BamHI and XbaI recognition sites 
which were not present in HMOX1 cDNA. The PCR product as well as 3 µg of pLVX-
puro vector were digested with XbaI/BamHI in 20 µl reactions for 1.5h at 37°C. A 
1.2% test agarose gel was run to assess digestion efficiency of vector and HMOX1 
PCR amplification specificity prior to purification using Zymo DNA Clean and 
Concentrator 5 Kit. 200 ng purified and digested vector backbone were ligated to 
HMOX1 cDNA inserts at 1:3 and 1:5 ratios using a T4-ligase reaction overnight at 
16°C (see Section 3.21.5). Stabl2 competent bacteria were transformed, plasmids 
of 14 mini-cultures screened by XbaI/BamHI test-digest and positive plasmids 
sequenced using the following primer prior to amplification by Midi cultures. 
 
PCR Primer: For_XbaI_Hmox1 (CCTCTAGAATGGAGCGTCCGCAACCCGACA), 
Rev_BamHI_Hmox1 (AAGGGATCCTTACTGCATTCACATGGCATAAAGCCCTACAGC) 
Sequencing primer: Seq_pLVX_HMOX1_For1 (GTTTAGTGAACCGTCAGATCGC), 
Seq_pLVX_HMOX1_For2 (CTGCCCTGGAGCAGGACC), Seq_pLVX_HMOX1_For3 
(GAGGGTGATAGAAGAGGCCA) 
 
Table 9: Cycling program used to amplify HMOX1 cDNA 
Step Temperature Duration Cycles 
Initialization 98°C 3 min 1x 
Denaturation 98°C 20 sec 
35x Annealing 72 °C 20 sec 
Extension 72°C 40 sec 
Final Extension 72°C 5 min 1x 
 
3.23 Delivery methods into human cells 
3.23.1 Transfection of vectors expressing Cas9 and sgRNAs for CRISPR/Cas9-
mediated gene knockout 
For CRISPR/Cas9-mediated gene knockout, cells were transiently transfected with 
the Cas9/GFP expressing pSpCas9(BB)-2A-GFP plasmid (Ran et al., 2013) 
together with a cloned gRNA_neo construct containing 1-4 sgRNAs targeting genes 
of interest (see Section 3.22.1 and 3.22.2). This strategy allows CRISPR/Cas9 
modification in the target locus only in a short period without possible, undesired 
long-term effects introduced by stable lentiviral transductions. For transfection, 1.5 
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to 2 x 105 cells were seeded per well in a 6-well plate. The next day, the medium 
was replaced with 1.8 ml with respective complete growth medium. 200 µl basal 
DMEM was mixed with 1 µg of pSpCas9(BB)-2A-GFP plasmid and the gRNA_neo 
vector with sgRNAs at a molar ratio of 1:3 (in total approximately 2-2.5 µg) prior to 
addition of 7.5 µl room-temperature equilibrated TransIT-X2 transfection reagent 
according to manufacturer’s protocol. The transfection mix was vortexed and 
incubated for 15-30 min at RT prior to drop-wise addition to cells. After overnight 
incubation of cells at the 37°C cell incubator, the transfection medium was replaced 
by respective complete growth medium and two days later, GFP-positive cells were 
sorted by FACS as described in Section 3.14.2. 
 
3.23.2 Viral transduction  
Viral transduction was employed to stably introduce DNA into target cells and 
handled in agreement with recommended guidelines for working with BSL-2 safety 
class. 
 
3.23.2.1 Lentiviral production, concentration, and titration 
HEK293T were used to produce replication-incompetent viral particles by 
transfection of lentiviral vectors (pLKO-puro and pTRIPZ based vector) together with 
the second generation packaging plasmid pCMV-dR8.2 dvpr and envelope plasmid 
pCMV-VSV-G. 2 x 106 HEK293T cells (passage below 20) were seeded in a T175 
cm2 cell culture flask in standard DMEM. A transfection mix in 1500 µl basal DMEM 
was prepared consisting of 18 µg lentiviral vector, 6.3 µg pCMV-VSV-G, 11.7 µg 
pCMV-dR8.2 dvpr and 108 µl PEI, followed by extensive mixing and incubation for 
15-30 min at RT. The transfection mix was added drop-wise to HEK293T cells, 
incubated overnight prior to refreshing with standard DMEM medium. 24h later, viral 
particles contained in the medium supernatant were filtered through a 0.45 µm 
PVDF filter to remove cell fragments and concentrated by applying 30 ml filtered 
viral supernatant on 6 ml 20% sucrose in single-use ultracentrifugation tubes. After 
high-speed ultracentrifugation for 2-3h at 50000 x g at 4°C, the supernatant was 
completely removed and pelleted viral particles were resuspended in 75-120 µl 
medium of target cells and aliquots of 25 µl were frozen to -80°C. For titration of the 
virus, 5 x 104 HMLE cells were seeded into 24-well plates and the next day, different 
amounts of thawed virus aliquot were added per well overnight (10-fold dilutions 
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ranging from 10 µl to 0.001 µl, one well without virus). Then, cells were replated in 
a 6-well plate and after attachment of cells (3-4h later), antibiotic selection with 1 
µg/ml puromycin was started. Total colonies of wells with distinguishable colonies 
were counted once non-transduced cells were completely killed by puromycin and 
viral titer (averaged from different wells) calculated using the following formula: 
𝑇𝑖𝑡𝑒𝑟 (𝑇𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑈𝑛𝑖𝑡𝑠(𝑇𝑈) 𝑝𝑒𝑟 𝑚𝑙) = 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑚𝑒𝑑𝑖𝑢𝑚
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑎𝑙 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
 
Standard DMEM: DMEM, 10% FCS, 1% Pen/Strep 
 
3.23.2.2 Transduction of target cells with lentivirus 
Multiplicities of infection (MOI) between 0.2 and 10 were used to transduce target 
cells. The volume of virus required for transduction was dependent on the virus titer 
and the number of seeded cells and was calculated adjusting the following formula: 
𝑀𝑂𝐼 =
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑥 𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑒𝑒𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
Target cells at respective cell densities were seeded into 24-well to 6-well to reach 
a 60-70% confluency one day before overnight viral transduction. Cells were 
passaged and after attachment, selected with 1 µg/ml puromycin selection until non-
transduced control cells were completely killed. Selected, transduced cells were 
frozen to generate cell stocks prior to subsequent experimental procedures and 
analyses.  
 
3.24 Isolation of single-cell clones (SCCs) 
In order to purify clones derived from one single cell in order to isolate one specific 
genotype (for example after CRISPR/Cas9 genome-editing), single cells were 
seeded in 96-wells. Specifically, a cell suspension consisting of 0.5 to 1 cell per 100 
µl was prepared and seeded into each well of five 96-well plates. After 3-4 days, 
each well was visually inspected for single cells giving rise to one small colony. Wells 
containing one colony were passaged and expanded to 6-well prior to genotyping 
(see Section 3.21.8) and freezing into 1-2 cryotubes (see Section 3.3).  
 
3.25 Data presentation and statistical analyses 
Data presented show the mean ± SEM of n=x independently performed 
experiments, with x values indicated in the respective figure legends, unless stated 
otherwise. Within each independent experiment, 3-10 technical replicates per 
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condition were employed. An unpaired, two-tailed student’s t-test with Welch’s 
correction was used to compare two groups and a p-value below 0.05 was 
considered significant. Statistical analyses were conducted using Excel 2016 and 
GraphPad Prism 7.0 software. 
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4 Results 
4.1 Initial induction of ferroptosis in HMLE-Twist1-ER 24hi cells 
The activation of the EMT program has been associated with the induction of 
resistance to conventional therapies (Ansieau et al., 2014; Nieto et al., 2016). 
Several reports have suggested a connection between EMT and the upregulation 
or loss of metabolic genes regulating the generation of ROS (Dong et al., 2013; 
Masin et al., 2014; Shaul et al., 2014). As ferroptosis has been introduced as a newly 
recognized cell death modality reported to involve mitochondrial damage as well as 
lipid ROS-mediated toxicity (Dixon et al., 2012; Yagoda et al., 2007), I was interested 
whether epithelial and Twist1-induced mesenchymal cells are differentially affected 
by ferroptosis inducers. As an experimental EMT model, I used immortalized human 
mammary epithelial cells (HMLE) (Elenbaas et al., 2001) that express an inducible 
Twist1 protein (HMLE-Twist1-ER) (Mani et al., 2008). Therein, Twist1 is fused to a 
mutated estrogen receptor (ER) ligand domain keeping the EMT-TF in an inactive 
conformation until 4-hydroxytamoxifen (TAM) is added (Casas et al., 2011; Schmidt 
et al., 2015). Derived thereof, HMLE-Twist1-ER 24hi cells are a purified epithelial 
subpopulation based on the CD44+/CD24high cell surface marker expression 
(Schmidt et al., 2015). In an initial experiment, 2.5 x 103 epithelial or 15d TAM-
induced mesenchymal HMLE-Twist1-ER 24hi cells were seeded in 96-well plates 
and 48h later, the cells were treated with 3-fold dilutions of ferroptosis-inducing 
compounds such as RSL3 and ERA for 24h (Figure 3).  
 
Figure 3: HMLE-Twist1-ER 24hi cells are resistant to ferroptosis inducers 
Dose-response curves: epithelial (−TAM, orange) and 15d TAM-induced mesenchymal 
(15d+TAM, blue) HMLE-Twist1-ER 24hi cells were seeded at a cell density of 2500 cells per well 
in 96-well plates. 48h after plating, cells were treated with 3-fold dilutions of RSL3 or Erastin 
(ERA) for 24h prior to the assessment of cell viability using CellTiter-Glo assay. Data was 
normalized to DMSO control and show mean ± SD of n=5 wells. 
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However, neither RSL3 nor ERA affected cell viability in epithelial (–TAM) or 
mesenchymal (15d+TAM) HMLE-Twist1-ER 24hi compared to untreated control 
(Figure 3): Earlier studies using chemotherapeutics such as doxorubicin have shown 
a correlation between cell density and drug efficacy (Ohnuma et al., 1986; Takemura 
et al., 1991). Hence, I speculated that cell density might influence sensitivity to 
ferroptosis-inducing compounds. Therefore, 333, 1000 and 3000 cells were seeded 
in 96-well plates prior to incubation for 24h with abovementioned compounds (Figure 
4). Applied drug concentrations were chosen from dose-response curves shown in 
(Figure 3), in order to allow assessment of differences in cell death induction at lower 
seeding densities. While I did not observe major differences in cell viability at 
different seeding numbers when 3 µM ERA treatment was applied, RSL3 induced a 
reduction in cell viability that depended on seeded cell numbers in both epithelial 
and 15d TAM-induced mesenchymal HMLE-Twist1-ER 24hi cells (Figure 4). Both 
cell lines showed resistance to 300 nM RSL3 treatment at high density (3000 cells 
seeded per well in a 96-well plate). However, viability was decreased by 92-97% at 
low density (333 seeded cells) in comparison to the DMSO control. Interestingly, at 
an intermediate seeding density of 1000 seeded cells, a differential sensitivity 
between epithelial and 15d TAM-induced mesenchymal HMLE-Twist1-ER 24hi cells 
was observed, with mesenchymal cells showing increased sensitivity. The initial 
observation of cell density-dependent cell death induction by RSL3 was an 
unexpected and intriguing finding. Therefore, I decided to first validate this 
 
Figure 4: Sensitivity to RSL3 treatment depends on seeding density in HMLE-Twist1-ER 
24hi cells 
Viability assays: treatment of epithelial (−TAM, orange) and 15d TAM-induced mesenchymal 
(15d+TAM, blue) HMLE-Twist1-ER 24hi cells seeded at three different cell densities (333, 1000 
and 3000 cells) in 96-well plates. One day later, treatment with RSL3 or ERA at indicated 
concentrations was applied for 24h prior to measuring cell viability using CellTiter-Glo assay. 
Data was normalized to DMSO control within each cell density and cell line and show mean ± 
SD of n=5 wells. 
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observation and then to determine the mechanisms of cell density-dependent cell 
death induction by RSL3. 
 
4.2 RSL3 induces cell death in a cell density-dependent manner in both 
epithelial and Twist1-induced mesenchymal HMLE cells 
RSL3 induces ferroptosis by directly inhibiting the central ferroptosis regulator 
glutathione peroxidase 4 (GPX4) (Yang et al., 2014). For validation of above-
mentioned observations, viability assays with epithelial and Twist1-induced 
mesenchymal cells at different cell densities were repeated. In the following, high 
(hi), intermediate (med) and low cell density refers to 3000, 1000 and 333 cells 
seeded per well in a 96-well plate, if not otherwise indicated. Cell numbers were 
adjusted accordingly to other well and dish formats as described in Section 3.5. One 
day after plating, cells were treated for 24h with 300 nM RSL3 and cell viability was 
measured using the CellTiter-Glo assay. I observed a statistically significant cell 
density-dependent induction of cell death in both epithelial and Twist1-induced cells, 
with cells being highly sensitive at low cell density and resistant at high cell density. 
RSL3 treatment decreased cell viability by 90-93% at low cell density compared to 
DMSO treated control (Figure 5A). Again, I observed an increased sensitivity to 
RSL3-treatment in HMLE cells where Twist1 was induced for 15 days. Here, RSL3 
treatment diminished cell viability by 69% in HMLE-Twist1 cells, but only by 8% in 
HMLE cells compared to DMSO treated control (Figure 5A). Of note, an inactive 
diastereomer of RSL3 (inactive RSL3), used as a control for off-target effects (Yang 
et al., 2014), did not induce cell death at any cell density (Figure 5A). 
Next, HMLE-Snail1-ER 24hi cells that express the Snail1 EMT-TF which results in 
EMT induction upon TAM treatment (Mani et al., 2008; Schmidt et al., 2015), were 
also treated with RSL3. Again, RSL3 induced cell death in a cell density-dependent 
manner, but activation of Snail1 did not alter this sensitivity at intermediate seeding 
densities (Figure 5B). These data suggested on one hand that sensitivity to 
ferroptosis was not generally connected to EMT-induction, but in some conditions, 
i.e. at intermediate seeding density, Twist1 expression might increase sensitivity to 
ferroptosis (Figure 5A) . To further support these findings, I used parental epithelial 
HMLE and HMLE-Twist1 cells, which constitutively express Twist1 and are fixed in 
the mesenchymal state (Mani et al., 2008). Using viability assays, I determined that  
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Figure 5: RSL3 induces cell density-dependent cell death in both epithelial and Twist1-
induced mesenchymal HMLE cells 
(A) Viability assay: treatment of epithelial (−TAM) or 15d TAM-induced mesenchymal 
(15d+TAM) HMLE-Twist1-ER 24hi cells seeded the day before at low (orange, 333 cells), med 
(blue, 1000 cells) or hi (grey, 3000 cells) cell density in 96-well plates with 0.3% DMSO, 300 nM 
RSL3 or inactive RSL3 for 24h. n=3. (B) Viability assay: treatment of epithelial (−TAM) or 15d 
TAM-induced mesenchymal (15d+TAM) HMLE-Snail1-ER 24hi cells as described in A. Data 
show mean ± SEM of n=5 wells. (C) Bright-field microscopy: representative pictures of epithelial 
HMLE and mesenchymal HMLE-Twist1 (HTwist1) cells seeded at indicated cell densities in 6-
well plates 24h before treating cells with 0.1% DMSO control or 100 nM RSL3 for 24h and 
imaging. Scale bar: 200 µm. (D) Viability assay: treatment of HMLE and HTwist1 cells seeded 
at indicated densities in 96-well plates with 0.1% DMSO or 100 nM RSL3. n=6. Data were partly 
generated by Marie Bannier-Hélaouët (Intern). (E) Dose-response curves: treatment of HMLE 
and HTwist1 cells plated in 96-well plates with 3-fold dilutions of RSL3. n=4. (F) Immunoblot: 
protein expression of E-cadherin (E-cad), GPX4, Zeb1 and beta-actin in HMLE and HMLE-
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treatment with 100 nM RSL3 for 24h again significantly induced cell death in a cell 
density-dependent manner (Figure 5C and D). Moreover, cells plated at an 
intermediate cell density also showed intermediate levels of cell death (Figure 5D). 
Dose-response curves using 3-fold dilutions of RSL3 further supported the finding 
of a cell density-dependent induction of cell death by RSL3 (Figure 5E). A 
comparison of the calculated IC50 values at intermediate seeding densities for 
HMLE and HMLE-Twist1 showed an increased sensitivity of HMLE-Twist1 cells 
towards RSL3 treatment (449 nM vs 104 nM). These results suggested that 
activation of Twist1 increased sensitivity to ferroptosis.  
Since RSL3 directly inhibits GPX4 (Yang et al., 2014), immunoblotting for GPX4 was 
performed to assess whether GPX4 expression levels were dependent on cell 
density. GPX4 was expressed in both HMLE and HMLE-Twist1 cells at the same 
level irrespective of low or high cell density (Figure 5F). However, GPX4 expression 
levels were generally around 2.5-fold higher in HMLE-Twist1 compared to HMLE 
cells. As described previously, HMLE cells display an epithelial morphology and 
express the epithelial marker E-cadherin, whereas Twist1-overexpression induces 
an EMT, resulting in downregulation of E-cadherin and expression of the 
mesenchymal marker Zeb1 (Figure 5F) (Mani et al., 2008; Yang et al., 2004).  
Taken together, I validated my initial findings, showing that cell density is a critical 
factor that sensitized both epithelial and mesenchymal HMLE cells to GPX4 
inhibition by RSL3. In addition, Twist1-expression increased sensitivity towards 
RSL3 treatment at intermediate seeding densities. 
 
4.3 Ferroptosis is the cell death-modality in cell density-dependent cell death 
As GPX4 is a known key regulator of ferroptotic cell death (Yang et al., 2014), I 
wanted to further specify whether cell density sensitized cells specifically to this 
mode of cell death. To do so, cells were plated at a lower seeding density (600 cells) 
in 96-well plates and treated with RSL3 alone or in combination with compounds  
 
Twist1 seeded at high (hi) and low cell density in 10-cm dishes. Upper beta-actin protein band 
serves as a loading control for E-cad and GPX4, lower beta-actin protein band for Zeb1. 
Densitometric ratios of detected proteins bands of GPX4 to beta-actin are indicated in percent. 
kDa = kilo Dalton. Data (A, D, E) represent mean ± SEM. Viability was normalized to respective 
DMSO control within each cell density and cell line. Statistics: two-tailed, unpaired T-test with 
Welch’s correction (p-value: *<0.05, **<0.01, ***0.001, ****<0.0001, n.s. = not significant). 
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inhibiting either apoptosis, necroptosis or ferroptosis. zVAD-fmk (zVAD) inhibits 
apoptosis by inhibiting caspase activity necessary for apoptosis execution (SLEE et 
al., 1996). Nec1-S is a more potent derivative of Necrostatin-1 which inhibits the 
receptor-interacting protein kinase 1 (RIPK1), thereby blocking regulated necrosis 
(Degterev et al., 2005). For ferroptosis inhibition, Ferrostatin1 (Fer1) and 
Liproxstatin1 (Lip1) were employed (Dixon et al., 2012; Friedmann Angeli et al., 
2014). Upon 20-24h of RSL3-treatment, cell viability was decreased by 74-85% in 
HMLE and HMLE-Twist1 cells compared to the DMSO control (Figure 6A). When 
 
Figure 6: The cell death-modality in cell density-dependent cell death induced by RSL3 
is ferroptosis. 
(A) Rescue-viability assay: HMLE and HMLE-Twist1 cells were seeded at 600 cells 
(intermediate-low cell density) in 96-well plates and treated for 20-24h with DMSO control or 
100 nM RSL3 alone or in combination with 500 nM Liproxstatin (Lip1), 500 nM Ferrostatin-1 
(Fer1), 10 µM Necrostatin1-S (Nec1-S) or 50 µM zVAD-fmk (zVAD). n=3-5. Data shown 
represent mean ± SEM. Viability was normalized to respective DMSO control within each cell 
line. Statistics: two-tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, **<0.01, 
***0.001, ****<0.0001, n.s. = not significant). (B) Immunoblot: protein expression of uncleaved 
and cleaved PARP and Caspase 3 (Casp3) upon 20h 100 nM RSL3 or 10 µM Doxorubicin 
(DOXO) treatment of HMLE and HTwist1 cells seeded at intermediate cell density in 15-cm 
dishes. 0.1% DMSO treatment served as negative control while DOXO served as positive 
control for PARP and Casp3 cleavage. Beta-actin was used as loading control. Numbers shown 
indicate densitometric ratios of detected proteins (PARP, cleaved PARP, Casp3, cleaved 
Casp3) to respective beta-actin protein band in percent (from top to bottom). kDa= kilo Dalton, 
n.d. = not detectable. Immunoblot shown is representative for n=3 (PARP) and n=1 (Casp3). 
Data from rescue-viability assay were partly generated by and immunoblot analysis was 
performed by Felix Holstein (Master Student).  
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cells were co-treated with either 500 nM Fer1, 500 nM Lip1, 10 µM Nec1-S or 50 
µM zVAD, only Fer1 and Lip1 fully rescued RSL3-induced cell death (Figure 6A). 
Neither zVAD nor Nec1-S protected cells significantly from RSL3-induced cell death 
(Figure 6A). Importantly, the applied inhibitor concentrations were not toxic to the 
cells (Figure 6A) and were previously shown to be protective against the respective 
mode of cell death (Friedmann Angeli et al., 2014). To further rule out apoptosis as 
cell death modality, immunoblotting for the apoptosis markers Caspase 3 (Casp3) 
and PARP was performed. During the process of apoptosis, Casp3 is cleaved into 
its active isoform, inducing a process leading to DNA fragmentation (Fernandes-
Alnemri et al., 1994; Nicholson et al., 1995; Tewari et al., 1995; Wolf et al., 1999). 
PARP is involved in DNA repair and DNA stability, unless it is inactivated by Casp3 
cleavage, thereby leading to accumulation of double strand breaks and thus 
contribution to apoptosis (Boulares et al., 1999; Nicholson et al., 1995). For this 
purpose, HMLE and HMLE-Twist1 cells were seeded at an intermediate cell density 
and treated with 100 nM RSL3 for 20h. I could neither detect a cleavage of Casp3 
nor pronounced cleavage of its downstream target PARP (Figure 6B). In contrast, 
when cells were treated with 10 µM Doxorubicin (DOXO), both PARP and Casp3 
were cleaved, thus serving as a positive control (Figure 6B). DOXO is a 
chemotherapeutic agent that intercalates into DNA and compromises DNA 
synthesis, ultimately leading to apoptosis (Fornari et al., 1994; Tacar et al., 2013).  
Together, these data suggested that cell death induced by RSL3 treatment was 
mediated through ferroptosis and that thereby cell density sensitized both HMLE 
and HMLE-Twist1 to ferroptosis. 
 
4.4 Cell density-dependent ferroptosis is not directly linked to thiol and 
glutathione metabolism 
Previous reports have shown that reducing GSH levels by inhibiting the system xc− 
by ERA treatment or by direct interference with GSH synthesizing enzymes (for 
example by BSO) indirectly impairs GPX4 function and thus leads to ferroptosis 
(Friedmann Angeli et al., 2014; Yang et al., 2014). Therefore, I wanted to elaborate 
in more detail whether thiol and GSH metabolism upstream of GPX4 contributed to 
cell density-dependent ferroptosis induced by RSL3-treatment. To address this 
question, I again exposed epithelial and TAM-induced HMLE-Twist1-ER 24hi cells, 
seeded at an intermediate-low density (600 cells) in 96-well plates, to 3-fold 
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dilutions. In line with my initial observations when exposing cells to ERA treatment 
(Figure 3 and Figure 4), I observed that ERA treatment for 24h did not influence cell 
viability in HMLE-Twist1-ER 24hi cells (Figure 7A). Importantly, ferroptosis was 
efficiently induced by RSL3 treatment in both HMLE and HMLE-Twist1 cells at this 
cell density (Figure 6A). Next, I assessed the expression of the substrate specific 
light chain subunit SLC7A11 of system xc− (Lewerenz et al., 2012), and the 
expression of the catalytic subunit GCLC of GCL, the rate-limiting enzyme in GSH 
biosynthesis (Franklin et al., 2009). qPCR analysis revealed a reduction of both 
GCLC and SLC7A11 transcript levels in mesenchymal HMLE-Twist1 cells 
compared to parental epithelial HMLE cells. However, this reduction occurred 
irrespective of cell density (Figure 7B and C), indicating that GCLC and SLC7A11 
expression were not directly regulated by cell density, but rather by Twist1 
expression.  
To determine whether this reduction in gene expression was functionally relevant, I 
assessed thiol release as a proxy for system xc− activity and total GSH levels in 
collaboration with Dr. José-Pedro Friedman Angeli (Bannai and Ishii, 1980, 1982; 
Ishii et al., 1987). System xc− activity was 2-fold and total GSH levels were 1.5-fold 
reduced in 17d TAM-induced mesenchymal HMLE-Twist1-ER 24hi cells compared 
to parental epithelial HMLE cells (Figure 7D and E). These results suggested a lower 
abundance of reducing equivalents in Twist1-induced mesenchymal cells. 
Importantly, ERA treatment, serving as a control, completely abolished system xc− 
activity and depleted GSH content, which was expected since the cysteine that is 
necessary for GSH synthesis is derived via cystine import by system xc− (Figure 7D 
and E) (Ishii et al., 1987). Accordingly, Thioltracker Violet staining by flow cytometry 
revealed that reduced Thiols, serving as a proxy for reduced GSH content, were 
decreased upon Twist1-expression, both in HMLE-Twist1-ER 24hi cells and in 
HMLE-Twist1 cells compared to the parental, epithelial HMLE cells (Figure 7F). 
Again, these data indicated that Twist1-induced mesenchymal cells might have less 
reducing equivalents. Since both thiol and glutathione metabolism are connected 
with GPX4 function (Friedmann Angeli et al., 2014; Yang et al., 2014), GPX4 activity, 
measured by the specific reduction of phosphatidylcholine hydroperoxide (PCOOH), 
was assessed in collaboration with Dr. Irina Ingold. Surprisingly, GPX4 activity was 
not altered upon 17d TAM-induction compared to the parental cells (Figure 7G).  
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Figure 7: Thiol and glutathione metabolism are not directly linked with cell density-
dependent ferroptosis 
(A) Dose-response curves: treatment of epithelial (−TAM) or 15d TAM-induced mesenchymal 
(15d+TAM) HMLE-Twist1-ER 24hi cells seeded at 600 cells in 96-well plates with 3-fold dilutions 
of Erastin (ERA) for 24h. Data show mean ± SD. n=2. Viability was normalized to respective 
DMSO control within each cell line. (B) and (C) qPCR: relative (B) GCLC and (C) SLC7A11 
mRNA expression of HMLE and HMLE-Twist1 cells seeded at different cell densities in 6-cm 
dishes. Data show mean ± SEM. (D) Thiol release measurement as a proxy for system xc‒ 
activity in epithelial (−TAM) or 17d TAM-induced mesenchymal (17d+TAM) HMLE-Twist1-ER 
24hi cells plated in 12-well plates. ERA treatment (inhibiting system xc‒) served as positive 
control. Data shown quantified thiol release at 4h and represent mean ± SD. (E) GSH levels 
were measured as described in D. ERA treatment served as positive control to inhibit system 
xc‒ and thus cystine uptake necessary for GSH metabolism. Data show mean ± SD. n=2. (F) 
Flow cytometry: Thioltracker Violet staining of epithelial (−TAM, −Twist1 orange) and Twist1-
induced mesenchymal (16d+TAM, +Twist1 blue) HMLE-Twist1-ER 24hi and HMLE cells seeded 
at 1 x 105 cells in a 6-well. X-axis: log10 of Thioltracker fluorescence, Y-axis: percentage of 
maximum count. (G) GPX4-specific activity measurement in epithelial (−TAM) or 17d TAM-
induced mesenchymal (17d+TAM) HMLE-Twist1-ER 24hi cells. Data show mean ± SD of n=4 
samples obtained from confluent 15-cm dishes. Data (B, C, D, F) show one representative 
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Overall, these data suggested that system xc− activity as well as GSH levels were 
decreased upon Twist1-expression, but not by cell density. However, these changes 
did not seem to be sufficient to impact GPX4 activity, since both epithelial and 
Twist1-induced cells showed a similar GPX4 activity. Conclusively, upstream 
mechanisms did not directly influence cell density-dependent ferroptosis observed 
upon GPX4-inhibition. 
 
4.5 Cell density-dependent ferroptosis occurs upon GPX4-knockdown and 
knockout 
As described above, RSL3, but not ERA, led to cell density-dependent cell death 
and by using ferroptosis inhibitors, I specified the mode of cell death as ferroptosis. 
To pinpoint that the induced ferroptosis is dependent on GPX4-inhibition, I sought 
to confirm genetically that GPX4-inhibition led to cell density-dependent ferroptosis. 
To do so, I pursued two different strategies because CRISPR/Cas9 technology, 
used as a second approach to knockout GPX4, had to be established in our 
laboratory first. First, GPX4 expression was ablated by short hairpin RNA (shRNA)-
mediated gene silencing. Thereby, mRNA is degraded by the endogenous RNA-
induced silencing complex (RISC) loaded with the respective shRNA (Paddison et 
al., 2002). shRNAs were cloned from the pGIPZ lentiviral vectors containing shRNAs 
against GPX4 into the pTRIPZ lentiviral vectors (Dharmacon). The pTRIPZ lentiviral 
vector system enabled Dox-inducible shRNA expression and thus inducible GPX4 
knockdown. This strategy facilitated long-term culture of cells in the absence of Dox 
since a genetic knockout of GPX4 was shown to be lethal (Imai et al., 2003; Yant et 
al., 2003). HMLE 24hi cells were transduced with pTRIPZ lentiviral vectors containing 
non-targeting shRNAs (sh-nt) or GPX4-targeting shRNAs (sh-GPX4) at a MOI of 
0.7. Induction of shRNAs against GPX4 for 72h with 0.5 µg/ml Dox led to a reduction 
of GPX4 transcript levels of about 90% compared to untransduced control cells as 
assessed by qPCR (Figure 8A). Moreover, nt shRNA did not influence GPX4 
transcript levels (Figure 8A). To determine the impact on cell viability, viability 
assays were performed by counting the cells seeded in 24-well plates and by 
  
experiment performed independently two (D, F) or three (B, C) times. Data (D, E, G) were kindly 
provided (D, E) by Dr. José Pedro Friedmann Angeli and (G) by Dr. Irina Ingold.  
  Results 
95 
 
performing CellTiter-Glo assays. Since GPX4 might have residual activity after a 10-
fold decrease (Yang et al., 2014), low-dose RSL3 treatment was applied during 
viability assays using GPX4 knockdown cells. Importantly, in this case, RSL3 
treatment was used at a dosage previously shown to be non-toxic to cells with intact 
GPX4 expression (Figure 5E). To assess viability, HMLE 24hi cells containing 
shRNAs were seeded in 24-well plates at a low (1200 cells) or intermediate (3600 
 
Figure 8: Cell density-dependent ferroptosis occurs upon GPX4-knockdown 
(A) qPCR: relative GPX4 mRNA expression of non-transduced, control (ctrl) or pTRIPZ lentiviral 
vectors containing Dox-inducible non-targeting shRNAs (sh-nt) or GPX4-targeting shRNAs (sh-
GPX4) HMLE 24hi cells induced for 72h with 0.5 µg/ml doxycycline (Dox). Numbers indicate 
GPX4 levels normalized to control in percent. Data show mean ± SEM. (B) Bright-field 
microscopy: representative pictures of 96h Dox-treated HMLE 24hi cells expressing sh-nt and 
sh-GPX4 seeded at low (1200 cells) or intermediate (3600 cells) cell density in 24-well plates 
and treated for 24h with 0.01% DMSO or 10 nM RSL3. Scale bar: 200 µm. (C) Viability assay: 
assessment of cell viability by counting HMLE 24hi cells plated and treated as described in B. 
Data shown represent mean ± SD of one representative experiment performed independently 
two times. (D) Viability assay: control (ctrl) and Dox-inducible sh-nt or sh-GPX4 HMLE 24hi cells 
plated at different cell densities (167-500-2000 cells, low-med-hi) in 96-well plates were treated 
with 0.5 µg/ml Dox for 96h. During the last 24h, DMSO, 10 nM or 100 nM RSL3 treatment was 
applied. Data shown represent mean ± SEM. n=2. Viability was normalized to respective DMSO 
control within each cell line and cell density. 
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cells) cell density and the next day, shRNA expression was induced by Dox-
treatment. After 48h Dox-treatment, cells were additionally treated with 10 nM RSL3 
or 0.01% DMSO (solvent control), the next day trypsinized and total cell number 
assessed by counting (Figure 8B). As expected, a similar cell number compared to 
DMSO control was counted when 10 nM RSL3 treatment was applied to sh-nt 
expressing cells at a low and at an intermediate seeding density (Figure 8C). In 
contrast, compared to the DMSO control, RSL3-treatment reduced cell numbers by 
54-fold at low and by 12-fold at intermediate density in HMLE 24hi cells with GPX4 
knockdown (Figure 8C). 
In a second line of experiments, untransduced control (ctrl), sh-nt or sh-GPX4 HMLE 
24hi cells were seeded in 96-well plates at 167, 500 and 2000 cells (low, med, high 
cell density). Of note, cell numbers were lower than those used in previous viability 
assays because cells were grown for 72h prior to RSL3 treatment. Cells were 
treated with Dox and 10 nM RSL3 as described for viability assays performed in 24-
well plates, but instead of counting cells, viability was measured by the CellTiter-Glo 
assay. As a control, cells were not treated with Dox, but instead with 100 nM RSL3, 
which was shown to efficiently induce cell density-dependent ferroptosis (Figure 
8D). Again, I noticed that 10 nM RSL3 induced cell density-dependent ferroptosis 
upon GPX4 knockdown to a similar extent as in control cells that were treated with 
100 nM RSL3. However, cell viability was only slightly impacted by 10 nM RSL3 
treatment in sh-nt expressing cells which was comparable to the viability of 10 nM 
RSL3-treated control cells (Figure 8D). Together, these data indicated that GPX4 
was the regulator of cell density-dependent ferroptosis.  
However, although RSL3 was used at a low-dose during GPX4 knockdown 
experiments, off-target effects of RSL3 could not be excluded. Furthermore, the ratio 
of RSL3 molecules to the numbers of seeded cells might be altered in cell density 
experiments, thereby explaining the observed effects. Therefore, to establish a 
stronger genetic link between GPX4 and cell density-dependent ferroptosis, I 
knocked out GPX4 in HMLE and HMLE-Twist1 cells using the CRISPR/Cas9 
system. For this purpose, plasmids containing Cas9 and sgRNAs targeting GPX4 
were transiently transfected into both cell lines to avoid long-term off-target effects. 
Transfections of only the plasmid containing Cas9 served as a control for wild-type 
GPX4 expression. After single cell seeding and expansion, I derived several single- 
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Figure 9: Cell density-dependent ferroptosis occurs upon GPX4-knockout 
(A) Immunoblot: GPX4 and beta-actin (loading control) protein expression in single-cell clones 
(SCCs) derived by CRISPR/Cas9 genome-editing in the GPX4 locus of bulk HMLE and HMLE-
Twist1 cells. kDa= kilo Dalton. One representative immunoblot performed independently two 
times is shown. (B) Viability assay: treatment of SCCs with GPX4-knockout (KO) plated at 
indicated cell densities in 96-well plates in presence or absence of 1 µM Liproxstatin-1 (Lip1) 
for 48h. n=2 for HMLE SCCs, n=4 for HMLE-Twist1 SCCs. Statistics: two-tailed, unpaired T-
test with Welch’s correction (p-value: *<0.05, **<0.01, ****<0.0001). (C) Viability assay: 
assessment of cell viability, including a treatment with 500 nM Fer1, as described in B. n=2 for 
HMLE SCCs, n=3-4 for HMLE-Twist1 SCCs. (D) Viability assay: treatment of CRISPR/Cas9-
derived control SCCs with intact GPX4 expression (wildtype = WT) plated at indicated cell 
densities in 96-well plates with 1 µM Lip1, 100 nM RSL3 or without Lip1 (‒Lip1) for 48h. n=2 for 
HMLE SCCs, n=2-4 for HMLE-Twist1 SCCs. Data shown (B, C, D) represent mean ± SEM. 
Viability was normalized to respective Lip1 control within each cell line and cell density.  
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cell clones (SCCs) with no detectable GPX4 protein (GPX4-KO) or with intact GPX4 
expression (GPX4-WT) (Figure 9A). Since the lethal effect of the full knockout of 
GPX4 (Imai et al., 2003; Yant et al., 2003) can be rescued by Lip1 (Friedmann Angeli 
et al., 2014) (Figure 6A), SCCs were kept in 1 µM Lip1-containing medium. Next, I 
conducted viability assays using three HMLE (H1, H5, H6) and HMLE-Twist1 (HT1, 
HT2, HT3) SCCs with a full GPX4 knockout (GPX4-KO) and challenged them by 
withdrawal of Lip1 for 48h upon seeding. Again, I noticed that cell death was induced 
in a cell density-dependent manner: cells seeded at low cell density were highly 
susceptible to cell death induced by GPX4 loss while high cell density induced 
complete resistance (Figure 9B). At intermediate seeding densities, an intermediate 
cell death induction was observed. However, in contrast to treatment with RSL3, I 
did not detect a pronounced difference in cell death induction at intermediate cell 
densities between HMLE and HMLE-Twist1 SCCs (Figure 9B and C). Importantly, 
addition of 500 nM Fer1 rescued cell death induction upon GPX4-KO to a similar 
extent as 1 µM Lip1 (Figure 9C), further supporting that ferroptosis was the observed 
cell death modality (Dixon et al., 2012; Friedmann Angeli et al., 2014). In order to 
ensure that analyzed SCCs were representative of the bulk population, two control 
SCCs with intact GPX4 expression of HMLE and HMLE-Twist1 cells were applied 
to 100 nM RSL3 treatment in viability assays. Again, RSL3 treatment elicited cell 
density-dependent ferroptosis (Figure 9D). In contrast to a full genetic knockout of 
GPX4, I observed an increased sensitivity of HMLE-Twist1 SCCs to GPX4 inhibition 
at intermediate seeding densities compared to HMLE SCCs (Figure 9D).  
In summary, a full genetic knockout of GPX4 confirmed that GPX4 function directly 
mediated cell density-dependent ferroptosis both in epithelial and in Twist1-induced 
mesenchymal HMLE cells. Cell death induction occurred to a similar extent in 
epithelial HMLE and mesenchymal HMLE-Twist1 upon GPX4 knockout without any 
major differences at intermediate cell densities. These results suggested that similar 
pathways contributed to cell density-dependent ferroptosis in both cell lines that 
were most likely downstream of GPX4. Therefore, I focused on elucidating the 
pathways that might contribute to cell density-dependent ferroptosis. 
 
4.6 Oncogenic signaling does not affect cell density-dependent ferroptosis 
Recent studies have shown that RSL3 induces oncogenic-RAS-synthetic lethality in 
hTERT immortalized and SV40 large and small T containing fibroblasts (Yang and 
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Stockwell, 2008). Furthermore, MEK inhibitor that target mitogen-activated protein 
kinase (MAPK) signaling downstream of Ras, rescue RSL3-induced ferroptosis 
(Yang and Stockwell, 2008; Yang et al., 2014). Similar to these engineered 
fibroblasts (Hahn et al., 1999; Yang and Stockwell, 2008), HMLE cells were derived 
by introducing vectors expressing hTERT and the SV40 large T early region, 
containing both large T and small T, into primary human mammary epithelial cells. 
To transform cells and acquire tumorigenic cells, oncogenic HRASG12V needs to be 
expressed (HMLE-Ras) (Elenbaas et al., 2001; Ince et al., 2007). Since both 
epithelial and Twist1-induced mesenchymal HMLE cells are equally susceptible to 
GPX4 inhibition or knockout, irrespective of the cellular phenotype, I hypothesized 
that the genetic background of these cells might influence cell density-dependent 
ferroptosis. To test whether oncogenic transformation also impacted cell density-
dependent ferroptosis, I assessed RSL3-sensitivity in oncogene-transformed HMLE 
cells overexpressing HRAS or neuNT oncogenes (Mani et al., 2008), the latter 
serving as a model for Her2 overexpressing breast cancer (Chen et al., 2005b). 
Again, RSL3 induced cell death in a cell density-dependent manner in HMLE cells, 
but neither overexpression of HRAS nor of neuNT oncogenes altered sensitivity of 
the cells to RSL3 (Figure 10A). Likewise, overexpression of HRAS in HMLE-Twist1 
cells did not confer any additional sensitivity to cell density-dependent ferroptosis 
induced by RSL3 treatment (Figure 10B).  
PTEN is another frequently mutated or deleted gene in cancer, leading to tumor 
progression and poor prognosis (Chen et al., 2005b; Jones et al., 2013; Li et al., 
1997; Steck et al., 1997). PTEN opposes phosphoinositide 3-kinase (PI3K) signaling 
which regulates proliferation, survival and metabolism via the downstream targets 
AKT, a serine/threonine kinase and the mammalian target of rapamycin (mTOR) 
pathway (Yu and Cui, 2016). Phosphorylation of AKT at Ser473 indicates active 
PI3K signaling (Hyun et al., 2000; Wan and Helman, 2003). Since PTEN-deleted 
cancer cells are selectively lethal to compounds targeting mTOR, for instance to 
CCI-779 (Neshat et al., 2001), I wondered whether PTEN deletion might also 
influence RSL3 sensitivity. CRISPR/Cas9 PTEN-deleted HMLE-Twist1-ER 24hi cells 
were kindly generated and provided by Hilary Ganz, a PhD student in the Scheel 
laboratory (Mammary Stem Cells, Helmholtz-Center Munich). First, I confirmed the 
PTEN deletion in SCCs KO-1 and KO-2 by immunoblotting for phosphorylated AKT.  
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Figure 10: Cell density-dependent ferroptosis is not affected by oncogenic signaling 
(A) Viability assay: treatment of HMLE, HMLE-HRasG12V and HMLE-neuNT cells plated at 
indicated cell densities in 96-well plates with 0.3% DMSO or 300 nM RSL3 for 24h. n=2. (B) 
Viability assay: treatment of HMLE-Twist1 and HMLE-Twist1-RasG12V with 30 nM RSL3 for 24h 
as described in A. n=2. (C) Immunoblot (upper part): protein expression of phosphorylated AKT 
at serine residue 473 (pAKT Ser473), total AKT 1 and 2 isoforms (pan AKT) and beta-actin 
(loading control) in CRISPR/Cas9-derived PTEN-wildtype (WT) and PTEN-knockout single-cell 
clones (SCCs, KO-1 and KO-2) of HMLE-Twist1-ER 24hi cells plated in 10-cm dishes. Cells were 
grown in growth-factor containing medium (PC-medium, ctrl) or starved overnight in basal 
DMEM/F-12 medium (starve) prior to protein extraction. kDa = kilo Dalton. Cell viability (lower 
part): treatment of PTEN-WT, KO-1 and KO-2 SCCs with 0.1% DMSO or 100 nM RSL3 for 24h 
as described in A. n=3. (D) Immunoblot: protein expression of phosphorylated ERK1/2 (pERK 
1/2), total ERK, pAKT Ser473, pan AKT and beta-actin (loading control) in HMLE and HMLE-
Twist1 cells plated at high or low cell density in 10-cm dishes. Starvation as described in C. Data 
shown represent one representative experiment performed independently two times. Data 
shown (A, B, C) represent mean ± SEM. Viability was normalized to respective DMSO control 
within each cell line and cell density. Statistics: two-tailed, unpaired T-test with Welch’s correction 
(p-value: *<0.05, n.s. = not significant).  
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Indeed, I observed an upregulation of AKT phosphorylation at Ser473 in PTEN-
deleted SCC KO-1 and KO-2 compared to a control SCC (WT) (Figure 10C). 
However, when I submitted PTEN-deleted SCCs to viability assays, I did not 
observe an effect beyond cell density-dependent ferroptosis upon treatment with 
100 nM RSL3. Moreover, RSL3 treatment induced cell death in PTEN-deleted SCCs 
to a similar extent as in the PTEN-WT SCC (Figure 10C). Finally, to exclude any 
contribution of MAPK and PI3K signaling to cell density-dependent ferroptosis, I 
assessed whether cell density impacted MAPK signaling, activated downstream of 
RAS (McCubrey et al., 2007), and PI3K signaling in HMLE and HMLE-Twist1 cells. 
To this end, immunoblots for phosphorylated ERK1/2 (pERK1/2) and 
phosphorylated AKT at Ser473, as readouts for active MAPK and PI3K signaling, 
respectively (McCubrey et al., 2007; Yu and Cui, 2016), were performed. As 
expected, I did not observe a cell density-dependent regulation of pERK1/2 or pAKT 
Ser473 in HMLE and HMLE-Twist1 cells (Figure 10D). Compared to parental HMLE 
cells, Twist1-expression elevated total ERK1/2 and AKT levels (Figure 10D). 
Conclusively, these data suggested that changes in MAPK or PI3K signaling that 
occur during oncogenesis did not modulate cell density-dependent ferroptosis. 
 
4.7 Cell density-dependent ferroptosis is present in primary mammary 
epithelial cells 
HMLE cells were immortalized and had undergone subsequent selection processes 
(Elenbaas et al., 2001), raising the question whether cell density-dependent 
ferroptosis-sensitivity depended on the immortalization process or whether it 
constituted an intrinsic property of human mammary epithelial cells. To address this 
question, primary human mammary epithelial cells (HMECs) were isolated from 
three breast reduction mammoplasties donated by healthy women. After 
establishing primary HMECs in an initial 2D culture, cells were plated in 96-well 
plates at different densities and treated for 24h with 100 nM RSL3. Interestingly, 
RSL3 treatment led to cell density-dependent ferroptosis in bulk cells of all three 
donors M16, M29 and M19 respectively (Figure 11A). All samples were similarly 
sensitive to RSL3 treatment and cell death was induced at both ambient oxygen 
atmosphere (20%) as well as 3% oxygen, the latter mimicking physiological tissue 
pressure (Figure 11A). Furthermore, I observed a comparable cell density-
dependent cell death induction by RSL3 when CD10-positive HMEC of the basal 
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lineage (B+, CD10+/CD49fhi/EpCAM−) prospectively isolated from donor M16 were 
submitted to viability assays (Figure 11B).  
Together, these data indicated that cell density-dependent ferroptosis-sensitivity 
was a trait that was not acquired during the immortalization process, but that was 
already present in HMECs. 
 
4.8 GPX4 inhibition by RSL3 prevents organoid formation in 3D collagen gels 
by primary HMECs 
As described above, upon inhibition of GPX4 in 2D cultures, cell density-dependent 
ferroptosis was induced in both immortalized and primary HMECs. It has been 
reported that absence of GPX4 does not impact colony formation of transformed 
MEFs in Matrigel which provides an ECM enabling three dimensional (3D) growth. 
In contrast, 2D viability has been highly impaired in the absence of GPX4 (Schneider 
et al., 2010). Therefore, I wanted to assess how a 3D-environment impacted 
sensitivity towards ferroptosis in primary as well as immortalized HMECs. 
To do so, primary HMECs were plated as single cells in floating 3D-collagen gels as 
recently described (Linnemann et al., 2015). In this organoid assay, Collagen I 
provides an ECM that mimics a physiological environment, thereby allowing the 
formation of organoids by primary HMECs. More precisely, prospectively isolated 
 
Figure 11: Cell density-dependent ferroptosis is a trait of primary HMECs 
(A) Viability assay: treatment of bulk primary human mammary epithelial cells (HMECs) of three 
different donors (M16, M29, M19) plated at indicated cell densities in 96-well plates with 0.1% 
DMSO or 100 nM RSL3 for 24h at oxygen levels present in tissues (normoxia 3%) or at ambient 
oxygen level (20%). n=3. Statistics: two-tailed, unpaired T-test with Welch’s correction (p-value: 
*<0.05, **<0.01, ****<0.0001). (B) Viability assay: treatment of prospectively, sorted CD10-
positive primary HMECs of the basal lineage of donor M16 with 0.1% DMSO or 100 nM RSL3 
as described in A. n=2. Data shown (A, B) represent mean ± SEM. Viability was normalized to 
respective DMSO control within each donor and cell density.  
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cells of the basal lineage (B+, CD10+/CD49fhi/EpCAM−) form branched organoids 
that resemble mammary gland architecture. In contrast, prospectively isolated 
progenitor cells of the luminal lineage (LP, CD49f+/EpCAM+) mainly form spheres 
(Linnemann et al., 2015). For viability assays, primary bulk HMECs as well as sorted 
B+ and LP cells were seeded as single cells into 3D collagen gels. After five days of 
an initial survival culture, allowing the establishment of single cells, RSL3, Lip1 or a 
combination of both were applied to cultures every two to three days. As expected, 
bulk primary HMECs gave rise to both branched organoids as well as spheres in the 
DMSO and Lip1 control (Figure 12A). Furthermore, branched organoids were 
established by B+ cells and spheres by LP cells (Figure 12B). Continuous RSL3-
treatment strongly impaired organoid formation in all samples, leading to either the 
absence of colonies or the generation of smaller colonies that appeared fragmented 
(Figure 12A and B). Simultaneous Lip1 application during RSL3 treatment partially 
rescued organoid formation in bulk as well as sorted B+ and LP cells (60-100% of 
DMSO control) (Figure 12A and B). To analyze whether organoids present after 
RSL3 treatment were still proliferative, I performed immunofluorescent staining for 
the proliferation marker Ki67 and used DAPI to visualize cell nuclei. For organoids 
formed by basal B+ cells, vimentin staining was performed to visualize morphology 
of branched structures. Cells stained positive for Ki67 in the DMSO and Lip1 control 
as well as in Lip1-rescued RSL3-treated organoids for both B+- and LP-derived 
organoids (Figure 12C). However, Ki67 staining was absent in organoids that had 
been continuously treated with RSL3 and nuclear staining by DAPI indicated their 
fragmentation (Figure 12C). Moreover, B+-derived organoids displayed vimentin-
positive cells at a basal position in DMSO, Lip1 and Lip1/RSL3 conditions. On the 
contrary, vimentin-positive cells appeared disordered and fragmented in RSL3-
treated organoids (Figure 12C).  
Together, these data indicated that both bulk cells, as well as prospectively sorted 
primary HMECs were highly susceptible to GPX4 inhibition by RSL3 at the single 
cell level. Thereby, continuous RSL3 treatment impaired proper organoid formation 
by primary HMECs, resulting in non-proliferative, disorganized organoids. 
Conclusively, a three dimensional matrix provided by Collagen I did not enable 
organoid formation of primary HMEC plated as single cells in presence of RSL3.  
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Figure 12: Cell density-dependent ferroptosis prevents organoid formation of primary 
HMECs 
(A) 3D-collagen gels: bulk primary human mammary epithelial cells (HMECs) of donor M16 
were treated with 0.1% DMSO, 100 nM RSL3, 500 nM Lip1 or a combination of RSL3 and Lip1 
for 7 days prior to quantification of organoids. Representative bright-field images of organoids 
are shown on the left. Data shown represent mean ± SD of 3-4 collagen gels. Scale bar: 200 
µm. (B): 3D-collagen gels: prospectively sorted CD10-positive basal (B+) or luminal progenitor 
(LP) primary HMECs were treated as indicated in A for 7-10d prior to quantification. 
Representative bright-field images of organoids are shown on the left. Data shown represent 
mean ± SD of 3-4 collagen gels from one representative experiment performed independently 
two times. Scale bar: 200 µm. (C) Confocal microscopy of 3D-collagen gels: staining of 
organoids cultured as described in B with Ki67 (red), vimentin (green) and DAPI (blue). DAPI 
was used as nuclear staining. Scale bar: 50 µm.  
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4.9 Knockdown or knockout of GPX4 impairs organoid formation in 3D-
collagen gels by immortalized HMLE cells 
In contrast to immortalized and tumorigenic MEFs (Schneider et al., 2010), inhibition 
of GPX4 impacted organoid formation of primary HMECs in a 3D environment. 
Primary HMECs plated in 3D-collagen gels require an initial five day survival phase 
prior to initiation of organoid formation (Linnemann et al., 2015), indicating elevated 
levels of cellular stress which might explain the observed sensitivity to GPX4 
inhibition in 3D. Furthermore, although both primary as well as immortalized HMECs 
showed cell density-dependent ferroptosis upon RSL3 treatment, the 
immortalization process could potentially affect sensitivity to GPX4-inhibition in a 3D 
environment. Therefore, I wanted to determine whether colony formation of 
immortalized HMLE cells was influenced in 3D collagen gels as well. As previously 
shown, HMLE cells plated in 3D collagen gels give rise to multicellular spheres 
depending on the amount of seeded cells (Schmidt et al., 2015). For this purpose, 
HMLE cells with a partial knockdown of GPX4 or with a complete loss of GPX4 by 
CRISPR/Cas9-mediated gene knockout were plated into 3D collagen gels.  
First, 500 HMLE 24hi cells with (sh-GPX4) or without (sh-nt) a pTRIPZ construct 
targeting GPX4 were seeded into 3D collagen gels. Dox-treatment was immediately 
applied to induce expression of shRNAs and was refreshed every two days. Both 
HMLE 24hi cells containing sh-nt or sh-GPX4 were able to form colonies in control 
conditions (DMSO) to the extent. On the contrary, 0.5 µg/ml Dox treatment led to a 
5-fold decrease in arising colonies upon induction of GPX4 knockdown without 
impacting colony formation of sh-nt-containing cells (Figure 13A). These data 
showed that induction of GPX4 knockdown in immortalized HMLE 24hi cells at the 
single cell level resulted in impaired colony formation in 3D collagen gels. Taken 
together, this indicated that both primary and immortalized HMECs are susceptible 
to ferroptosis induction in a 3D environment.  
Since cell density predicts ferroptosis-sensitivity in 2D cultures, I wondered whether 
the latter was also influenced by seeded cell numbers or by the size of colonies 
(single cells versus small colonies) in a 3D environment. To address this question, I 
plated HMLE GPX4-KO SCCs (H5) at different densities in 3D collagen gels and 
cultured them in three different conditions. The medium was either supplemented 
with 500 nM Lip1 (+Lip1) or directly deprived of Lip1 (−Lip1). In a third condition, 
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Figure 13: Cell density-dependent ferroptosis impairs colony formation of GPX4-
knockdown and knockout cells 
(A) Carmine staining and quantification of 3D-collagen gels: treatment of 500 plated HMLE 24hi 
cells containing Dox-inducible non-targeting (sh-nt) or GPX4-targeting (sh-GPX4) shRNAs in 
3D-collagen gels with DMSO solvent control or 0.5 µg/ml Dox for 9-11 days. Representative 
pictures of carmine-stained 3D-collagen gels are shown on the left and quantification of colonies 
is shown on the right. Data shown represent mean ± SD of three collagen gels from one 
representative experiment performed independently two times. (B) and (C) Carmine staining of 
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cells were grown for three days in Lip1-containing medium which allowed the 
generation of small colonies prior to withdrawal of Lip1 (+/−Lip1). As expected, I 
observed the formation of spheres in Lip1-containing medium irrespective of 
seeding density (Figure 13B). Direct withdrawal of Lip1 (−Lip1) from the culture 
medium led to complete growth inhibition, similar to what was observed at low 
seeding density in 2D cultures. In the third condition (+/−Lip1), Lip1 withdrawal after 
three days of culture still enabled outgrowth of colonies (Figure 13B). However, 
these colonies were smaller and appeared to be less proliferative compared to 
colonies generated during continuous Lip1-cultures (Figure 13C). In order to 
quantify the number and size of colonies, images were converted to binary pictures 
and automatically analyzed using ImageJ (Figure 13D). Indeed, ImageJ analysis 
confirmed that direct withdrawal of Lip1 (−Lip1) prevented colony formation 
independently of seeding density (Figure 13E). Moreover, ImageJ analysis revealed 
that upon delayed withdrawal of Lip1 (+/−Lip1), colonies were formed to a similar 
extend as in control Lip1 cultures (+Lip1). However, the number of colonies with an 
area greater than 7500 µm2 were either strongly reduced (85-90% less for low and 
med cell density respectively) or reduced by 50% for high cell density in the +/−Lip1 
condition compared to the +Lip1 condition (Figure 13E). These data suggested that 
proliferation has been disturbed when Lip1 was withdrawn at a later time point. 
Alternatively, the appearance of smaller colonies might be the consequence of cell 
death induction by GPX4 inhibition.  
To differentiate between induction of cell death and inhibition of proliferation, I 
assessed whether the residual, smaller colonies contained proliferating cells. 
Immunofluorescent staining for the proliferation marker Ki67 was performed on 
spheres generated at the intermediate seeding density. Interestingly, Ki67-positive 
3D-collagen gels: HMLE single-cell clone (SCC) H5 with GPX4-knockout (KO) was seeded at 
indicated cell densities (75 (low), 225 (med), 675 (hi) cells) in 3D-collagen gels in medium with 
500 nM Lip1 (+Lip1), without Lip1 (‒Lip1) or for 3d in an initial Lip1-culture prior to withdrawal 
of Lip1 (+/‒Lip1) for 7-10 days. Representative pictures of (B) carmine-stained 3D-collagen gels 
and (C) magnifications of colonies grown in 3D-collagen gels are shown. (D) Representative 
converted, binary picture for ImageJ quantification obtained from carmine-stained 3D-collagen 
gels as described in B. (E) Quantification of carmine-stained colonies formed by HMLE SCC 
H5 with GPX4-KO treated as described in B. Data shown represent mean ± SD of 3-4 collagen 
gels from one representative experiment performed independently two times. (F) Confocal 
microscopy of 3D-collagen gels: staining of colonies treated as described in B at an intermediate 
seeding density (225 cells, med) with Ki67 (red), vimentin (green) and DAPI (blue). DAPI was 
used as nuclear staining. Scale bar: 50 µm.   
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cells were only observed in spheres cultured in Lip1-containing medium, while 
spheres arising in +/−Lip1 cultures did not stain positively for Ki67 (Figure 13F). 
Furthermore, based on immunostaining for vimentin, these spheres appeared to be 
less compact and fragmented when Lip1 was withdrawn after three days (+/–Lip1) 
compared to continuous Lip1 cultures (+Lip1) (Figure 13F). These results indicated 
that proliferation was impaired, but cell death was not induced in all cells within one 
colony, at least at the chosen endpoint of this experiment. For cultures grown without 
Lip1 (–Lip1), I could only detect some residual cells that neither stained positively 
for Ki67 nor showed any vimentin staining (Figure 13F), indicating induction of cell 
death in single cells. Together, these data suggested that GPX4 knockout, if induced 
at the single-cell level, prevented sphere formation of HMLE cells in 3D collagen 
gels. Of note, this effect occurred independently of the initial seeding density. 
However, once small colonies had formed, GPX4 knockout impaired expansion in 
3D-cultures, but did not lead to complete disappearance of colonies, suggesting 
some resistance to GPX4 knockout-induced cell death. 
Overall, these results showed that ferroptosis could be induced in a 3D environment 
in both primary as well as immortalized HMECs, as long as cells remained single 
cells. Since high cell density completely protected from ferroptosis in 2D culture and 
the formation of small colonies partially protected from ferroptosis in 3D cultures, it 
could be possible that not the absolute cell number, but the proximity and distance 
of cells to each other determined ferroptosis sensitivity in HMECs. 
 
4.10 Cell density-dependent ferroptosis is not affected by secreted factors or 
cell-cell-adhesions 
I established that cell density-dependent ferroptosis is an intrinsic property of both 
primary as well as immortalized HMECs. Furthermore, ferroptosis, induced by 
inhibition or knockout of GPX4, was independent of oncogenic signaling and 
occurred in cells cultured both in 2D and 3D cultures. To further shed light on what 
exactly might trigger ferroptosis at low density, I undertook a series of experiments 
addressing potential differences concerning proliferation, secreted factors and cell-
cell adhesion signaling.  
Since cell density is known to affect proliferation (Abercrombie; Stoker and Rubin, 
1967), proliferation rates of HMLE and HMLE-Twist1 cells seeded at different  
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Figure 14: Cell density-dependent ferroptosis is not affected by secreted factors or cell-
cell-adhesions 
(A) Proliferation curve: measurement of metabolically active HMLE and HMLE-Twist1 cells plated 
at indicated densities in 96-wells every 24h for a period of 96h. Data shown represent mean ± SD 
of n=10 wells per time point normalized to the 24h measurement. (B) Cell-cycle analysis by flow 
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densities were assessed. Both cell lines showed similar proliferation rates which 
were not affected by density (Figure 14A), at least in short-term cultures that were 
also used for viability assays. Cell cycle analysis supported this finding (Figure 14B), 
ruling out differences in proliferation as regulator of ferroptosis sensitivity and 
resistance in cell density-dependent ferroptosis.  
Moreover, it has been shown that ROS level vary between dense and sparse 
cultures (Limoli, 2004; Pani et al., 2000). Therefore, I assessed general ROS levels 
using the flow-cytometry compatible fluorescent dye CellRox Deep Red. Indeed, I 
observed an increase in ROS levels in low cell density culture compared to high cell 
density culture both in HMLE and HMLE-Twist1 cells (Figure 14C). These results 
revealed an elevation of oxidative stress at low density that was not directly related 
to proliferation. 
In Burkitt’ Lymphoma (BL) cells, low cell density leads to an oxidative stress-induced 
cell death that can be rescued by co-culture with irradiated fibroblasts (Falk et al., 
1993, 1998). Mechanistically, secretion of cysteine by fibroblasts fuels a 
cystine/cysteine redox cycle within BL cells, thereby inducing a reducing 
cytometry: staining of HMLE and HMLE-Twist1 cells seeded at indicated densities in 10-cm dishes 
for 48h prior to fixation and staining with propidium iodide (PI). X-axis: linear scale of PI 
fluorescence. Y-axis: percentage of maximum count. Data show one representative experiment 
performed independently two times. (C) Flow cytometry: CellRox Deep Red staining of HMLE and 
HMLE-Twist1 cells seeded at indicated densities in 6-cm dishes for 48h. X-axis: log10 of CellRox 
Deep Red fluorescence. Y-axis: percentage of the maximum count. Data show one representative 
experiment performed independently two times (D) Experimental setup for co-culture experiments. 
(E) Quantification of co-culture experiment as outlined in D: assessment of cell viability of HMLE 
and HMLE-Twist1 cells treated with 100 nM RSL3 for 20-24h without or during co-culture. Mean 
± SEM is shown. n=5. Data were partly generated by Marie Bannier-Hélaouët (Intern). (F) 
Quantification of co-culture experiment (as outlined in D) using HMLE 24hi cells expressing Dox-
inducible non-targeting (sh-nt) or GPX4-targeting (sh-GPX4) shRNAs, pre-treated for 24h with 0.5 
µg/ml Dox which was further applied during the experiment. Sh-nt cells were used for high seeding 
density co-culture (+). 10 nM RSL3 treatment was applied for 20-24h. Mean ± SD is shown. n=2. 
(G) Viability assay: the same cell number of HMLE cells was plated distributed or on one spot in 
6 cm-dishes as illustrated followed by treatment with 100 nM RSL3 for 18h. Representative bright-
field images of treated cells are shown on the right. Scale bar: 200 µm. Data shown represent 
mean ± SD of n=3 6-cm dishes. (H) Cell-scatter experiment: HMLE cells were pre-treated with 1 
µg/ml HECD-1 prior to plating 600 cells in 96-well plates. Cells were treated for 24h with 30 nM 
RSL3 and 500 nM Lip1. Representative bright-field images of HECD-1-treated HMLE cells plated 
in 96-well plates prior to RSL3-treatment are shown. Scale bar: 200 µm. Mean ± SEM is shown. 
n=3. Statistics: two-tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, n.s. = not 
significant). (I) Viability assay: treatment of 450 plated HMLE and 1000 plated HMLE-Twist1 cells 
cultured in basal or growth-factor containing (Standard) PC medium in 96-well plates with 100 nM 
RSL3 for 24h. Mean ± SD is shown. n=2. Viability (E-I) was normalized to respective DMSO control 
within each cell line. 
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extracellular environment protecting BL cells from cell death induced by low seeding 
density (Banjac et al., 2008; Falk et al., 1993, 1998). To assess whether a similar 
mechanism sensitized cells in low density to ferroptosis, I asked whether one or 
several secreted factors, secreted by cells cultured at high density, might protect 
them from cell death induced by GPX4 inhibition. To test this hypothesis, HMLE and 
HMLE-Twist1 cells were seeded at a low density at the bottom of a 24-well plate 
and for co-cultures, cells were additionally seeded at a high density in inserts placed 
into the 24-well plate (Figure 14D). This system enabled a direct exchange of 
secreted factors between cultures seeded at low and high cell density. In the 
absence of a co-culture, RSL3 reduced the viability of cells seeded at low cell density 
by 80-88% compared to the DMSO control (Figure 14E). When cells were cultured 
in the co-culture condition, RSL3 reduced viability of cells seeded at low cell density 
to a similar extent (Figure 14E). These data indicated that co-culture with cells 
seeded at high cell density did not rescue cell death induction of cells seeded at low 
cell density. Experiments were repeated using HMLE 24hi cells with (sh-GPX4) or 
without (sh-nt) a Dox-inducible GPX4 knockdown. Hereby, sh-nt cells were seeded 
into high cell density co-cultures for both GPX4 knockdown and sh-nt control HMLE 
24hi cells to avoid an impact of Dox-induction and 10 nM RSL3 treatment on the 
viability of cells seeded at high cell density (Figure 8). While sh-nt seeded at low cell 
density remained viable to a similar extent in both conditions (with or without co-
culture), Dox and low-dose RSL3 treatment induced cell death in GPX4 knockdown 
cells which was again not rescued upon co-culture (Figure 14F). Together, these 
data suggested that cells seeded at high cell density did not secrete soluble factors 
that induced an environment that protected them from cell density-dependent 
ferroptosis induced by GPX4-inhibition. 
In 3D cultures, ferroptosis was efficiently induced at the single-cell level, but once 
small colonies were generated, a partial protection was observed (Figure 13B, C 
and E). These indicated that the proximity of cells and the formation of cell-cell-
adhesions might play a role in cell density-dependent ferroptosis. Since a major 
difference between low and dense 2D cultures are the size of colonies and the 
distance between cells (Figure 5C), I mimicked low and dense cultures by seeding 
the amount of cells in two different ways. HMLE cells were seeded either distributed 
at a low cell density on a 6-cm dish, thereby forming small, spread colonies. 
Alternatively, exactly the same amount of HMLE cells were seeded on a defined, 
  Results 
112 
 
small area bordered by a sticky insert within a 6-cm dish, resulting in one large, 
dense and compact colony (Figure 14G). The next day, the sticky insert was 
removed and cells were treated for 18h with 100 nM RSL3 prior to measuring cell 
viability. Interestingly, although the same cell number was seeded, RSL3 induced 
cell death only in the condition where cells were distributed on the 6-cm dish while 
RSL3 failed to do so in the dense condition (Figure 14G). These results indicated 
that not the seeded cell number itself determined sensitivity to GPX4 inhibition, but 
rather the distribution and relationship of seeded cells to each other (proximity of 
cells).  
HMLE-Twist1 cells did not form dense colonies connected by cell-cell adhesions 
such as E-cadherin (Figure 5F) (Mani et al., 2008), but still showed resistance at 
high cell densities to cell death induced by GPX4 inhibition (Figure 5D and E). 
However, HMLE-Twist1 cells are able to form weak cell-cell adhesion mediated by 
another cadherin, namely N-cadherin (Ganz et al., 2006; Mani et al., 2008), 
suggesting that cell-cell adhesions mediated by N-cadherin might be upregulated at 
high cell density. Intercellular contacts of HMLE cells are mainly formed by E-
cadherin and disruption leads to cell scattering (Onder et al., 2008). Therefore, I 
determined whether treatment of HMLE with an E-cadherin neutralizing antibody 
(HECD-1), that has been shown to induce cell scattering (Chartier, 2006; Wong and 
Gumbiner, 2003), impacted cell death induction by GPX4-inhibition when cells were 
plated at an intermediate-low density (600 cells) in 96-well plates. Thereby, I wished 
to further clarify the mechanism of cell density-dependent ferroptosis. HMLE cells 
were pre-treated with HECD-1 for 24h and then plated into viability assays during 
which HECD-1 was further applied. As expected, HECD-1 treatment induced cell 
scattering and loosened the compactness of colonies formed by HMLE cells (Figure 
14H). When cells were exposed to 30 nM RSL3 treatment, HECD-1-induced 
scattering did not impact RSL3-induced cell death induction compared to the RSL3-
treated control (Figure 14H). Of note, Lip1 rescued RSL3-induced cell death in both 
conditions (Figure 14H). These results indicated that that cell-cell-adhesion-linked 
signaling did not determine cell density-dependent ferroptosis. 
Interestingly, the absence (basal PC) and presence (Standard PC) of growth factor 
supplements in culture medium affected sensitivity to RSL3 treatment in both HMLE 
and HMLE-Twist1 cells. When 450 HMLE cells or 1000 HMLE-Twist1 cells were 
plated in 96-well plates, cells were less sensitive to RSL3-treatment when cultured 
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in basal PC medium compared to culture in Standard PC-medium (Figure 14I). 
These results suggested that metabolic pathways fueled by growth factors 
contributed to cell density-dependent ferroptosis induced by GPX4-inhibition. 
Taken together, these data revealed that cell density-dependent ferroptosis was not 
directly linked to differences in proliferation, secreted factors or cell-cell adhesions. 
Overall, I could not yet determine one or several factors that explained cell density-
dependent ferroptosis sensitivity of HMLE and HMLE-Twist1 cells to GPX4-
inhibition. 
 
4.11 Cell density is not a determinant of ferroptosis-sensitivity in a panel of 
breast cancer cell lines 
Cell density-dependent ferroptosis induced by GPX4 is an intrinsic trait of both 
primary as well as immortalized HMECs. A recent study has revealed that triple-
negative breast cancer (TNBC) cell lines are highly sensitive to ferroptosis induction 
due to the expression of the acyl-CoA synthetase long chain family member 4 
(ACSL4). Thus, ACSL4 emerged as a marker for ferroptosis sensitivity that shapes 
lipid composition within cells (Doll et al., 2017). Moreover, another publication has 
revealed that in order to support glutamine-dependence of TNBC, expression of the 
system xc− is increased in TNBC cell lines (Timmerman et al., 2013). Together, these 
studies imply that ferroptosis sensitivity of TNBC cell lines is regulated by several 
pathways. For these reasons, I wondered whether cell density impacted ferroptosis-
sensitivity in a panel of breast cancer cell lines as well. For this purpose, two 
epithelial hormone receptor-positive (MCF7 and T-47D) and three TNBC (epithelial 
MDA468 and mesenchymal MDA231 and MDA157) cell lines were seeded at 
different densities in 96-well plates and exposed to 100 nM RSL3 treatment. None 
of the analyzed breast cancer cell lines showed a cell density-dependent cell death 
induction by RSL3 treatment (Figure 15A). However, these experiments confirmed 
that MDA468, MDA231 and MDA157 cell lines were highly sensitive for ferroptosis, 
whereas MCF7 cells were resistant to RSL3 treatment (Figure 15A). In contrast to 
published data (Doll et al., 2017), I observed an intermediate sensitivity of T-47D 
cells. In T-47D cells, RSL3-treatment reduced viability by 60-67% compared to the 
DMSO control irrespective of seeding density (Figure 15A). Moreover, when 
different concentrations of RSL3 were employed for dose-response curves, I did not 
detect cell density-dependent ferroptosis in MCF7 and MDA231 cells (Figure 15B 
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and C). Immunoblotting for GPX4 revealed similar expression levels of GPX4 
between cell lines (Figure 15D), suggesting that ferroptosis sensitivity was not 
directly linked to different GPX4 expression levels in this panel of breast cancer cell 
lines. 
Conclusively, I did not determine a cell density-dependent ferroptosis-sensitivity in 
a panel of breast cancer cell lines. Furthermore, these data suggested that most 
likely a different mechanism than ACSL4 marker expression induced ferroptosis-
sensitivity in primary and immortalized HMECs. 
 
4.12 Iron availability and lipoxygenation, but not ACSL4 contribute to cell 
density-dependent ferroptosis induction by GPX4 inhibition 
To further characterize cell density-dependent ferroptosis induced in primary and 
immortalized HMECs, known ferroptosis modulators were employed in viability 
 
Figure 15: Cell density is not determining ferroptosis-sensitivity in a panel of breast 
cancer cell lines 
(A) Viability assay: treatment of indicated breast cancer cell lines seeded at different densities 
in 96-well plates with 0.1% DMSO or 100 nM RSL3 for 24h. Mean ± SEM is shown. n=4. (B) 
Dose-response curves: treatment of MCF7 and MDA231 with 3-fold dilutions of RSL3 as 
described in A. Mean ± SD is shown of n=5 wells. (C) Viability assay: treatment of MDA231 
plated at a cell density of 600 cells in 96-well plates with 3-fold dilutions of RSL3 for 24h. Mean 
± SEM is shown. n=3. (D) Immunoblot: protein expression of GPX4 and beta-actin (loading 
control) in indicated breast cancer cell lines. kDa= kilo Dalton. Viability (A-C) was normalized to 
respective DMSO control within each cell line. 
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assays to examine their ability to rescue RSL3-induced cell death at intermediate-
low density (600 cells) in HMLE and HMLE-Twist1 cells. Compared to the DMSO 
control, 100 nM RSL3 treatment alone reduced viability by 72% in HMLE and by 
83% in HMLE-Twist1 cells, respectively (Figure 16A). RSL3-induced cell death was 
significantly rescued by DFO-mediated iron chelation, inhibition of lipoxygenases by 
both PD146176 (inhibition of Alox15) and BWA4C (inhibition of both Alox5 and 15) 
and by the lipophilic antioxidant α-toc (Figure 16A), as previously reported (Dixon et 
al., 2012; Friedmann Angeli et al., 2014; Seiler et al., 2008; Yang et al., 2016). In 
contrast to published data (Dixon et al., 2012), the iron chelator CPX did not rescue 
RSL3-induced cell death (Figure 16A). Mechanistically, CPX directly leads to 
intracellular iron chelation, thereby affecting iron-containing enzymes (Cao and 
Dixon, 2016), which might disturb cellular functions of HMLE and HMLE-Twist1 cells 
and thus counteract rescuing effects. This hypothesis was further supported by the 
fact that in CPX control treatment without RSL3, viability of HMLE-Twist1 cells was 
impacted, which I did not observe for the other modulators (Figure 16A). ACSL4 was 
described as a marker for ferroptosis sensitivity by increasing the pool of oxidation-
sensitive PUFAs within membranes (Doll et al., 2017; Kagan et al., 2017). Therefore, 
cells were pre-treated with ROSI, a PPARγ agonist which has been shown to 
specifically inhibit ACSL4 as well (Kim et al., 2001), and its impact on RSL3-induced 
cell death was assessed. Surprisingly, ROSI failed to rescue RSL3-induced cell 
death both in HMLE and HMLE-Twist1 cells (Figure 16A), although both cell lines 
expressed ACSL4 at the protein level as confirmed by immunoblotting (Figure 16B). 
ACSL4 presence or absence at the protein level was linked to ferroptosis-sensitivity 
and –resistance (Doll et al., 2017) and the rescuing abilities of ROSI might be 
shaded due to effects on PPARγ (Lehmann et al., 1995). For these reasons, I 
performed CRISPR/Cas9-mediated gene knockout of ACSL4 in HMLE GPX4-KO 
SCCs (H5). As assessed by immunoblotting, I obtained several SCCs without 
ACSL4 protein expression (ACSL4-KO: A1, A3, A4, A5, A7, A8) as well as WT-
controls (ACSL4-WT: A2 and A6) (Figure 16C). Importantly, these SCCs did not 
show any differences on a morphological level (Figure 16D). For viability assays, 
these SCCs were plated at different cell densities into 96-well plates and exposed 
to GPX4-KO by Lip1 withdrawal. Again, cell density determined sensitivity towards 
GPX4-KO-induced cell death (Figure 16E). Surprisingly, presence or absence of 
ACSL4 at the protein level did not impact sensitivity towards GPX4-KO-induced cell 
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death at all (Figure 16E), suggesting that ACSL4 did not impact cell density-
dependent cell death. Notably, dependence on ACSL4 in HMLE-Twist1 cells was 
not assessed, since no SCC with an ACSL4 knockout had been derived.  
In sum, these data suggested that the labile iron pool as well as LOX-mediated 
oxidation processes contributed to cell density-dependent ferroptosis in both HMLE 
and HMLE-Twist1 cells. At least in HMLE cells, cell death induction upon GPX4 
knockout was not dependent on ACSL4 expression.  
 
Figure 16: Cell density-dependent ferroptosis is dependent on iron and lipoxygenation, 
but independent of ACSL4 
(A) Rescue-viability assay: treatment of HMLE and HMLE-Twist1 cells plated at 600 cells in 96-
well plates with 100 nM RSL3 or a combination with the indicated compounds for 20-24h. 
Rosiglitazone (ROSI) treatment was additionally applied for 24h prior to RSL3 treatment. DFO: 
Deferoxamine, CPX: Ciclopirox α-toc: α-tocopherol. n=2-5. Data were partly generated by Felix 
Holstein (Master Student). (B) Immunoblot: protein expression of ACSL4 and beta-actin 
(loading control) in HMLE and HMLE-Twist1 cells plated at high cell density in 10-cm dishes. 
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4.13 Lipid peroxidation levels do not correlate with cell density-dependent 
ferroptosis upon GPX4 inhibition or knockout 
As a consequence of GPX4 inhibition, the accumulation of lipid hydroperoxides is 
regarded as a hallmark of ferroptosis (Dixon et al., 2012; Doll et al., 2017; Kagan et 
al., 2017; Yang et al., 2014). Furthermore, I established an involvement of 
lipoxygenases and iron in cell density-dependent ferroptosis which had been 
previously shown to contribute to lipid peroxidation (Dixon et al., 2012; Yang et al., 
2014, 2016). Therefore, I measured lipid ROS levels in HMLE and HMLE-Twist1 
using C11-BODIPY staining in flow cytometry analyses (Drummen et al., 2002). For 
this purpose, HMLE and HMLE-Twist1 cells were plated at intermediate cell density 
and treated for 6h or 20h with RSL3. Compared to unstained control (dashed), 
staining with C11-BODIPY led to a detectable increase in the fluorescence signal in 
the control staining (ctrl, orange) for both HMLE and HMLE-Twist1 cells (Figure 
17A). However, I did not observe a further increase in C11-BODIPY fluorescence 
when these cell lines were treated for 6h (blue) or 20h (grey) with RSL3 (Figure 
17A). These results were surprising since several reports showed that C11-BODIPY 
fluorescence increases upon RSL3 treatment (Friedmann Angeli et al., 2014; Yang 
et al., 2014). To rule out inappropriate handling of C11-BODIPY as a reason for 
these results, cumene hydroperoxide (CH) was used as a positive control. CH is a 
known inducer of lipid peroxidation (Weiss and Estabrook, 1986). Indeed, CH 
treatment led to a strong increase in C11-BODIPY fluorescence in both HMLE and 
HMLE-Twist1 cells compared to control treatment (Figure 17B). These data 
suggested that a pronounced increase in lipid peroxidation was not involved in cell 
density-dependent ferroptosis.  
kDa= kilo Dalton. (C) Immunoblot: ACSL4 and beta-actin (loading control) protein expression 
in single-cell clones (SCCs) derived by CRISPR/Cas9 genome-editing in the ACSL4 locus of 
HMLE H5 SCC with GPX4-KO plated at intermediate cell density in 10-cm dishes. kDa= kilo 
Dalton. (D) Representative bright-field images of SCCs described in C. Scale bar: 200 µm. (E) 
Viability assay: withdrawal of 1 µM Liproxstatin (Lip1) for 48h of HMLE H5 GPX4-KO SCCs with 
or without ACSL4 expression as shown in C plated at indicated cell densities in 96-well plates. 
WT = wildtype. n=3. Data shown (A, E) represent mean ± SEM. Viability was normalized to 
respective DMSO control (A) or Lip1 control (E) within each cell line and cell density. Statistics: 
two-tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, **<0.01, ***<0.01, 
****<0.0001, n.s. = not significant). 
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Figure 17: RSL3 treatment does not result in a global increase in lipid peroxidation 
(A) Flow cytometry: C11-BODIPY staining of HMLE and HMLE-Twist1 cells plated at 
intermediate density in 6-cm dishes treated with 100 nM RSL3 for the indicated time points. X-
axis: log10 of C11-BODIPY fluorescence. Y-axis: percentage of the maximum count. Data were 
partly generated by Marie Bannier-Hélaouët (Intern) and by Felix Holstein (Master Student). (B) 
Flow cytometry: C11-BODIPY staining of HMLE and HMLE-Twist1 cells as described in A 
treated for 1h with 100 µM cumene hydroperoxide (CH). Data were generated by Felix Holstein 
(Master Student). (C) Immunofluorescence: staining of lipid peroxidation (green) in HMLE and 
HMLE-Twist1 cells using Click-iT chemistry after treatment for 1.5h with 50 µM alkyne-modified 
linoleic acid (LAA) in presence or absence of 100 nM RSL3 and 500 nM Fer1. Cell nuclei were 
stained with DAPI (blue). Scale bar: 200 µm. (D) Flow cytometry: staining of lipid peroxidation 
in HMLE and HMLE-Twist1 cells using Click-iT chemistry as described in C. X-axis: log10 of 
Alexa-488 (lipid peroxidation detection) fluorescence. Y-axis: percentage of the maximum 
count. (E) Immunofluorescence: staining of lipid peroxidation (green) in HMLE and HMLE-
Twist1 cells using Click-iT chemistry as described in C using 100 µM CH instead of RSL3-
treatment. Cell nuclei were stained with DAPI (blue). Scale bar: 200 µm. Data (A-E) show one 
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Next, I wanted to measure lipid peroxidation by other means than C11-BODIPY 
staining. The Click-iT® Lipid Peroxidation Imaging Kit (Thermo Fisher Scientific) has 
been previously shown to visualize ferroptosis-related lipid peroxidation occurring 
during neuronal reprogramming (Gascón et al., 2016). Thereby, cells are incubated 
with an alkyne-modified linoleic acid (LAA), a PUFA that incorporates into the cell 
membrane. In the presence of lipid peroxidation, oxygenation of LAA leads to 
chemical reactions with intracellular proteins that can be detected with Click-iT® 
chemistry, yielding green fluorescence. Therefore, I used the Click-iT® Lipid 
Peroxidation Imaging Kit to assess whether RSL3 induces lipid peroxidation in 
HMLE and HMLE-Twist1. For this purpose, 48h after seeding HMLE and HMLE-
Twist1 cells on coverslips for immunofluorescence or in 6-well plates for flow 
cytometry, cells were incubated for 1.5h with 50 µM LAA in the presence or absence 
of 100 nM RSL3, 500 nM Fer1 or a combination of both. Then Click-iT® chemistry 
was performed prior to analyzing lipid peroxidation levels by immunofluorescence 
or by flow cytometry. Both analyses revealed that lipid peroxidation levels, indicated 
by a similar green fluorescence signals, did not increase upon RSL3-treatment 
compared to the DMSO control in both HMLE and HMLE-Twist1 cells (Figure 17C 
and D). In contrast, treatment with Fer1 alone or in combination with RSL3 
completely abolished the green fluorescence signal (Figure 17C and D), indicating 
that Fer1 reduced lipid peroxidation. Furthermore, CH treatment led to the detection 
of lipid hydroperoxides in both cell lines, but levels were not increased compared to 
the control (Figure 17E). However, CH treatment induced cellular stress, indicated 
by small cell nuclei, stained with DAPI, and disorganized cell shapes, outlined by 
the lipid peroxidation staining (Figure 17E). These data indicated an induction of cell 
death by CH. Interestingly, lipid peroxidation levels were not reduced by Fer1 when 
cells were treated with CH. Additionally, Fer1 did not rescue cell death induction, 
since cell nuclei were still small and cell shapes were still disorganized upon 
simultaneous CH and Fer1 treatment (Figure 17E). 
Notably, the levels of lipid peroxidation varied within the colonies formed by HMLE 
cells: smaller colonies showed higher lipid peroxidation levels than bigger colonies 
representative experiment performed independently two (C, D, E), at least three (B) or four (A) 
times. 
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(Figure 17C). Furthermore, cells at the border of colonies showed slightly elevated 
lipid peroxidation levels than cells in the middle of the colonies (Figure 17C). 
Together, these data suggested that lipid peroxidation levels were overall high in 
HMLE and HMLE-Twist1 cells. However, RSL3 did not induce a further increase in 
lipid peroxidation. The observed differences in lipid peroxidation levels within 
colonies of HMLE cells might indicate a differential sensitivity of cells within one 
colony towards RSL3 treatment. Furthermore, since Fer1 treatment reduced lipid 
peroxidation levels in both DMSO and RSL3-treated cells, but not in CH-treated. 
These data indicated that cell death induced by CH was different to RSL3-induced 
cell death in HMLE and HMLE-Twist1 cells. This might explain why CH, but not 
RSL3 treatment increased lipid peroxidation level detected by C11-BODIPY. 
Overall, I was not able to detect an increase in lipid peroxidation upon RSL3 
treatment in both HMLE and HMLE-Twist1 cells detected by C11-BODIPY staining 
or with the Click-iT® Lipid Peroxidation Imaging Kit. 
Since these results were surprising and unexpected, lipid peroxidation levels were 
again measured as soon as I had derived GPX4 knockout SCCs. Thereby, I wanted 
determine on a genetic level whether the GPX4 knockout correlated with lipid 
peroxidation and how this in turn correlated to ferroptosis sensitivity. To do so, SCCs 
were seeded at different cell densities either in presence or in absence of Lip1 in 6-
cm dishes for 48h before staining the cells with C11-BODIPY. Unexpectedly, C11-
BODIPY fluorescence increased upon Lip1-withdrawal (orange) in both HMLE and 
HMLE-Twist1 SCCs compared to Lip1-cultured cells (blue) (Figure 18A). The 
increase of C11-BODIPY fluorescence was not connected to the cell density. 
Moreover, the magnitude of C11-BODIPY levels greatly varied between the different 
SCCs upon Lip1-withdrawal (Figure 18A). On average, I observed at least a 2-fold 
increase in C11-BODIPY levels upon Lip1-withdrawal (Figure 18B). Despite an 
upregulation of C11-BODIPY levels upon Lip1-withdrawal at all cell densities, these 
SCCs were similarly sensitive to GPX4 knockout at low cell density while being 
resistant at high cell density (Figure 9B).  
Together, these data suggested that GPX4-inhibition by RSL3 did not induce a 
global increase in lipid peroxidation. In contrast, lipid peroxidation levels increased 
to some extent upon GPX4 knockout which was not connected with the seeding 
density. Importantly, RSL3 treatment was sufficient to induce cell density-dependent 
ferroptosis and this effect was genetically confirmed by GPX4 knockout. Therefore, 
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these lipid peroxidation data indicated that global lipid peroxidation level did not 
directly contribute to cell density-dependent ferroptosis. Furthermore, these data 
suggested that cell death might be triggered by the oxidation of specific lipids, rather 
than by an overall increase in lipid peroxidation.  
To this end, I showed that Fer1 rescued cell density-dependent cell death induction 
upon GPX4 inhibition or knockout (Figure 5A, Figure 6A and Figure 9C) and at the 
same time, Fer1 reduced lipid peroxidation levels in both HMLE and HMLE-Twist1 
cells (Figure 17C and D). Moreover, ACSL4, increasing the amount of PUFAs within 
membranes, did not determine cell density-dependent ferroptosis sensitivity in 
HMLE cells (Figure 16E). Since culture of cells in basal medium protected from 
RSL3-induced cell death (Figure 14I), I hypothesized that metabolic pathways fueled 
 
Figure 18: Lipid peroxidation level do not correlate with ferroptosis-sensitivity in GPX4-
knockout single-cell clones 
(A) Flow cytometry: C11-BODIPY staining of GPX4-knockout (KO) single-cell clones (SCCs) of 
HMLE and HMLE-Twist1 cells 48h after plating cells at different densities in 6-cm dishes in 1 
µM Lip1 (+Lip1, blue) culture or in medium without Lip1 (‒Lip1, orange). X-axis: log10 of C11-
BODIPY fluorescence. Y-axis: percentage of the maximum count. One representative 
experiment visualizing variation of C11-BODIPY fluorescence between SCCs is shown. n=2-4 
for each SCC (B) Quantification of C11-BODIPY fluorescence of HMLE (H) and HMLE-Twist1 
(HT) SCCs (two SCCs of H-SCCs and three SCCs for HT-SCCs) as described in A. Data were 
normalized to respective Lip1-treated control and represent mean ± SEM. n=6. Statistics: two-
tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, n.s. = not significant). 
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by growth factors might be involved in cell density-dependent ferroptosis. Moreover, 
I hypothesized that only some specific lipids might be oxidized during cell density-
dependent ferroptosis. In turn, cells seeded at low or high density might cope 
differently with these oxidized lipids and as a result, a vulnerable cell state towards 
GPX4-inhibition might be induced. 
 
4.14 Proteomic study reveals several regulated proteins both by cell density 
by RSL3 treatment 
As described above, I showed that sensitivity to cell death upon GPX4 inhibition was 
dependent on cell density and that sensitivity was most likely regulated by some 
kind of proximity-sensing or short-distance paracrine signaling that was not directly 
linked with cell-cell-adhesion signaling. Therefore, I concluded that intracellular 
metabolic pathways might be regulated by cell density that led to a vulnerability of 
cells to GPX4 inhibition. Given that this regulation was a fast process immediately 
induced by plating cells at different densities, I hypothesized that analyzing the 
proteome of both HMLE and HMLE-Twist1 cells at cell density could provide insights 
into the mechanisms of cell density-dependent ferroptosis induced by GPX4 
inhibition. Further, by assessing the proteins regulated by RSL3 treatment of cells 
seeded at intermediate cell density could further reveal mechanistic details. 
Therefore, a proteomic study of both HMLE and HMLE-Twist1 cells seeded at 
different densities as well as upon RSL3 treatment was performed in collaboration 
with the laboratory of Dr. Stefanie Hauck. For data analysis, I filtered on one hand 
for proteins that were at least 1.5-fold up- or downregulated (p<0.05) in low cell 
density compared to high cell density in both HMLE and HMLE-Twist1 cells and on 
the other hand for proteins that were at least 1.5-fold up- or downregulated (p<0.05) 
upon 5h RSL3 treatment compared to non-RSL3 treated control. Thereby, I obtained 
190 up- and 57 down-regulated proteins at low cell density and 274 up- and 349 
downregulated proteins upon RSL3 treatment. To further identify potential candidate 
proteins involved in cell density-dependent ferroptosis induced by GPX4-inhibition, 
I assessed the overlap between up- or downregulated overlapping proteins both at 
low cell density and by RSL3 treatment. The rationale behind this strategy was that 
proteins up- or downregulated by low density could confer sensitivity to cell density-
dependent ferroptosis. Moreover, if the same proteins were similarly regulated  
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Figure 19: Proteomic study identifies regulated proteins by both cell density and RSL3 
treatment 
(A) Venn diagram of proteomic data sets representing >1.5-fold downregulated proteins (p-value 
<0.05) in cell density (left) and upon 5h 100 nM RSL3-treatment (right). The left circle indicates 
commonly downregulated proteins in low cell density compared to high cell density in both HMLE 
and HMLE-Twist1 cells. The right circle indicates commonly downregulated proteins upon RSL3 
treatment compared to non-RSL3 treated control cells at intermediate cell density in both cell lines. 
The overlapping 16 proteins are downregulated by both low cell density and RSL3 treatment. (B) 
Venn diagram of proteomic data sets representing >1.5-fold upregulated proteins (p-value<0.05) 
in cell density (left) and upon 5h 100 nM RSL3-treatment (right) as described in A. 119 proteins 
were upregulated by both low cell density and RSL3-treatment. (C) Top ten-downregulated 
proteins by both low cell density and RSL3-treatment in both cell lines as described in A. (D) GO-
term analyses: top ten, significantly enriched terms (biological processes) using DAVID of 
upregulated proteins (119) by both cell density and RSL3-treatment as described in B. 
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during RSL3 treatment, this might imply a direct involvement in cell density-
dependent ferroptosis induced by GPX4-inhibition. 
With this strategy, I identified 16 proteins that were downregulated and 119 proteins 
that were upregulated in both low cell density and upon RSL3 treatment (Figure 19A 
and B, Table 10 and Table 11 in the Appendix). For instance, within the top ten-
downregulated proteins, Stearoyl-CoA Desaturase (SCD) might be a potential hit 
involved in a lipid-mediated oxidative cell death (Figure 19C). SCD is a key enzyme 
in monounsaturated fatty acid metabolism (Paton and Ntambi, 2009) and its genetic 
absence was implied in increasing fatty acid oxidation (FAO) (Dobrzyn et al., 2004). 
Interestingly, Carnitine Palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme 
for FAO, was upregulated at low cell density as well (Appendix Table 11). However, 
since more than 7-fold more proteins were upregulated by both low cell density and 
upon RSL3 treatment (Figure 19B), I submitted them to GO-term enrichment 
analysis of biological processes using DAVID (Figure 19D) (Huang et al., 2009b, 
2009a). Thereby, some interesting terms were enriched. For example, the enriched 
term “transferrin transport” further indicated a contribution of iron to cell density-
dependent ferroptosis (Figure 19D). Moreover, the upregulated protein Heme 
oxygenase 1 (HMOX1) (Appendix Table 11), shown to be involved in iron 
reutilization (Poss and Tonegawa, 1997a), was already implicated in Erastin-
induced ferroptosis in HT-1080 fibrosarcoma cells (Kwon et al., 2015). Another 
interesting term within the top-ten regulated pathways was “positive regulation of 
triglyceride catabolic process”, further suggesting a regulation of lipid metabolism by 
cell density and an involvement in RSL3-induced cell death (Figure 19D).  
Together, the proteomic analysis revealed candidate proteins that were potential 
candidates in the regulation of cell density-dependent ferroptosis. 
 
4.15 HMOX1 does not impact cell density-dependent ferroptosis induced by 
GPX4 inhibition 
Several studies have implied a role for HMOX1 in ferroptosis (Chang et al., 2018; 
Hassannia et al., 2018; Kwon et al., 2015) and therefore, I wanted to elucidate 
whether HMOX1 also contributed to cell density-dependent ferroptosis. To validate 
proteomics data, HMOX1 expression was assessed at both transcript as well as 
protein level. By qPCR, I found a 2-fold or 9-fold upregulation of HMOX1  
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Figure 20: Overexpression of HMOX1 does not impact cell density-dependent ferroptosis 
induced by GPX4 inhibition 
(A) qPCR: relative HMOX1 mRNA expression of HMLE and HMLE-Twist1 cells seeded at different 
densities in 6-cm dishes for 48h. n=3. (B) Immunoblot: protein expression of HMOX1 and beta-
actin (loading control) of HMLE and HMLE-Twist cells seeded at low or high cell density in 10-cm 
dishes for 48h. Numbers shown indicate densitometric ratios of detected HMOX1 to beta-actin 
protein band. One representative experiment performed independently two times is shown. (C) 
qPCR: relative HMOX1 mRNA expression of non-transduced HMLE cells (control, ctrl) or of HMLE 
cells transduced with lentiviruses containing HMOX1 cDNA at indicated multiplicity of infections 
(MOIs). n=3. (D) Immunoblot: protein expression of E-cadherin (E-cad), HMOX1, GPX4 and beta-
actin (loading control) in HMLE cells overexpressing HMOX1 as described in C. (E) Viability assay: 
treatment of HMLE cells overexpressing HMOX1 as described in C plated at indicated densities 
in 96-well plates with 100 nM RSL3 for 24h. n=3. Statistics: two-tailed, unpaired T-test with Welch’s 
correction (p-value: *<0.05, n.s. = not significant). (F) Dose-response curve: treatment of HMLE 
cells overexpressing HMOX1 as described in C plated at 600 cells in 96-well plates with 3-fold 
dilutions of RSL3 for 24h. n=3. (G) Rescue-viability assay: treatment of HMLE cells over-
expressing HMOX1 as described in C plated at 600 cells in 96-well plates with 100 nM RSL3, 500 
nM Liproxstatin-1 (Lip1), 100 µM deferoxamine (DFO), 10 µM α-tocopherol (α-toc) , 5 µM BWA4C 
or a combination of these compounds for 24h. n=2. Data shown (A, C, E, F, G) represent mean ± 
SEM. Viability (E, F, G) was normalized to respective DMSO control within each cell line and cell 
density. 
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transcripts in low cell density compared to high cell density in HMLE and HMLE-
Twist1 cells, respectively. However, expression levels were higher in HMLE-Twist1 
cells (Figure 20A). By immunoblotting, I observed a strong expression of HMOX1 in 
HMLE-Twist1 cells seeded at low cell density, being more than 2-fold higher than 
the expression levels of cells seeded at high cell density (Figure 20B). In contrast, 
HMLE cells showed no expression of HMOX1 at high cell density and only a very 
low expression level at low cell density (Figure 20B), suggesting a minor role of 
HMOX1 for HMLE cells. To further elaborate the role of HMOX1 in cell density-
dependent ferroptosis, HMOX1 cDNA was overexpressed in HMLE cells and its 
impact on cell viability was determined. For this purpose, HMOX1 cDNA transcribed 
from RNA extracted from HMLE-Twist1 cells was used since HMLE-Twist1 
upregulated HMOX1 both at the RNA and protein level at low cell density. Then, 
HMLE cells were transduced with lentiviruses containing HMOX1 cDNA at three 
different MOIs (0.5, 5 and 10). After selection with 1 µg/ml puromycin, HMOX1 
overexpression (OE) was confirmed by qPCR and immunoblotting, revealing in 
comparison to non-transduced control a successful increase in expression levels 
(Figure 20C), comparable to those of HMLE-Twist1 cells seeded at low cell density 
(Figure 20A). Of note, different MOIs used for transductions did not yield different 
HMOX1 expression levels (Figure 20C). Further, HMOX1 overexpression did also 
not impact E-cadherin or GPX4 expression levels, as assessed by immunoblotting 
(Figure 20D). Next, I plated HMOX1-overexpressing HMLE cells into viability assays 
at different cell densities and treated them the next day with 100 nM RSL3 for 24h. 
Again, as expected for control HMLE cells, I observed cell density-dependent 
ferroptosis upon RSL3 treatment with cells at low cell density being highly sensitive 
and cells at high cell density being resistant to GPX4-inhibition (Figure 20E). The 
amount of cell death induction was similar between HMOX1 OE and control cells 
(Figure 20E). In line, when cells seeded at an intermediate-low density (600 cells) 
were submitted to treatment with different concentrations of RSL3, I did not observe 
any difference in cell death induction between control and HMOX1 OE HMLE cells 
(Figure 20F). The ferroptosis inhibitors Lip1, α-Toc, DFO and BWA4C were able to 
rescue cell death induced by 100 nM RSL3 treatment in HMOX1 OE HMLE cells to 
comparable levels as observed in control cells (Figure 20G). Together, HMOX1 OE 
in HMLE cells suggested that HMOX1 did not impact sensitivity to cell density-
dependent ferroptosis induced by GPX4 inhibition.  
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Since the assembly of a fully functional enzyme might be impacted by HMOX1 OE, 
CRISPR/Cas9-mediated HMOX1 knockout was performed in both HMLE and 
HMLE-Twist1 cells. Knockout efficiency was not high, but I derived one SCC with 
no HMOX1 expression for each cell line (SCC7-2 and SCC3-1, respectively) and 
several with low HMOX1 expression levels (Figure 21A and B). For SCCs of both 
HMLE and HMLE-Twist1 cells, cell density-dependent ferroptosis was observed 
upon 100 nM RSL3 treatment to a similar extent as in control SCCs (Cas9-only 
transfected cells without sgRNAs against HMOX1) and in HMOX1-modified SCCs 
(Figure 21C and D). Of note, SCC3-3, derived after CRISPR/Cas9-editing in HMLE-
Twist1, showed increased sensitivity at high cell density (reduction in viability by 
67% for SCC3-3 compared to 17% and 13% for SCC3-1 and SCC4-1 respectively) 
(Figure 21D). However, this SCC still showed low expression levels of HMOX1 by 
immunoblotting (Figure 21B), suggesting that increased sensitivity was most likely 
not induced through HMOX1 expression, but through other intrinsic properties of this 
SCC.  
Conclusively, these data indicated that HMOX1 did not play a major role in cell 
density-dependent ferroptosis upon GPX4 inhibition. 
 
Figure 21: Genetic knockout of HMOX1 does not impact cell density-dependent ferroptosis 
induced by GPX4 inhibition 
(A) and (B) Immunoblot: protein expression of HMOX1 and beta-actin (loading control) of single-
cell clones (SCCs) derived by CRISPR/Cas9 genome-editing in the HMOX1 locus of bulk (A) 
HMLE and (B) HMLE-Twist1 cells plated at intermediate cell density in 10-cm dishes. kDa= kilo 
Dalton. (C) Viability assay: treatment of HMLE SCCs derived by CRISPR/Cas9 with or without 
HMOX1-knockout (KO) as described in A plated at indicated cell densities in 96-well plates with 
100 nM RSL3 for 24h. n=2. (D) Viability assay of HMLE-Twist1 SCCs as described in B with 100 
nM RSL3 for 24h as described in C. n=2. Data shown (C, D) represent mean ± SD. Viability was 
normalized to respective DMSO control within each cell line and cell density. 
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4.16 ATGL-regulated lipid droplet catabolism at low cell density is connected 
with cell density-dependent ferroptosis 
Since I hypothesized that specific lipids are oxidized during cell density-dependent 
ferroptosis (Figure 16-Figure 18), I next focused on the enriched GO Term “positive 
regulation of triglyceride catabolic process” (Figure 19D). As both the adipose 
triglyceride lipase (ATGL = PNPLA2) and its co-activator lipase 1-acylglycerol-3-
phosphate O-acyltransferase (ABDH5) are involved in the turnover of 
triacylglycerides (TAGs) stored in lipid droplets (LDs) (Smirnova et al., 2006; Wang 
et al., 2011; Zimmermann et al., 2004), their expression was examined. By qPCR, I 
observed that both HMLE and HMLE-Twist1 cells expressed both PNPLA2 and 
ABDH5, however, transcript levels were not regulated by cell density (Figure 22A 
and B). In contrast, regulation of ATGL expression by cell density was detectable by 
immunoblotting (Figure 22C). In line with the proteomic data, low cell density 
resulted in strongly upregulated ATGL protein levels compared to high cell density 
in both HMLE and HMLE-Twist1 cells (Figure 22C). Interestingly, HMLE cells did 
not express ATGL protein at high cell density in contrast to HMLE-Twist1 cells 
(Figure 22C). To connect the upregulation of ATGL to its function, the LD content 
was measured using the fluorescent dye BODIPY493/503, commonly used to stain 
LDs (Smirnova et al., 2006). Consequently, I found that BODIPY493/503 
fluorescence intensity simultaneously declined with decreasing the seeding density 
in both HMLE and HMLE-Twist1 cells (Figure 22D), indicating that LD content was 
reduced from high to low cell density. At high cell density, BODIPY493/503 
fluorescence intensity was higher in HMLE cells compared to HMLE-Twist1 cells, 
but decreased to a similar level in both cells lines at low seeding density (Figure 
22D). These results reflected ATGL protein expression levels of HMLE and HMLE-
Twist1 cells. Staining for lipid ROS using C11-BODIPY dye revealed the reverse 
regulation. Both cell lines showed higher lipid ROS levels at low cell density 
compared to high cell density (Figure 22D). These results suggested that cells 
suffered from increased lipid-mediated stress at low cell density.  
Next, I inhibited ATGL by Atglistatin (ATGLi) during viability assays. To do so, I 
plated HMLE and HMLE-Twist1 cells at a low cell density and pre-incubated them 
with ATGLi prior to RSL3 treatment. RSL3 induced cell death by 70% compared to 
the DMSO control which was rescued by simultaneous ATGLi administration in both 
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Figure 22: ATGL-regulated lipid droplet catabolism at low cell density is linked to cell 
density-dependent ferroptosis 
(A) and (B) qPCR: relative (A) PNPLA2 (ATGL) and (B) ABDH5 mRNA expression of HMLE and 
HMLE-Twist1 cells seeded at different densities in 6-cm dishes for 48h. (C) Immunoblot: protein 
expression of ATGL and beta-actin (loading control) of HMLE and HMLE-Twist cells seeded at 
indicated cell densities in 10-cm dishes for 48h. (D) Flow cytometry: BODIPY493/503 (lipid 
droplets) and C11-BODIPY (lipid ROS) staining of HMLE and HMLE-Twist1 cells seeded at 
indicated densities in 6-cm dishes for 48h. X-axis: log10 of respective fluorescence, Y-axis: 
percentage of the maximum count. (E) Viability assay: treatment of HMLE and HMLE-Twist1 
plated at low cell density in 96-well plates with 0.1% DMSO (‒RSL3) or 100 nM RSL3 (+RSL3) 
without (control, ctrl) or in combination with 20 µM Atglistatin (ATGLi) for 24h. Cells were 
additionally pre-treated with ATGLi for 24h prior to DMSO/RSL3 treatment. n=4. (F) Viability assay: 
treatment of GPX4-knockout (KO) single-cell clones HMLE H5 and HMLE-Twist1 HT1 plated at 
indicated cell densities in 96-well plates without (ctrl) or with 20 µM ATGLi in presence or absence 
of 1 µM Lip1 for 48h. ATGLi-treated cells were additionally pre-treated with ATGLi in presence of 
Lip1 for 24h in 6-wells prior to the viability assay. n=3. Data shown (A, B, E, F) represent mean ± 
SEM. Viability was normalized to respective DMSO control (E) or respective Lip1 control (F) within 
each cell line and cell density. One representative experiment (A, B, C, D) performed 
independently two (A, B, C) or three (D) times is shown. Statistics: two-tailed, unpaired T-test with 
Welch’s correction (p-value: *<0.05, **<0.01, n.s. = not significant). 
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HMLE and HMLE-Twist1 cells (Figure 22E). Notably, administration of only ATGLi 
did not affect viability compared to the DMSO controls (Figure 22E). Likewise, ATGLi 
incubation rescued cell density-dependent ferroptosis in GPX4-KO SCCs H5 and 
HT1, when they were cultured in the absence of Lip1 (Figure 22F).  
ATGLi has been described to efficiently inhibit murine ATGL in adipocytes, but to 
target human ATGL only by 10% (Schweiger et al., 2017). To elucidate whether 
ATGLi non-specifically rescued RSL3-induced cell death, breast cancer cell lines, 
that did not show cell density-dependent ferroptosis induction upon GPX4-inhibition 
(Figure 15A), were pre-incubated with ATGLi prior to RSL3 treatment and viability 
was measured. ATGLi significantly rescued RSL3-mediated cell death in T-47D cells 
and in epithelial MDA468 cells, but did not do so in mesenchymal MDA231 and 
MDA157 cells (Figure 23A). These results revealed that ATGLi was not generally 
able to rescue RSL3-mediated cell death. Again, ATGLi did not impact viability in 
control treatments (Figure 23B). Notably, all breast cancer cell lines expressed 
ATGL at the protein level (Figure 23C), indicating that cells might rely to a different 
extent on the catabolic pathway mediated by ATGL. 
 
Figure 23: RSL3-induced ferroptosis of T-47D and MDA468 breast cancer cells is rescued 
by ATGLi 
(A) Viability assay: treatment of indicated breast cancer cell lines plated at intermediate cell density 
in 96-well plates with 0.1% or 100 nM RSL3 without (ctrl) or in combination with 20 µM Atglistatin 
(ATGLi) for 24h. n=3. Statistics: two-tailed, unpaired T-test with Welch’s correction (p-value: 
*<0.05, **<0.01, n.s. = not significant). (B) Viability assay as described in A. Data show DMSO-
treated cells. n=3. (C) Immunoblot: protein expression of ATGL and beta-actin (loading control) of 
indicated breast cancer cell lines seeded at intermediate cell density in 10-cm dishes for 48h. Data 
shown (A, B) represent mean ± SEM. Viability was normalized to respective DMSO control within 
each cell line. 
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Conclusively, these data implied that ATGL expression, upregulated by low cell 
density, controlled liberation of TAGs from LDs in a cell density-dependent manner 
in both HMLE and HMLE-Twist1 cells. Thereby, lipid-mediated ROS level were 
increased that might indicate a vulnerability of cells at low cell density to GPX4-
inhibition. 
 
4.17 Oleic acid supplementation rescues cell density-dependent ferroptosis 
To better understand the connection between ATGL-mediated turnover of LDs and 
sensitivity to cell density-dependent ferroptosis, I wished to interfere with LD 
metabolism in a different manner than by inhibiting ATGL. An earlier study has 
shown that the monounsaturated fatty acid oleic acid (OA) increases the amount of 
LDs within cells in cell culture (Smirnova et al., 2006). Therefore, I supplemented 
the culture medium of HMLE and HMLE-Twist1 cells, that were seeded at different 
cell densities, with 100 µM OA for 24h and measured the LD content using 
BODIPY493/503 staining. BODIPY493/503 fluorescence intensity increased upon 
OA treatment compared to the control in all cell densities for both cell lines (Figure 
24A). These data indicated that the amount of LDs increased upon OA treatment. 
By contrast, OA supplementation decreased C11-BODIPY fluorescence (Figure 
24A), suggesting that lipid ROS level decreased in OA-treated cells and again, 
indicating an opposite correlation between LD amount and lipid ROS level. In order 
to assess how this translated to RSL3-sensitivity, control and OA-supplemented 
HMLE and HMLE-Twist1 cells plated at different cells densities were submitted to 
100 nM RSL3 treatment during viability assays. For both cell lines, I observed that 
cell density-dependent ferroptosis, induced by RSL3 treatment, was rescued by OA 
supplementation (Figure 24B). Furthermore, I noticed a minor impact on cell viability 
by OA treatment alone (Figure 24C).  
In sum, these data suggested that the OA-induced increase in the amount of LD 
resulted in lower lipid ROS level within cells, thereby lowering lipid-mediated stress 
and protecting cells from RSL3-mediated cell death. These data supported the 
hypothesis that the turnover of LDs was indeed connected with an induced 
vulnerability to GPX4 inhibition at low cell density.  
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4.18 Energy metabolism shifts to beta-oxidation by cell density 
Next, I wanted to determine why low cell density upregulated LD catabolism at the 
expense of inducing a vulnerable cell state. Recent studies indicated that fatty acids 
(FAs), stored within LDs, are liberated by ATGL during periods of starvation or 
cellular stress in order to enable oxidative metabolism within mitochondria (Jarc et 
al., 2018; Rambold et al., 2015; Wright et al., 2017). Since the proteomic data 
suggested a regulation of the enzyme CPT1A which is essential for β-oxidation 
(Appendix Table 11), I hypothesized that low cell density might trigger ATGL-
mediated LD turnover in order to fuel β-oxidation.  
  
 
Figure 24: Oleic acid supplementation rescues cell density-dependent ferroptosis 
(A) Flow cytometry: BODIPY493/503 (lipid droplets) and C11-BODIPY (lipid ROS) staining of 
HMLE and HMLE-Twist1 cells seeded at indicated densities in 6-cm dishes for 48h treated without 
(ctrl) or for 24h with 100 µM oleic acid (OA). X-axis: log10 of respective fluorescence, Y-axis: 
percentage of the maximum count. One representative experiment performed independently two 
times is shown. (B) Viability assay: treatment of HMLE and HMLE-Twist1 cells plated at indicated 
cell densities in 96-well plates with 0.1% DMSO or 100 nM RSL3 without (ctrl, orange) or with 100 
µM oleic acid (OA, blue) for 24h. OA was additionally applied for 24h prior to the viability assay. 
n=3. (C) Viability assay as described in B. Data show DMSO-treated cells. n=3. Data shown (B, 
C) represent mean ± SEM. Viability was normalized to respective DMSO control within each cell 
line and cell density. Statistics: two-tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, 
**<0.01, ***<0.001, n.s. = not significant). 
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Figure 25: Energy metabolism shifts to beta-oxidation by low cell density 
(A) and (B) qPCR: relative (A) CPT1A and (B) ACAA2 mRNA expression of HMLE and HMLE-
Twist1 cells seeded at different densities in 6-cm dishes for 48h. (C) Flow cytometry: MitoSox 
(mitochondrial ROS) staining of HMLE and HMLE-Twist1 cells seeded at indicated densities in 6-
cm dishes for 48h. X-axis: log10 of MitoSox fluorescence, Y-axis: percentage of the maximum 
count. (D) Viability assay: treatment of HMLE and HMLE-Twist1 plated at low cell density in 96-
well plates with 0.1% DMSO (‒RSL3) or 100 nM RSL3 (+RSL3) without (ctrl) or in combination 
with 100 µM Etomoxir (ETX) for 24h. n=4. (E) Viability assay: treatment of GPX4-knockout (KO) 
single-cell clones HMLE H5 and HMLE-Twist1 HT1 plated at indicated cell densities in 96-well 
plates without (ctrl) or with 100 µM Etomoxir (ETX) for 48h in presence or absence of 1 µM Lip1. 
n=3. Data shown (A, B, D, E) represent mean ± SEM. Viability was normalized to respective DMSO 
control (D) or respective Lip1 control (E) within each cell line and cell density. One representative 
experiment (A, B, C) performed independently two (A, B) or four (C) times is shown. Statistics: 
two-tailed, unpaired T-test with Welch’s correction (p-value: *<0.05, **<0.01, ***<0.01, n.s. = not 
significant). 
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First, I assessed the expression of β-oxidation related enzymes by qPCR in both 
HMLE and HMLE-Twist1 cells. In line with the proteomic data, CPT1A transcript 
levels as well as those of Acetyl-CoA Acyltransferase 2 (ACAA2), catalyzing the last 
step of β-oxidation, were increased at low cell density compared to high cell density 
(Figure 25A and B). Next, basal mitochondrial ROS levels were assessed by 
MitoSox staining, which serves as a proxy of mitochondrial activity. MitoSox 
fluorescence shifted to higher levels from high to low cell density in both cell lines 
(Figure 25C). These data indicated increased levels of mitochondrial ROS at low 
cell density, thus pointing to higher mitochondrial activity, potentially induced by 
increased level of β-oxidation. To further analyze β-oxidation in HMLE and HMLE-
Twist1 cells, CPT1A function was inhibited by Etomoxir (ETX) treatment at low cell 
density during viability assays. Treatment with 100 µM ETX diminished cell viability 
compared to controls in both cell lines, while a combination of ETX with RSL3 did 
not further impact cell viability (Figure 25D). Furthermore, when GPX4-KO SCCs H5 
and HT1 were exposed to ETX treatment in presence of Lip1, viability was strongly 
reduced at all seeding densities. However, cells at low cell density were around 1.5-
fold less viable compared to cells at high cell density (Figure 25E). Again, Lip1-
withdrawal unveiled GPX4-KO effects leading to cell density-dependent ferroptosis 
in both SCCs, but simultaneous ETX treatment did not reveal sound additive effects 
on cell viability (Figure 25E).  
Collectively, these data suggested that cell density regulated the expression of 
enzymes required for β-oxidation which led to a greater dependence of HMLE and 
HMLE-Twist1 cells seeded at low density on β-oxidation. At the same time, both cell 
lines were generally sensitive to inhibition of β-oxidation.  
Overall, these data indicated that in order to fuel β-oxidation, cells at low density 
increased LD turnover by ATGL upregulation which, in turn, induced lipid-mediated 
toxicity. With respect to cell density-dependent ferroptosis, this mechanism induced 
a vulnerability towards lipid-mediated stress provoked by GPX4 inhibition.
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5 Discussion 
Worldwide, breast cancer is the most frequently diagnosed cancer and the leading 
cause of cancer-related death in women (Bray et al., 2018). Importantly, whereas 
localized breast cancer is associated with a good prognosis, 5-year survival is below 
30% for advanced and metastatic disease (Noone et al., 2017). The identification 
and characterization of molecular breast cancer subtypes based on global gene 
expression have helped to better understand this complex and heterogeneous 
disease. Specifically, a subset of breast cancer belonging to the molecular subtypes 
of basal-like or claudin-low breast cancer has been associated with a poor clinical 
outcome. Together they represent approximately 80% of all TNBC which are 
characterized by a lack of HR and HER2 expression and therefore are limited in 
targeted therapies opportunities (Prat and Perou, 2011). Both claudin-low and basal-
like breast cancer have been shown to correlate with an EMT and a stem-cell-like 
signature (Herschkowitz et al., 2007; Sarrió et al., 2008). Since activation of EMT-
TFs and the process of EMT are implicated in tumor progression and metastasis 
and confer resistance to conventional therapies like radio- or chemotherapy 
(Ansieau et al., 2014; Nieto et al., 2016), using EMT models and thus studying EMT 
may enable to develop novel therapies for TNBC patients as well as for patients with 
metastatic and therapy refractory breast cancer.  
Ferroptosis is a regulated non-apoptotic cell death, induced through genetic 
inactivation or pharmacological inhibition of GPX4 (Dixon et al., 2012; Yang et al., 
2014). Several players and metabolic regulators such as glutathione biosynthesis 
and iron metabolism have been identified to be involved in ferroptosis (Hao et al., 
2018). Central to ferroptosis is the accumulation of lipid peroxidation of specific 
phospholipids like phosphatidylethanolamines (PE) containing long-chain 
polyunsaturated fatty acids (such as arachidonic acid (AA) and adrenic acid (AdA)) 
prior to cell death. Specifically, ACSL4 leads to AA and AdA esterification into PEs 
while lipoxygenases oxygenate this PE species, thereby converting them into a 
ferroptotic death signal (Doll et al., 2017; Kagan et al., 2017). Several reports have 
associated EMT with changes in cellular metabolism along with altered redox 
regulation and lipid metabolism (Dong et al., 2013; Sciacovelli and Frezza, 2017; 
Shaul et al., 2014), leading to the hypothesis that ferroptosis might be used to target 
EMT-induced cells. My work focused on studying ferroptosis in the context of 
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mammary epithelial cells (HMECs) and during Twist1-induced EMT. More precisely, 
I wished to elucidate molecular determinants of ferroptosis sensitivity in human 
mammary epithelial cells. The major finding of this work is the establishment of cell 
density, independently of EMT and other oncogenic signaling, as an important 
predictor of ferroptosis sensitivity in both primary as well as immortalized human 
mammary epithelial cells (HMECs). Specifically, cells at high cell density acquire 
resistance to ferroptosis while cells at low cell density are sensitive to ferroptosis 
induced by pharmacologic or genetic inhibition of GPX4 (Figure 5, Figure 8, Figure 
9 and Figure 11). To my knowledge, cell density has not yet been described as a 
regulator of ferroptosis sensitivity.  
 
5.1 Cell density determines ferroptosis-sensitivity in both epithelial and 
Twist1-induced HMLE cells 
Since I hypothesized that EMT-induction might sensitize cells to ferroptosis, I initially 
elicited ferroptosis in a cellular model of EMT. For this purpose, I used immortalized 
mammary epithelial cells (HMLE) and induced EMT by activating Twist1 in a 
conditional manner by TAM-administration or in a constitutive manner (Mani et al., 
2008; Schmidt et al., 2015). Doing so, I observed a strong reduction in viability at 
low seeding density upon inhibition of GPX4 in both epithelial and Twist1-induced 
mesenchymal cells. Irrespective of the cellular phenotype, both cell types became 
resistant to GPX4-inhibition with increasing cell densities (Figure 5A, C, D and E). 
Similarly, RSL3 treatment led to cell density-dependent ferroptosis in Snail1-induced 
EMT cells (Figure 5B). Moreover, I ruled out necrosis or apoptosis as cell death 
modalities (Figure 6). My findings are to some extent in contrast with a recent paper 
stating that therapy-resistant high mesenchymal cell states sensitize cells to 
ferroptosis (Viswanathan et al., 2017), since I did not observe a consistent difference 
in sensitivity in HMLE cells before and after EMT. Instead, my data indicate a 
different mechanism of cell density-dependent ferroptosis irrespective of cell state. 
However, in support of my data, although the mesenchymal-state vulnerability has 
been previously correlated with sensitivity in diverse cancer line lineages, no such 
correlation has been observed in breast cancer cell lines (Viswanathan et al., 2017). 
Additionally, the authors do not provide any information about seeding densities 
during viability assays in their research paper (Viswanathan et al., 2017), it is 
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impossible to directly compare my finding of a cell density-dependent ferroptosis to 
the finding of a mesenchymal cell state-dependent ferroptosis. 
 
5.2 Thiol and glutathione metabolism do not directly impact cell density-
dependent ferroptosis but could be linked to metastasis 
Upstream of GPX4, the system xc− supplies cysteine for GSH biosynthesis which, in 
turn, is necessary for proper GPX4 activity (Friedmann Angeli et al., 2014; Yang et 
al., 2014). In contrast to RSL3, ERA treatment, which inhibits system xc− upstream 
of GPX4, did not impact cell viability at any cell density in both HMLE and HMLE-
Twist1 (Figure 5A, D and E, Figure 7A). In line with these observations, cell density 
did not regulate key genes of the system xc− like SLC7A11 and of GSH biosynthesis 
like GCLC (Figure 7B) that have been shown to modulate sensitivity to cystine 
deprivation (Dixon et al., 2012; Gao et al., 2015). Although this observation was 
surprising to some extent, ERA-resistant cell lines have been described before. For 
instance, oncogenic RAS-expressing fibroblasts (BJ-TERT/LT/ST/RASV12), but not 
their parental counterparts, are sensitive to ERA treatment, which led to its 
terminology “eradicator of Ras and ST”-expressing cells (Erastin) (Dolma et al., 
2003). Since the generation of BJ and HMLE cells is based on the same genetic 
elements like the introduction of hTERT and the SV40 large T early region (Elenbaas 
et al., 2001; Hahn et al., 1999), oncogenic Ras expression in HMLE cells might 
induce ERA-sensitivity. Although one would need to test this possibility, it is quite 
unlikely. BJ-TERT/LT/ST/RASV12 cells also undergo ferroptosis upon RSL3 
treatment compared to BJ-TERT/LT/ST cells (Yang and Stockwell, 2008), but 
oncogenic Ras did not confer further sensitivity to RSL3 treatment in HMLE and 
HMLE-Twist1 beyond the cell density-dependency (Figure 10A and B). Another 
explanation might be that HMLE and HMLE-Twist1 cells derive cysteine by other 
means than the system xc−. Recently, resistance to ERA-induced ferroptosis has 
been linked to the transsulfuration pathway which provides intracellular cysteine 
from methionine (Hayano et al., 2016). Indeed, an active transsulfuration pathway 
has been shown to participate in GSH biosynthesis in primary HMECs (Belalcázar 
et al., 2014). Burkitt’s Lymphoma (BL) cells suffer from oxidative stress-induced cell 
death when they are seeded at low densities. Co-culture of BL-cells with irradiated 
fibroblasts has been reported to rescue cell death since fibroblasts supply cysteine 
to cells (Falk et al., 1993, 1998). By overexpression of SLC7A11 in BL-cells, it has 
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been shown that cysteine induces protection from low seeding densities by 
generating a reducing extracellular microenvironment fueled by cystine/cysteine 
redox cycle, but not by increasing GSH metabolism (Banjac et al., 2008). However, 
in my own experiments, co-culture with cells seeded at high cell density did not 
protect cells seeded at low cell density from ferroptosis (Figure 14D-F). Hence, this 
implies another mechanism in cell density-dependent cell death induction by GPX4 
inhibition in HMECs than that observed for BL cells. Together, these data suggest 
that system xc− and GSH metabolism do not directly impact cell density-dependent 
ferroptosis observed upon GPX4 inhibition or knockout. 
Interestingly, compared to parental HMLE cells, Twist1-induced EMT reduced both 
SLC7A11 and GCLC expression which led to a reduction in thiols, serving as a proxy 
for cysteine levels, and to a reduction in reduced as well as total GSH levels (Figure 
7B-F). A possible mechanism for a reduction of SLC7A11 and GSH levels upon 
Twist1-induced EMT could be the isoform switch of the cell surface marker CD44 
that occurs during EMT (Brown et al., 2011; Ishimoto et al., 2011). A shift in 
expression of CD44 from variant isoforms (CD44v) to the standard isoform (CD44s) 
is as a critical event during Twist1-induced EMT in HMLE cells. Expression of the 
CD44s isoform has been connected to apoptosis-resistance by inducing survival 
signaling via AKT and has been found to be expressed in high-grade breast tumor 
samples (Brown et al., 2011). By contrast, the CD44v isoform has been shown to 
stabilize SLC7A11, thereby regulating GSH levels in gastrointestinal cancer cell 
lines. Further, stabilization of SLC7A11 by CD44v has been shown to promote tumor 
growth (Ishimoto et al., 2011). Since metastasizing melanoma cells have been 
shown to suffer from elevated oxidative stress which has to be reduced for 
metastatic outgrowth (Piskounova et al., 2015), reduction in the antioxidant capacity 
during Twist1-induced EMT might facilitate invasion and progression. Further 
experiments are required to elaborate this mechanism which might constitute an 
opportunity to therapeutically target metastatic progression.  
Alternatively, one could hypothesize that these observations might explain why 
Twist1-induced cells seeded at intermediate seeding densities were slightly more 
sensitive to RSL3 treatment (Figure 5D and E). A small reduction in reducing 
equivalents might impact the threshold when cells are pushed into cell death upon 
RSL3 inhibition. At intermediate seeding densities, this deadly threshold might be 
reached earlier in HMLE-Twist1 cells compared to HMLE cells upon RSL3 inhibition. 
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However, this explanation contrasts to some extent with the observations that the 
reductions in thiol and GSH metabolism that I detected upon Twist1-induced EMT 
did not directly alter GPX4 activity (Figure 7G). Further, I did not observe that GPX4-
KO resulted in different sensitivities of HMLE and HMLE-Twist1 SCCs seeded at 
intermediate cell densities (Figure 9B and C). Together, these data suggest that 
Twist1-induced changes in thiol and GSH metabolism might modulate RSL3 
sensitivity at intermediate cell densities, however, upon complete loss of GPX4, 
these upstream mechanisms do not have a significant role in impacting sensitivity 
to ferroptosis. Furthermore, GPX4 might not only utilize GSH as a cofactor but also 
other thiol-containing substrates (Roveri et al., 1994) or protein thiols (Maiorino et 
al., 2005; Ursini et al., 1999), explaining why GPX4-activity is not altered in Twist1-
induced cells. Additionally, it is possible that the thioredoxin antioxidant system 
might compensate for a reduction in GSH levels (Mandal et al., 2010). Although loss 
of GCL, the rate-limiting enzyme in GSH biosynthesis, is lethal to cells, Mandal and 
colleagues have been shown that GCL knockout cells are able to proliferate when 
SLC7A11 is simultaneously overexpressed, leading to higher cystine import into 
cells. Within the cells, TXNRD1 reduces cystine to cysteine, thereby enabling these 
cells to maintain a reducing microenvironment independently of GSH (Mandal et al., 
2010). Again, as explained before, other cysteine sources could compensate for the 
reduction of system xc−. For example, a recent study has shown by metabolomics 
profiling that Cystathionine, a precursor of homocysteine in the transsulfuration 
pathway, was 11-fold enriched in HMLE-Twist1 cells compared to parental HMLE 
cells (Bhowmik et al., 2015).  
 
5.3 Cell density-dependent ferroptosis is an intrinsic property of mammary 
epithelial cells 
After establishing that cell density-dependent ferroptosis occurred irrespective of the 
epithelial or mesenchymal phenotype and was consistently observed upon RSL3-
mediated GPX4 inhibition or GPX4 knockout, I set out to further elaborate the 
underlying mechanisms. Despite the recognition that RAS-expressing fibroblast are 
particularly sensitive to RSL3 treatment (Yang and Stockwell, 2008), I was not able 
to link oncogenic RAS expression or PTEN loss to cell density-dependent ferroptosis 
in the HMLE system (Figure 10). This is not too surprising since it has been shown 
that sensitivity to ferroptosis is not necessarily predicted by the RAS mutation status 
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across a large panel of cancer cell lines (Yang et al., 2014). Another study has 
reported a similar finding for other known tumor mutations in RAF, PIK3CA and 
TP53 (Lachaier et al., 2014). Moreover, I discovered that cell density-dependent 
sensitivity towards RSL3-induced cell death was already present in primary HMECs 
(Figure 11). These data suggest that ferroptosis might be an intrinsic mechanism in 
the mammary gland to promote elimination of single detached cells when the 
epithelial integrity is disturbed. Accordingly, a recent study has shown that in 
immortalized non-tumorigenic MCF10A cells and a panel of breast cancer cell lines, 
detachment of cells from the extracellular matrix (ECM) triggers ferroptosis (Brown 
et al., 2017). In this context, ECM detachment has been modeled by culturing cells 
in low-adhesion plates which had been previously shown to induce anoikis, a form 
of programmed cell death (Frisch and Francis, 1994). Mechanistically, the authors 
have shown that α6β4 integrin expression leads to ferroptosis resistance during 
ECM detachment. At the molecular level, α6β4 integrin inhibits ACSL4 expression 
in a Src-dependent manner, thereby suppressing pro-ferroptotic changes in 
membrane composition (Brown et al., 2017). In a follow-up study, the authors have 
reported that in the absence of α6β4, cell-clustering during detachment mediated 
through PVRL4 (Nectin-4) dictates ferroptosis sensitivity. In contrast, without this 
clustering during detachment, susceptibility to anoikis is increased in single cells 
(Brown et al., 2018). However, I did not establish a link to ACSL4 expression 
because ACSL4-KO did not impact cell density-dependent ferroptosis, at least not 
in HMLE cells (Figure 16C-E). Therefore, the mechanism proposed by Brown and 
colleagues might be different from cell density-dependent ferroptosis. Furthermore, 
I observed that RSL3 prevented the organoid formation of primary HMECs seeded 
into 3D-collagen gels (Figure 13). Collagen I provides an ECM enabling growth as 
branched organoids of primary HMECs that resemble terminal ductal-lobular units 
of the mammary gland. Integrin α6 is expressed at a basal position in organoids 
formed by primary HMECs (Linnemann et al., 2015). Therefore, it is very interesting 
to assess how GPX4 inhibition impacts organoids that were already formed or 
whether they become resistant to GPX4 inhibition. It has been shown that TAM-
inducible GPX4-KO fibroblasts are able to form colonies in a 3D Matrigel assay at a 
similar number as control cells. In these assays, 5 x 104 cells per gel have been 
seeded, a cell density at which cells die in 2D cultures (Schneider et al., 2010). In 
contrast, by culturing a GPX4-KO SCC of HMLE cells in 3D-collagen gels, I 
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observed that exposure to GPX4-KO by withdrawal of Lip1 at the single-cell level 
completely abolished sphere formation. After three days of culture in presence of 
Lip1, small colonies appeared and here, withdrawal of Lip1 impaired further 
proliferation, but did not induce complete regression of spheres (Figure 13B-F). In 
these 3D-collagen gels, I did not establish a direct correlation between seeded cell 
densities and resistance to ferroptosis (Figure 13B-F). However, the cell numbers 
that I have seeded into 3D collagen gels were 10-fold to 74-fold lower than those 
employed by Schneider and colleagues (Schneider et al., 2010). Although that study 
does not provide a mechanism for the difference between 2D and 3D ferroptosis-
sensitivity, I propose that cell density-dependent ferroptosis observed in HMECs is 
mechanistically different to the sensitivity observed in fibroblasts. This hypothesis is 
further corroborated by a series of additional experiments using HMLE cells. There, 
I was able to induce cell death by RSL3 treatment if cells were distributed at low cell 
density in several small colonies spread across the entire surface of 6-cm dishes. In 
contrast, seeding the same cell number as one large dense and compact colony in 
the middle of such a dish resulted in resistance to RSL3-treatment (Figure 14G). 
Moreover, scattering epithelial colonies by neutralization of E-cadherin-mediated 
cell-cell adhesions did not alter RSL3 sensitivity. Notably, despite the disruption of 
adherens junctions, these scattered cells were still in close distance to each other 
(Figure 14H). Together, my data gained from 3D and 2D experiments imply that not 
necessarily the number of seeded cells determines ferroptosis sensitivity, but the 
proximity of cells to each other might play an additional role in ferroptosis sensitivity. 
Hence, organoids grown in 3D cultures or large colonies grown in 2D cultures might 
be considered as a cluster of cells in very close proximity that provides resistance, 
possibly by some specific integrin signaling like α6β4, as recently proposed (Brown 
et al., 2017). However, how integrin signaling is linked with cell-cell proximity 
signaling constitutes an aim of future studies. Another explanation how cell density, 
cell-cell adhesions and ferroptosis-sensitivity might be linked is discussed in Section 
5.6.  
However, cell-cell adhesions might be important for ferroptosis sensitivity after all. 
First, HMLE cells seeded at low cell density form small epithelial clusters as well 
although they are sensitive to ferroptosis (Figure 5C-E). Second, EMT-induced 
HMLE-Twist1 cells also form cell-cell adhesions mediated by N-cadherin (Ganz et 
al., 2006; Mani et al., 2008). These interactions might be increased at high cell 
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density since cells are in close-proximity and have more contact points to each other 
(Figure 5C). Similarly, neural crest cells are connected by N-cadherin-mediated cell-
cell adhesions during collective migration which leads to cell polarity and formation 
of protrusions at the leading edge of the cluster (Theveneau et al., 2010). A similar 
mechanism with respect to N-cadherin-induced polarity has been found in HeLa 
cells which involves integrin signaling molecules (Yano et al., 2004). Therefore, I 
hypothesize that the threshold of ferroptosis sensitivity might be determined by 
integrin signaling. Again, how exactly ferroptosis-sensitivity regulated by cell density 
is linked with integrin signaling remains to be determined in future studies.  
There might be yet another mechanism how cells sense their neighbors. For 
instance, Calcium signaling could play a possible role. It has been proposed that 
calcium released into the surrounding medium informs adjacent cells via the 
extracellular Ca2+-sensing receptor about their Ca2+-signaling status (Hofer et al., 
2004). Furthermore, an increase in intracellular calcium concentrations has been 
linked to cytotoxicity induced by peroxynitrite and hydrogen-peroxide oxidative 
stress in HaCaT cells (a keratinocyte cell line). The authors have connected this 
oxidative stress-induced cell toxicity with cell density. Moreover, at high cell 
densities, PARP activation and thus apoptotic pathways have been reduced 
(Bakondi et al., 2003). In support of this hypothesis, intracellular calcium chelators 
have been found to be protective in hydrogen peroxide-induced renal tubular cell 
injury as well as in ischemic neuronal injury (Tymianski et al., 1993; Ueda and Shah, 
1992). These observations might constitute a link between ferroptosis and calcium 
signaling since ferroptosis has been implied in ischemia-reperfusion injuries of the 
brain and kidney (Friedmann Angeli et al., 2014; Linkermann et al., 2014; Tuo et al., 
2017). Although calcium chelation did not rescue ERA-induced cell death in HT-
1080 cells (Dixon et al., 2012), but ERA also did not impact viability in HMECs 
(Figure 7A), the assessment of calcium-signaling in cell density-dependent 
ferroptosis might be an avenue to consider in future experiments. 
 
5.4 An increase in lipid peroxidation is not directly linked to cell density-
dependent ferroptosis  
Generation and accumulation of lipid peroxidation caused by GPX4 inhibition or 
GPX4 knockout is considered a hallmark and mediator of ferroptosis (Dixon et al., 
2012; Doll et al., 2017; Friedmann Angeli et al., 2014; Kagan et al., 2017; Yang et 
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al., 2014). To detect an increase in lipid peroxidation upon GPX4 inhibition, 
fluorescent C11-BODIPY dye and the Click-iT Lipid Peroxidation Imaging Kit are in 
widespread use (Dixon et al., 2012; Gascón et al., 2016; Yang et al., 2014). By 
contrast, I did not detect a significant increase in lipid peroxidation in RSL3-treated 
HMLE and HMLE-Twist1 cells when using these dyes (Figure 17A, C and D). This 
was unexpected since I had ruled out necrosis and apoptosis as cell death 
modalities and established that cell density-dependent cell death was rescued by a 
variety of agents that block ferroptosis (Figure 6 and Figure 16A). Importantly, I used 
cumene hydroperoxide as a positive control to measure lipid peroxidation (Figure 
17B and E) (Weiss and Estabrook, 1986), ruling out technical issues with these 
assays. Even more surprising was my finding that when using GPX4-KO HMLE and 
HMLE-Twist1 SCCs, I discovered an increase in lipid peroxidation levels by C11-
BODIPY staining which (I) was highly variable between different SCCs and which 
(II) was not directly linked to cell density (Figure 18A). However, low seeding density 
reliably sensitized all these SCCs to ferroptosis (Figure 9C). Specifically, Lip1 
withdrawal increased lipid peroxidation levels on average by 2-fold in all densities 
(low, intermediate and high seeding densities) compared to Lip1-cultured cells 
(Figure 18B). Since both RSL3 and GPX4-KO lead to cell density-dependent 
ferroptosis, I conclude that a general increase in lipid peroxidation is not the direct 
cause of cell death in cell density-dependent ferroptosis. However, since both 
lipophilic antioxidants and LOX inhibitors rescued RSL3-induced ferroptosis in 
HMLE and HMLE-Twist1 cells (Figure 16A), my data suggest that lipid peroxidation 
is critically involved. Indeed, LOX enzymes have been shown to oxidize PUFAs 
which sensitize cells to ferroptosis (Seiler et al., 2008; Yang et al., 2016). Moreover, 
it has been reported that ALOX15, a specific LOX enzyme, is involved in lipoprotein 
oxygenation and organelle degradation (Belkner et al., 1993; van Leyen et al., 
1998). Therefore, instead of inducing a global increase in lipid peroxidation, it could 
be possible that very specific lipid metabolites are oxidized in HMLE and HMLE-
Twist1 cells that serve as mediators of cell death. These metabolites might be crucial 
for cell survival or might serve as metabolites for other cellular processes. Based on 
my proteomics screen, I propose that cell density regulates the liberation of fatty 
acids from lipid droplets which are used for fatty acid oxidation in the mitochondria. 
This mechanism will be discussed in more detail in Section 5.6. Another report has 
established ACSL4 as a determinant in ferroptosis by increasing oxidation-prone 
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PUFAs in membranes (Doll et al., 2017). Specifically, ACSL4 expression leads to 
the enrichment of PEs, a specific class of phospholipids, containing AA and AdA 
species, within cellular membranes. Furthermore, double and triple oxygenated AA- 
and AdA-containing PEs have been identified as mediators in ferroptosis (Doll et al., 
2017; Kagan et al., 2017). However, I discovered that although both HMLE and 
HMLE-Twist1 cells expressed ACSL4 (Figure 16B), neither inhibition of ACSL4 by 
rosiglitazone (ROSI) nor genetic deletion of ACSL4 rescued cell density-dependent 
ferroptosis (Figure 16A, C and E). I cannot rule out that another ACSL enzyme 
compensates for ACSL4 activity during ACSL4-KO. For instance, ACSL3 can use 
AA as a substrate as well (Ansari et al., 2017; Van Horn et al., 2005). Moreover, a 
regulation of another lipid-metabolizing enzyme by cell density, namely 
lysophosphatidylcholine acyltransferase 3 (LPCAT3), which incorporates ACSL-
activated acyl-CoAs into phospholipids (PL) (Shindou and Shimizu, 2009) may play 
a role in cell density-dependent ferroptosis. LPCAT3 has been identified to 
contribute to RSL3 and ML162, but not ERA-induced ferroptosis (Dixon et al., 2015). 
Since ERA-treatment does not elicit cell density-dependent ferroptosis, LPCAT3 
could be considered in future experiments. To clarify mechanisms of cell density-
dependent ferroptosis, experiments involving the deletion of other ACSL proteins 
will provide further insights. 
I did not observe cell density-dependent ferroptosis upon GPX4 inhibition in a panel 
of breast cancer cell lines (Figure 15). In this panel, ACSL4 expression has been 
described to confer ferroptosis sensitivity. For instance, MCF7 and T-47D cells 
showed resistance while MDA468, MDA231 and MDA157 cells were sensitive to 
RSL3-induced ferroptosis correlating to absence (MCF7 and T-47D) and presence 
(MDA231 and MDA157) of ACSL4 expression (Doll et al., 2017). These data again 
support the hypothesis that another mechanism confers sensitivity in cell density-
dependent ferroptosis. ACSL4 expression might be a predictor for ferroptosis 
sensitivity depending on the cellular context. Likewise, oncogenic RAS confers 
ferroptosis sensitivity only in specific cellular contexts (Dolma et al., 2003; Lachaier 
et al., 2014; Yang and Stockwell, 2008; Yang et al., 2014).  
Moreover the role of LOX enzymes in ferroptosis is highly debated. For instance, 
deletion of the 12/15-lipoxygenase (ALOX15) resulted in resistance to BSO-induced 
ferroptosis (Seiler et al., 2008), but did not rescue mice with an inducible GPX4-KO 
from ferroptosis-induced acute renal failure and early death (Friedmann Angeli et 
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al., 2014). In the latter case, a possible compensation by ALOX5, another LOX 
enzyme, was excluded (Friedmann Angeli et al., 2014). Moreover, the authors from 
a recently published study suggest that ferroptosis sensitivity is simply determined 
by the pool of autoxidizable lipids. Every modulation increasing this pool then 
induces ferroptosis susceptibility (Shah et al., 2018). Further, this study showed that 
LOX inhibitors possess unspecific radical scavenging properties. Nonetheless, 
additional studies involving genetic modulation of LOX genes and PUFA-related 
genes would be required to better understand how cellular context shapes sensitivity 
to ferroptosis. Accordingly, large-scale analyses of cellular lipids (lipidomics), 
especially of PUFAs in phospholipids, in HMLE and HMLE-Twist1 cells seeded at 
different cell densities will be performed in addition to further loss-of function 
analyses of PUFA-modifying enzymes. Likewise, as previously reported (Kagan et 
al., 2017), assessing the oxi-lipidome will enable us to shed light on which lipid 
metabolites are oxidized during cell density-dependent ferroptosis. Together, these 
experiments will provide further insights into the mechanisms of ferroptosis 
sensitivity induced by low cell density in HMECs.  
 
5.5 The role of iron in cell density-dependent ferroptosis remains unclear 
5.5.1 Does ferritinophagy play a role in cell density-dependent ferroptosis? 
Iron-dependent lipid peroxidation is considered as a hallmark in ferroptosis and even 
informed its terminology (Cao and Dixon, 2016; Dixon et al., 2012). Indeed, I 
observed that iron chelation by deferoxamine (DFO), but not by ciclopirox (CPX) 
partially rescued cell density-dependent ferroptosis induced by RSL3 treatment 
(Figure 16A). Both iron chelators have been described to protect from ferroptosis 
(Dixon et al., 2012, 2015; Yang and Stockwell, 2008). However, they possess 
distinct modes of action due to differential abilities to cross cellular membranes (Hao 
et al., 2018). Since DFO chelates lysosomal iron while CPX binds the cytoplasmic 
labile iron pool (Hao et al., 2018), one could hypothesize that lysosomal iron plays 
a role in cell density-dependent ferroptosis. For instance, it has been shown that 
oxidative-stress-induced cell death was prevented by DFO-mediated chelation of 
redox-active iron in lysosomes (Kurz et al., 2004; Persson et al., 2003; Yu et al., 
2003). Only recently, lysosomal degradation of ferritin providing labile iron (Fe2+) 
that involves an autophagic process termed ferritinophagy has been connected to 
ferroptosis (Gao et al., 2016; Hou et al., 2016; Torii et al., 2016). Mechanistically, 
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inhibition of autophagy by chemical inhibitors or knockdown of autophagy-related 
proteins (for instance Atg5, Atg7, Atg3 and Atg13) protected from FIN-induced 
ferroptosis in fibroblasts and cancer cells by preventing the accumulation of labile 
iron and ROS (Gao et al., 2016; Hou et al., 2016; Torii et al., 2016). Further, the 
nuclear receptor coactivator 4 (NCOA4), which is a selective cargo receptor for 
ferritinophagy, has been linked to modulate ferroptosis when NCOA4 was knocked 
down or overexpressed during ferroptosis induction (Gao et al., 2016; Hou et al., 
2016). Interestingly, senescent MEFs, induced by oncogenic Ras expression, have 
been shown to accumulate iron due to impaired ferritinophagy. In addition, they were 
resistant to ERA and RSL3-induced ferroptosis (Masaldan et al., 2018). Overall, 
these data hint to an association between autophagy, and more specifically 
ferritinophagy with ferroptosis. Notably, “transferrin transport” and “regulation of 
macroautophagy” are two biological GO-terms enriched in low cell density in both 
HMLE and HMLE-Twist1 identified during my proteomic study (Figure 19D). 
Therefore, it might be that cell density impacts ferritinophagy and thereby 
ferroptosis-sensitivity. However, in the study performed by Masaldan and 
colleagues, pharmacological induction of ferritinophagy did not re-sensitize 
senescent cells to ferroptosis (Masaldan et al., 2018), further showing that more 
research is necessary to assess the contribution of ferritinophagy in ferroptosis. 
Future experiments are required to address the role of lysosomal iron, possibly 
provided during ferritinophagy, in cell density-dependent ferroptosis.  
 
5.5.2 HMOX1 does not contribute to cell density-dependent ferroptosis 
Another iron metabolism-related protein that was enriched in low density in my 
proteomic study was heme oxygenase 1 (HMOX1) (Appendix Table 11). By 
degrading heme and heme-containing proteins, HMOX1 leads to the release of 
ferrous iron (Fe2+). In contrast to the ubiquitously expressed isoform HMOX2, 
HMOX1 is induced by a variety of external stimuli like oxidative stress, hypoxia or 
iron starvation (Dunn et al., 2014). It has been shown that HMOX1 expression 
increases ERA-induced ferroptosis (Kwon et al., 2015). Therefore, HMOX1 was 
validated as one potential protein which might influence cell density-dependent 
ferroptosis. Indeed, I discovered that cell density upregulates HMOX1 at the 
transcriptional and protein level in HMLE-Twist1 cells. However, HMLE cells 
expressed HMOX1 only at very low levels that were very slightly upregulated by low 
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cell density (Figure 20A and B). Moreover, although lentiviral-mediated HMOX1 
overexpression resulted in high HMOX1 levels in HMLE cells (Figure 20C and D), 
no impact on cell density-dependent ferroptosis induced by RSL3 treatment was 
observed (Figure 20E and F). Likewise, CRISPR/Cas9 genome-editing in the 
HMOX1 locus in both HMLE and HMLE-Twist1 cells, yielding at least one SCCs with 
HMOX1-KO, did not alter cell density-dependent ferroptosis (Figure 21). Together, 
my data suggested that HMOX1 does not contribute to cell density-dependent 
ferroptosis in HMLE and HMLE-Twist1. One explanation is that overexpression of 
HMOX1, which was derived from cloned cDNA transcribed from HMOX1 RNA 
expressed by HMLE-Twist1 cells at low cell density, did not result in the assembly 
of a fully functional enzyme in HMLE cells (Figure 20D). Furthermore, CRISPR/Cas9 
genome-editing in the HMOX1 locus had a low efficiency resulting in only one SCCs 
with a full HMOX1 knockout (Figure 21A and B), opening the possibility that these 
data might not be sufficient to exclude HMOX1 as a potential candidate. For 
instance, further evidence could be provided by experiments modulating HMOX1 
activity either by addition of the HMOX1 inhibitor zinc protoporphyrin IX or the 
inducer Hemin during RSL3-induced ferroptosis, as previously described (Kwon et 
al., 2015). Since endogenous HMOX1 levels are very low in HMLE cells (Figure 
20B), a contribution of HMOX1 at least in HMLE-observed cell density-dependent 
ferroptosis is unlikely. A controversial role of HMOX1 in ferroptosis has been also 
reported in recent literature. Genetic deletion of HMOX1 in renal proximal tubule 
cells increased sensitivity to ERA- and RSL3-induced ferroptosis compared to 
HMOX1 wildtype cells (Adedoyin et al., 2018). Likewise, knockdown of HMOX1 in 
hepatocellular carcinoma cells (HCCs) augmented their sensitivity to ferroptosis. In 
HCCs cells, the nuclear factor erythroid 2-related factor 2 (NRF2), as a master 
regulator of antioxidant response inducing, for instance, the transcription of HMOX1, 
conferred resistance to ferroptosis (Sun et al., 2016). Similarly, the NRF2-HMOX1 
pathway has been associated with resistance to artesunate-induced ferroptosis in 
cisplatin-resistant head and neck cancer cells (Roh et al., 2017). By contrast, several 
reports have linked HMOX1 expression to ferroptosis sensitivity (Chang et al., 2018; 
Hassannia et al., 2018; Kwon et al., 2015). For instance, withaferin A increases the 
labile Fe2+ pool by inducing HMOX1 which results in increased ferroptosis induction 
in neuroblastoma cell lines (Hassannia et al., 2018). Moreover, BAY 11-7085-
induced ferroptosis has been shown to be mediated by an upregulation of an NRF2-
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SLC7A11-HMOX1. Here, HMOX1 overexpression accelerated ferroptosis (Chang 
et al., 2018). These studies clearly demonstrate that HMOX1 might have a dual role 
in ferroptosis. HMOX1-deficient mice were shown to be susceptible to oxidative 
stress (Poss and Tonegawa, 1997b). By contrast, depending on the expression 
levels of HMOX1, HMOX1 either induced a cytoprotective or, at higher expression 
levels due to an increase in labile Fe2+, a cytotoxic response (Suttner and Dennery, 
1999). Therefore, upregulation of HMOX1 during ferroptosis, possibly through 
NRF2-mediated response to oxidative stress, might occur as a compensatory 
mechanism at the expense of increasing the redox-sensitive labile iron pool. 
Depending on the ability to buffer iron, for instance by iron storage in ferritin or iron 
export, these contradictory results might be explained. Similarly, upregulation of 
SLC7A11 during ERA-induced ferroptosis has been shown to occur as a 
compensatory mechanism (Dixon et al., 2012). Likewise, one could hypothesize that 
the observed upregulation of HMOX1 at low density in both cell lines is a 
consequence of increased oxidative stress which is indicated by increased cytosolic, 
mitochondrial and lipid-derived ROS levels (Figure 14C, Figure 22D and Figure 
25C). 
Heme degradation by both HMOX1 and HMOX2 leads as another product to 
biliverdin which is reduced to bilirubin by the biliverdin reductase (BVR) (Dunn et al., 
2014). The redox cycle of biliverdin and bilirubin by BVR has been shown to possess 
potent antioxidant activity (Baranano et al., 2002). However, in a recent study, 
bilirubin have been associated to protect from lipid peroxidation in contrast to GSH 
which was more connected to protect from protein oxidation (Sedlak et al., 2009). 
Indeed, earlier studies have shown that HMOX2 has a neuroprotective role by 
protecting against oxidative stress and lipid peroxidation (Chang et al., 2003; Chen 
et al., 2005a; Doré et al., 1999). For instance, HMOX2-KO mice were still able to 
induce HMOX1 after traumatic brain injury, but compared to HMOX2-WT littermates, 
protection against lipid peroxidation and neuronal loss was greatly reduced (Chang 
et al., 2003). Therefore, it is possible that cell density regulates HMOX2 and BVR in 
HMECs. The induction of HMOX1 observed at low cell density might be a marker 
for increased cellular stress, but neither sufficient nor driving protection against cell 
density-dependent ferroptosis. 
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5.6 Cell density-dependent regulation of lipid droplet metabolism linked to a 
switch to oxidative metabolism might explain differential vulnerability to 
GPX4-mediated ferroptosis at low and high cell density 
During the analysis of the proteomics data, the GO Term “positive regulation of 
triglyceride catabolic process” attracted my attention (Figure 19D). Since I 
hypothesized that specific lipids might be oxidized during cell density-dependent 
ferroptosis (see also Section 5.4), I decided to validate the two hits adipose 
triglyceride lipase (ATGL = PNPLA2) and its co-activator lipase 1-acylglycerol-3-
phosphate O-acyltransferase (ABDH5). ATGL catalyzes the first step in the lipolytic 
breakdown of triacylglycerides (TAGs) from intracellular lipid droplets to liberate one 
fatty acid (FA) and yield diacylglycerol (DAG). FAs are subsequently hydrolyzed 
from DAG by the hormone-sensitive lipase (HSL) and monoacylglycerol lipase 
(MAGL). Thereby, liberated FAs from TAGs can be transferred to mitochondrial β-
oxidation as an energy source, serve as a source for the synthesis of membrane 
lipids or can be re-esterified as TAGs (Walther and Farese, 2012). Indeed, I 
observed that low cell density upregulated ATGL protein in both HMLE and HMLE-
Twist1 cells which inversely correlated with the LD droplet amount measured by the 
fluorescent dye BODIPY493/503 (Figure 22C and D). In support of my data, a key 
role of ATGL-induced lipolysis of LDs was described for mammalian cells (Smirnova 
et al., 2006). Interestingly, at the transcript level, regulation of ATGL and ABDH5 by 
cell density was not evident (Figure 22A), indicating that either mRNA is degraded 
or protein stability of ATGL is modulated. For instance, short-term fasting of worms 
have been shown to result in ATGL-1-mediated lipolysis that was activated by LID-
1, an orthologue of human ABDH5. Thereby, increased cyclic AMP (cAMP) levels 
activated protein kinase A (PKA) activation which in turn stabilized ATGL-1 together 
with LID-1 at LDs (Lee et al., 2014). Perilipins (PLIN) are another protein family that 
regulates LD metabolism and ATGL-mediated lipolysis (Khor et al., 2013). During 
hepatic nutrient starvation, LD-associated PLIN2 and PLIN3 has been shown to be 
degraded via chaperone-mediated autophagy (CMA), followed by an increase in 
ATGL levels and association of macroautophagy proteins on LDs (Kaushik and 
Cuervo, 2015). Further, both ATGL and ABDH5 are bound by PLIN5 at the surface 
of LDs, thereby inhibiting lipolysis. In that study, PKA activation only modestly 
increased lipolysis (Wang et al., 2011). On the contrary, in C.elegans, the AMP-
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activated protein kinase (AMPK) has been shown to phosphorylate the C.elegans 
homolog of ATGL (ATGL-1), thereby inducing binding sites for the C.elegans 
homolog of 14-3-3 protein (PAR5). PAR5 interaction with ATGL-1 removes ATGL-1 
from LDs, guiding it to proteasome-mediated degradation (Xie and Roy, 2015). 
AMPK is activated by binding of AMP or ADP when ATP levels drop for instance 
during low nutrient supply. Furthermore, AMPK has to be phosphorylated at Thr172 
which occurs by the serine/threonine kinase LKB1 or in response to calcium flux 
(Mihaylova and Shaw, 2011). Together, these studies suggest that depending on 
the cellular context, lipolysis is tightly regulated at the basal level and during nutrient 
stress. In this study, cell density might be the trigger to stimulate ATGL-mediated 
LD breakdown. Importantly, a decrease of LD content at low cell density was 
associated with an increase in lipid ROS level in both HMLE and HMLE-Twist1 cells 
(Figure 22D), suggesting that lipid peroxidation increases. Moreover, inhibition of 
ATGL by Atglistatin rescued RSL3-induced and GPX4-KO-mediated ferroptosis 
(Figure 22E and F). Likewise, supplementation with the mono-unsaturated fatty acid 
oleic acid (OA), increasing the amount of LDs, rescued RSL3-induced cell death 
(Figure 24). Previously, it has been shown that OA supplementation induces the 
translocation of the LD-associated hydrolase (LDAH) from the endoplasmic 
reticulum to newly formed LDs where it induces LD fusion. Moreover, 
polyubiquitination and proteasomal degradation of ATGL is increased by LDAH 
(Goo et al., 2017), suggesting a possible contribution of LDAH in regulating ATGL 
levels at high cell density. Furthermore, OA supplementation was associated with a 
decrease in lipid ROS level (Figure 24A), indicating that LDs might buffer lipid 
peroxidation. A recent study has shown that LDs might serve as an antioxidant 
organelle protecting breast cancer cells from nutrient and lipotoxic stress. Thereby, 
the breakdown of LDs by ATGL increased PUFA-mediated lipotoxicity during 
starvation. Importantly, utilization of fatty acids in β-oxidation was shown to enhance 
cell survival during nutrient-stress. Two compensatory mechanisms were described. 
First, MDA-MB-231 breast cancer cells were protected from PUFA-induced 
lipotoxicity during nutrient starvation by the liberation of unsaturated FAs from 
phospholipid membranes by the human group X secreted phospholipase (hGX 
sPLA2), thereby increasing the abundance of low-level unsaturated FAs like OA in 
LDs. Second, inhibition of ATGL-induced lipolysis further protected from PUFA-
induced lipotoxicity during nutrient starvation (Jarc et al., 2018). Therefore, my data 
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suggest that ATGL-mediated degradation of LDs increase lipotoxic stress at low cell 
density at a basal level. Then, simultaneous inhibition of GPX4, resulting in a 
decreased ability to remove lipid peroxides, might increase lipid-mediated stress to 
a level that cells are no longer able to cope with. However, lipid ROS were not 
significantly different when GPX4 was inhibited at different cell densities (Figure 17 
and Figure 18). Therefore, while cell density appears to increase on its own lipid-
mediated stress, this cellular stress is more detrimental at low cell density than at 
high cell density. One reason might be that liberated FAs, especially PUFAs, are 
used in β-oxidation as previously described (Ong et al., 2011). I discovered that 
HMLE and HMLE-Twist1 cells rely on β-oxidation (Figure 25). Therefore, when 
GPX4 is inhibited at low cell density, the elevated lipid-mediated stress might lead 
to oxidation of these FAs, thereby inhibiting β-oxidation and resulting in cell death. 
This mechanism will be explained in more detail in the following paragraphs.  
Of note, my data provide a possible explanation for the beneficial effect OA. Another 
study has been already observing that OA strongly rescued RSL3-induced 
ferroptosis in BJeLR, HT-1080 and G-401 cells (Yang et al., 2016). Accordingly, 
generation of LDs has been found to reduce FA-induced lipotoxicity. 
Mechanistically, supplementation with OA or increased stearoyl-CoA desaturase 1 
(SCD-1) activity increased the amount of unsaturated fatty acids like OA, which in 
turn promoted TAG accumulation of both saturated and unsaturated FA 
(Listenberger et al., 2003). Interestingly, my proteomic study indicated an 
upregulation of SCD at high cell density (Figure 19C), further suggesting a possible 
difference of cells seeded at low and high cell density with respect to LD biogenesis. 
Importantly, it has been recently suggested that reducing the pool of autooxidizable 
lipids will inevitably inhibit ferroptosis, no matter by what means (Shah et al., 2018). 
Thus, the amount of LD present in cells or changing the fraction of highly 
unsaturated PUFAs by OA supplementation might buffer lipotoxic effects as recently 
proposed (Jarc et al., 2018; Listenberger et al., 2003). Further, a recent report 
suggested that cells at high cell density might have a greater cell-to-cell 
heterogeneity of the LD content (overall higher than at low cell density), thereby 
reducing lipotoxicity for the whole population (Herms et al., 2013). In Drosophila, the 
proliferation of neuronal stem cells during oxidative stress was enabled by a 
mechanism involving LD biogenesis in adjacent niche glia cells. Here, oxidative 
stress induced the generation of TAGs by enzymes like diacylglycerol 
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acyltransferase1 (DGAT-1) that were stored as LDs in glial cells. These newly 
generated LDs sequestered PUFAs, thereby limited ROS and lipid peroxidation of 
PUFAs and in turn, protected neighboring neural stem cells (Bailey et al., 2015). 
Diacylglycerol acyltransferase1 (DGAT-1) has been shown to promote LD 
biogenesis of FAs liberated by autophagy during nutrient-stress. With this 
mechanism, mitochondrial function was preserved and lipotoxicity limited (Nguyen 
et al., 2017). Likewise, deletion of DGAT-1 impaired TAG synthesis and induced 
lipotoxicity mediated by both OA and palmitate overload (Listenberger et al., 2003). 
Together, these data suggest that cells suffer from higher oxidative stress at all cell 
densities, but cell-to-cell heterogeneity in LD metabolism at high cell density 
provides protection at the population level. Indeed, I observed that lipid peroxidation 
levels are higher in HMLE cells that are located at the border of bigger colonies 
formed by HMLE cells compared to those located within colonies (Figure 17C), 
indicating heterogeneity of lipid peroxidation levels within colonies. Since I observed 
a correlation between LD content and lipid ROS level, cells at the border might also 
have higher ATGL expression, less LD abundance and as a result higher lipid 
peroxidation levels. In contrast, LD biogenesis might be increased in cells located 
inside these colonies. In cases of increased lipid stress, i.e. during GPX4 inhibition, 
this heterogeneity might provide protection as indicated by previous studies (Bailey 
et al., 2015; Herms et al., 2013). Therefore, the balance between LD catabolism 
mediated by ATGL and biogenesis mediated by DGAT-1 might be crucial for cell 
density-dependent ferroptosis. Further, these observations indicate a connection 
between LD metabolism, autophagy and ferroptosis sensitivity that opens yet 
another interesting avenue for future research. Autophagy has been linked with 
ferroptosis previously (Gao et al., 2016; Hou et al., 2016; Torii et al., 2016) (see also 
Section 5.5.1). Interestingly, one of the top enriched GO Terms at low cell density in 
my proteomics data was “regulation of macroautophagy” (Figure 19D). With respect 
to LD metabolism, it has been previously shown that LD catabolism and fatty acid 
oxidation (FAO) was impaired when autophagy was inhibited in mouse hepatocytes 
and mice liver (Singh et al., 2009). Different mechanisms for this mechanism have 
been provided recently. For instance, during nutrient-stress in hepatocytes, ATGL 
levels and, presumably, lipolysis increased through the degradation of PLIN2 and 
PLIN3 by chaperone-mediated autophagy followed by the localization of 
macroautophagy proteins on LDs (Kaushik and Cuervo, 2015). Furthermore, it has 
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been shown that ATGL is both required and sufficient for LD breakdown by an 
autophagic/lipophagic process in hepatocytes. Specifically, ATGL was shown to 
control sirtuin 1 (SIRT1) activity which in turn regulates autophagy. Together, LD 
catabolism is induced which in turn fuels FAO (Sathyanarayan et al., 2017).  
Based on all of these data, I hypothesize that fatty acids, particularly PUFAs required 
for β-oxidation might be oxidized during GPX4-inhibition, thereby inducing an energy 
crisis and cell death at low cell density. In hepatocytes, ATGL-regulated LD turnover 
has been implicated in channeling fatty acids to mitochondrial FAO (Ong et al., 
2011). ATGL-mediated lipolysis has been shown to activate both peroxisome 
proliferator-activated receptor alpha activity (PPAR-α) and PPAR-γ coactivator 1-α 
(PGC-1α) signaling, thereby inducing mitochondrial biogenesis and oxidative gene 
expression (Haemmerle et al., 2011; Ong et al., 2011; Sapiro et al., 2009). Adding 
to this, a recent report has shown that LD lipolysis, autophagy and mitochondrial 
fusion dynamics are crucial to channel FAs to mitochondria to enable oxidative 
phosphorylation during nutrient-stress (Rambold et al., 2015). Indeed, I observed 
upregulation of genes involved in mitochondrial FAO like CPT1A and ACAA2 as well 
as increased mitochondrial ROS levels at low cell density (Figure 25A-C). Treatment 
with Etomoxir, an inhibitor of β-oxidation, elicited cell death induction in both HMLE 
and HMLE-Twist1 cells in all cell densities (Figure 25D and E), indicating that β-
oxidation is in general crucial for the survival of HMLE and HMLE-Twist1 cells. 
Together, these data indicate that cell density induces ATGL-dependent LD 
breakdown. In turn, liberated FAs might induce both mitochondrial biogenesis and 
fuel β-oxidation at low cell density. This mechanism might be induced at the expense 
of increasing the vulnerability of cells toward lipid toxicity at low cell density. One 
explanation, why these pathways are induced at low cell density, might be that 
thereby, migratory and invasive traits are induced. For instance, it has been shown 
that expression of the connected transmembrane glycoprotein, CUB-domain-
containing protein 1 (CDCP1) decreases LD abundance along with an increase 
FAO. This mechanism has been linked to metastasis of TNBC cell lines (Wright et 
al., 2017). Likewise, FAO driven by CPT1 and CPT2 have been implicated in 
migration, invasion and metastasis in vitro and in patient-derived xenograft models 
of TNBC (Park et al., 2016). Interestingly, PGC-1α has been linked to increased 
mitochondrial biogenesis and oxidative metabolism, necessary for migration, 
invasion and distant metastasis. However, while a knockdown of PGC-1α impacted 
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invasive properties, proliferation and EMT were not affected, implying that the EMT 
program is not directly connected to PGC-1α (LeBleu et al., 2014). These data could 
explain why the presumed metabolic switch to β-oxidation at low cell density that I 
observed occurs in both epithelial and Twist1-induced mesenchymal HMLE cells. 
Interestingly, a link between ferroptosis, fatty acid metabolism and FAO has been 
recently described involving yet another mechanism: the inhibitor CIL56 induces 
ferroptotic and necrotic cell death by acting on fatty acid synthesis by the rate-
limiting enzyme Acetyl-CoA Carboxylase 1 (ACC1). CIL56 led to an accumulation 
of long-chain saturated, monounsaturated and polyunsaturated fatty acids, possibly 
by inhibiting the mitochondrial breakdown of fatty acids or increased malonyl-CoA 
production by ACC-1, which is a negative regulator of β-oxidation (Dixon et al., 
2015).  
However, further experiments are necessary to elaborate on the proposed 
mechanism in detail. Since it has been shown that Atglistatin targets human ATGL 
only by 10% (Schweiger et al., 2017), loss-of-function experiments for ATGL are 
required. Further, measuring lipolysis and staining of LDs by immunofluorescence 
will shed further light on the contribution and localization of LDs and how this impacts 
cell density-dependent ferroptosis. Of note, RSL3-induced cell death was not 
generally rescued by Atglistatin, indicating that Atglistatin does not have generalized 
unspecific, antioxidative capacity. For example, Atglistatin rescued T-47D cells from 
RSL3-induced ferroptosis, but not MDA231 or MDA157 cells (Figure 23A). This 
finding could be interesting with respect to different mechanisms of ferroptosis. 
Furthermore, I did not establish a contribution of ACSL4 in cell density-dependent 
ferroptosis (Figure 16E) although ACSL4 expression has been shown to directly 
correlate with ferroptosis sensitivity by increasing oxidation-prone PUFAs in cellular 
membranes (Doll et al., 2017; Kagan et al., 2017) (see also Section 5.4). T-47D cells 
do not express ACSL4 and have been shown to be resistant to RSL3-induced 
ferroptosis (Doll et al., 2017). Therefore, the differences that I observed with respect 
to RSL3-sensitivity might be elicited by culturing cells in different growth media that 
modulate signaling and intracellular metabolism. T-47D cells might be used to study 
the proposed mechanism of cell density-dependent ferroptosis when culturing these 
cells in different growth media. Accordingly, HMLE and HMLE-Twist1 cells were less 
sensitive to RSL3-induced cell death when they were cultured in basal medium 
compared to growth-factor containing medium (Figure 14I). These data indicated 
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that metabolic pathways activated through factors in the growth medium play an 
important role in cell density-dependent ferroptosis. Interestingly, transcription levels 
of genes involved in LD breakdown like ATGL and MAGL and in FAO like CPT1A 
are enriched in HR+ breast cancer compared to TNBC (Monaco, 2017). Further, 
ACSL3 expression is enriched in HR+ breast cancer while ACSL4 expression marks 
TNBC (Monaco, 2017). In KRAS mutated non-small cell lung cancer cells 
(NSCLCs), ACSL3, activating long-chain FAs, has been shown to be required for β-
oxidation and lipid storage of TAGs. Suppression of ACSL3 highly impaired 
tumorigenesis and led to cell death in NSCLC (Padanad et al., 2016). Together, 
these data further support the notion that T-47D, an HR+ breast cancer cell line, 
could be used to study mechanisms of cell density-dependent ferroptosis. Moreover, 
these data indicate that other ACSL isoforms might contribute to ferroptosis 
depending on the cellular context. However, the proposed switch to oxidative 
metabolism needs to be addressed in more detail as well. In this regard, a recent 
report suggested that in T-cells depending on the concentration employed, ETX 
could either inhibit β-oxidation or inhibit ATP generation during mitochondrial 
respiration through inhibition of adenine nucleotide translocase (ANT), thereby 
inducing an uncoupling of the electron transport chain (Raud et al., 2018). Therefore, 
genetic interference by overexpression or knockdown of CPT1A and measurement 
of β-oxidation, for example by Seahorse analysis, are required to provide further 
evidence of the proposed metabolic switch to FAO. Furthermore, analysis of global 
metabolic changes of cells seeded in different cell densities as well as during GPX4 
inhibition/knockout using metabolomics, lipidomics as well as oxi-lipidomics will 
narrow down the mechanisms of cell density-dependent ferroptosis.  
 
5.7 Concluding remarks 
In this study, I elucidated the mechanisms of ferroptosis susceptibility in the context 
of human mammary epithelial cells. Initially, I was interested in determining whether 
ferroptosis could be employed to specifically target EMT-induced cells, previously 
shown to be chemotherapy-resistant (Ansieau et al., 2014; Nieto et al., 2016). 
Although the mesenchymal cell state has been connected to promote ferroptosis 
sensitivity in different cellular contexts (Viswanathan et al., 2017), I was not able to 
show that Twist1-induced mesenchymal HMLE cells are particularly sensitive to 
ferroptosis compared their epithelial counterparts. Instead, I discovered that cell 
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density plays a critical role in determining the sensitivity to ferroptosis in both 
immortalized and primary HMECs. Further, my data indicate that GPX4-inhibition in 
HMECs does not result in a consistent increase in lipid peroxidation. Therefore, 
ferroptosis induction is not directly linked to a global increase in lipid peroxidation in 
HMECs. To find potential candidates that contribute to cell density-dependent 
ferroptosis, I analyzed the proteome of HMLE and HMLE-Twist1 regulated by cell 
density and during GPX4-inhibition. The proteomic analysis provides several 
regulated proteins that might contribute to cell density-dependent ferroptosis whose 
exact role will be assessed in future studies. As one example, I identified ATGL as 
a potential hit that was further evaluated. Mechanistically, my data suggest that cell 
density-dependent vulnerability to ferroptosis depends on changes in lipid droplet 
metabolism that modulates lipid-mediated stress. Further, low cell density might 
induce a metabolic switch to fatty acid oxidation which is fueled by ATGL-liberated 
FAs. The proposed switch might potentially impact migratory and invasive behavior 
and might be elicited when tissue integrity is disturbed. Metastatic cells, at least in 
melanoma, have been shown to have increased oxidative stress which has to be 
limited at the distant site to enable metastatic outgrowth (Piskounova et al., 2015). 
Therefore, ferroptosis might be employed to target breast cancer cells during early 
stages of metastases as long as cells are present as single cells or small cluster 
clusters. However, the intrinsic property of mammary epithelial cells, i.e. being 
sensitive to ferroptosis at low cell density, has an important impact when considering 
ferroptosis as a treatment strategy in cancer treatment. Moreover, it will be 
interesting to determine whether ferroptosis has a physiological role in mammary 
gland development and function. For instance, ferroptosis might play a role during 
involution of the mammary gland after cessation of lactation. Interestingly, involution 
has been described to involve a lysosomal, non-apoptotic cell death triggered by OA 
liberated from TAGs (Magtanong et al., 2016). Further, it will be crucial to 
understand at the molecular level how cell density is sensed and how this sensing 
impacts LD metabolism and lipotoxicity. Therefore, on one hand, elucidating the 
molecular and genetic mechanisms of cell density-dependent ferroptosis in human 
mammary epithelial cells might yield fundamental insights into epithelial tissue 
function. On the other hand, a better understanding in the context of breast cancer 
will enable stratification of patient samples into sensitive and resistant tumors as the 
basis to translate mechanisms of ferroptosis sensitivity into therapeutic strategies. 
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7 Appendix 
Proteins that were at least 1.5-fold down- or upregulated both by low cell density 
and by 5h RSL3 treatment in both HMLE and HMLE-Twist1 cells (p<0.05, unpaired 
T-test with Welch’s correction) in the proteomics are listed in the following, (related 
to Figure 19). 
Table 10: Fold changes of downregulated proteins in low cell density and upon 5h RSL3 treatment 
in both HMLE and HMLE-Twist1 cells  
Uniprot 
Accession 
GeneID low vs. high density 
RSL3 vs. Ctrl  
(med density) 
Q15843 NEDD8 16.27 15.42 
Q9Y4H2 IRS2 6.10 3.96 
Q96CX6 LRRC58 3.17 5.66 
Q9Y6K5 OAS3 3.01 4.90 
Q9UKK3 PARP4 2.72 2.14 
Q96R06 SPAG5 2.50 2.05 
O00767 SCD 2.47 1.72 
P23469 PTPRE 1.96 1.76 
P62699 YPEL5 1.88 1.75 
O15020 SPTBN2 1.78 1.92 
P53384 NUBP1 1.74 2.26 
Q9UBT7 CTNNAL1 1.59 1.72 
Q16832;Q53FD0 DDR2 1.59 1.65 
Q96JH7 VCPIP1 1.57 1.78 
Q6PJG2 ELMSAN1 1.57 2.09 
P62241 RPS8 1.57 1.51 
 
Table 11: Fold changes of upregulated proteins in low cell density and upon 5h RSL3 treatment in 
both HMLE and HMLE-Twist1 cells 
Uniprot 
Accession 
GeneID low vs. high density 
RSL3 vs. Ctrl  
(med density) 
Q99969 RARRES2 316.58 154.78 
P02679 FGG 254.12 23.05 
P02649 APOE 56.88 7.75 
Q8NDH3 NPEPL1 47.35 18.74 
Q8WTS1 ABHD5 38.77 4.36 
P51888 PRELP 37.95 32.27 
P13796 LCP1 33.39 6.03 
Q14894 CRYM 29.93 19.47 
Q8IW45 NAXD 29.56 12.88 
P01185;P01178 AVP 29.25 23.34 
Q6NW29 RWDD4 28.97 9.58 
P51649 ALDH5A1 25.26 10.33 
Q9BUP3 HTATIP2 24.61 11.52 
Q96DC8 ECHDC3 22.00 13.25 
Q9HCE0 EPG5 21.16 8.08 
I1YAP6 TRIM77 19.49 8.78 
Q8TDX9 PKD1L1 17.29 5.16 
P09936 UCHL1 16.56 7.25 
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Uniprot 
Accession 
GeneID low vs. high density 
RSL3 vs. Ctrl  
(med density) 
Q9UQ10 DHDH 15.71 7.65 
P09471 GNAO1 15.61 6.41 
Q9HBL8 NMRAL1 15.58 5.25 
Q8NBE8 KLHL23 15.32 8.51 
A6NC98 CCDC88B 13.79 5.67 
Q96E35 ZMYND19 13.04 6.61 
Q7RTP6 MICAL3 12.41 4.44 
P02774 GC 11.93 7.19 
O94915 FRYL 11.68 4.47 
P01024 C3 11.65 9.15 
Q8TEB9 RHBDD1 11.33 6.27 
Q9P258 RCC2 11.26 5.58 
Q9NZR1 TMOD2 11.24 4.08 
Q7Z4S6 KIF21A 11.23 6.53 
F8WCM5 INS-IGF2 10.38 4.52 
P69905 HBA1 9.82 3.99 
Q5SZQ8 CELF3 9.57 8.36 
P08247 SYP 8.92 4.95 
Q9ULU8;Q86UW7 CADPS 8.65 5.99 
Q6Q4G3 LVRN 8.60 3.28 
Q9Y3E0 GOLT1B 8.42 4.74 
P21266 GSTM3 8.06 3.19 
Q9H4G4 GLIPR2 7.52 7.98 
P02788 LTF 6.64 3.71 
P54652 HSPA2 6.63 4.78 
P13929 ENO3 6.40 3.67 
P02675 FGB 6.12 3.70 
Q9UGM3 DMBT1 6.11 3.30 
Q96L91 EP400 6.09 3.92 
P28161 GSTM2 6.09 3.23 
P08910 ABHD2 5.90 3.28 
Q8N0Y7 PGAM4 5.84 4.41 
Q8WUH6 TMEM263 5.68 5.91 
Q9H1E3 NUCKS1 5.53 4.23 
Q13003 GRIK3 5.44 2.92 
O95834 EML2 5.30 2.84 
Q9UHG2 PCSK1N 5.22 3.90 
Q9H4F8 SMOC1 4.94 3.15 
Q96AD5 PNPLA2 4.74 3.75 
O43426 SYNJ1 4.63 2.22 
Q16527 CSRP2 4.26 2.16 
P09104 ENO2 4.22 2.51 
P51608 MECP2 4.20 2.24 
Q9P2J5 LARS 3.88 2.83 
P06727 APOA4 3.84 2.29 
Q8IZW8 TNS4 3.80 2.29 
P48506 GCLC 3.75 2.35 
Q9Y3E1 HDGFRP3 3.72 2.87 
Q02252 ALDH6A1 3.64 3.52 
Q96BY9 SARAF 3.64 2.73 
P09601 HMOX1 3.58 2.90 
Q5T0D9 TPRG1L 3.32 1.99 
P12277;P06732 CKB 3.32 2.14 
Q9Y5K8 ATP6V1D 3.28 2.33 
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Uniprot 
Accession 
GeneID low vs. high density 
RSL3 vs. Ctrl  
(med density) 
P13521 SCG2 3.16 2.50 
P20336 RAB3A 3.06 2.64 
P55327 TPD52 3.00 1.88 
Q8IVF2 AHNAK2 2.98 3.30 
Q8N8N7 PTGR2 2.98 3.35 
Q53EL6 PDCD4 2.97 2.38 
Q9UI12 ATP6V1H 2.96 2.43 
Q96DG6 CMBL 2.95 1.65 
Q6UWR7 ENPP6 2.95 1.77 
Q99536 VAT1 2.90 2.39 
Q01995 TAGLN 2.72 2.07 
Q02880 TOP2B 2.70 1.57 
A6ZKI3 FAM127A 2.68 2.03 
Q96G21 IMP4 2.64 1.72 
P01189 POMC 2.58 2.36 
P63027 VAMP2 2.56 2.29 
P36543;Q96A05 ATP6V1E1 2.52 1.67 
Q96HU1 SGSM3 2.50 2.35 
Q9NRF8 CTPS2 2.46 1.99 
P21281;P15313 ATP6V1B2 2.40 1.75 
Q9NP66 HMG20A 2.37 1.91 
P36871 PGM1 2.35 1.87 
P61020 RAB5B 2.27 1.98 
P32320 CDA 2.26 2.65 
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